CA2231425A1 - Detecting thermal discrepancies in vessel walls - Google Patents
Detecting thermal discrepancies in vessel walls Download PDFInfo
- Publication number
- CA2231425A1 CA2231425A1 CA002231425A CA2231425A CA2231425A1 CA 2231425 A1 CA2231425 A1 CA 2231425A1 CA 002231425 A CA002231425 A CA 002231425A CA 2231425 A CA2231425 A CA 2231425A CA 2231425 A1 CA2231425 A1 CA 2231425A1
- Authority
- CA
- Canada
- Prior art keywords
- radiation
- fiber
- vessel
- balloon
- fibers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 22
- 239000000463 material Substances 0.000 claims abstract description 18
- 210000000056 organ Anatomy 0.000 claims abstract description 7
- 239000000835 fiber Substances 0.000 claims description 152
- 230000005855 radiation Effects 0.000 claims description 137
- 238000000034 method Methods 0.000 claims description 64
- 230000003287 optical effect Effects 0.000 claims description 57
- 210000004027 cell Anatomy 0.000 claims description 40
- 239000013307 optical fiber Substances 0.000 claims description 19
- 239000012530 fluid Substances 0.000 claims description 16
- 210000004204 blood vessel Anatomy 0.000 claims description 15
- 238000001228 spectrum Methods 0.000 claims description 15
- 238000001514 detection method Methods 0.000 claims description 12
- 238000009987 spinning Methods 0.000 claims description 8
- 238000005070 sampling Methods 0.000 claims description 6
- 230000001747 exhibiting effect Effects 0.000 claims description 5
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 230000005540 biological transmission Effects 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 1
- 210000004969 inflammatory cell Anatomy 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 210000001367 artery Anatomy 0.000 abstract description 26
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 24
- 208000037260 Atherosclerotic Plaque Diseases 0.000 abstract description 16
- 235000012000 cholesterol Nutrition 0.000 abstract description 11
- 208000032843 Hemorrhage Diseases 0.000 abstract description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 3
- 229910052791 calcium Inorganic materials 0.000 abstract description 3
- 239000011575 calcium Substances 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 208000025865 Ulcer Diseases 0.000 abstract description 2
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- 206010000269 abscess Diseases 0.000 abstract 1
- 230000035508 accumulation Effects 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 230000030833 cell death Effects 0.000 abstract 1
- 230000036269 ulceration Effects 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 16
- 230000004087 circulation Effects 0.000 description 15
- 150000002500 ions Chemical class 0.000 description 14
- 241000282320 Panthera leo Species 0.000 description 10
- 238000002399 angioplasty Methods 0.000 description 10
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 210000002889 endothelial cell Anatomy 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 230000006378 damage Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 208000031481 Pathologic Constriction Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 230000036262 stenosis Effects 0.000 description 5
- 208000037804 stenosis Diseases 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 200000000007 Arterial disease Diseases 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 206010047139 Vasoconstriction Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- 208000006170 carotid stenosis Diseases 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000003325 tomography Methods 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 230000025033 vasoconstriction Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- YFONKFDEZLYQDH-OPQQBVKSSA-N N-[(1R,2S)-2,6-dimethyindan-1-yl]-6-[(1R)-1-fluoroethyl]-1,3,5-triazine-2,4-diamine Chemical compound C[C@@H](F)C1=NC(N)=NC(N[C@H]2C3=CC(C)=CC=C3C[C@@H]2C)=N1 YFONKFDEZLYQDH-OPQQBVKSSA-N 0.000 description 2
- 108010035766 P-Selectin Proteins 0.000 description 2
- 102000008212 P-Selectin Human genes 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000007814 Unstable Angina Diseases 0.000 description 2
- 229910007998 ZrF4 Inorganic materials 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000000746 body region Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 210000000497 foam cell Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000013147 laser angioplasty Methods 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000013160 medical therapy Methods 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 238000003333 near-infrared imaging Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000001931 thermography Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- OMQSJNWFFJOIMO-UHFFFAOYSA-J zirconium tetrafluoride Chemical compound F[Zr](F)(F)F OMQSJNWFFJOIMO-UHFFFAOYSA-J 0.000 description 2
- ZXEYZECDXFPJRJ-UHFFFAOYSA-N $l^{3}-silane;platinum Chemical compound [SiH3].[Pt] ZXEYZECDXFPJRJ-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 241001136792 Alle Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 206010051113 Arterial restenosis Diseases 0.000 description 1
- JBRZTFJDHDCESZ-UHFFFAOYSA-N AsGa Chemical compound [As]#[Ga] JBRZTFJDHDCESZ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 241000237074 Centris Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 239000003154 D dimer Substances 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 101100072702 Drosophila melanogaster defl gene Proteins 0.000 description 1
- 101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
- 101100010296 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) pol2 gene Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 244000228957 Ferula foetida Species 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 229910001218 Gallium arsenide Inorganic materials 0.000 description 1
- 108091092889 HOTTIP Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 241000234269 Liliales Species 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101150095197 PALD1 gene Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000201776 Steno Species 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 229910003069 TeO2 Inorganic materials 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 208000007474 aortic aneurysm Diseases 0.000 description 1
- 208000028922 artery disease Diseases 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 150000004770 chalcogenides Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000013156 embolectomy Methods 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 108010052295 fibrin fragment D Proteins 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 229920002457 flexible plastic Polymers 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 210000003090 iliac artery Anatomy 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- WPYVAWXEWQSOGY-UHFFFAOYSA-N indium antimonide Chemical compound [Sb]#[In] WPYVAWXEWQSOGY-UHFFFAOYSA-N 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 238000002608 intravascular ultrasound Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- SDQFDHOLCGWZPU-UHFFFAOYSA-N lilial Chemical compound O=CC(C)CC1=CC=C(C(C)(C)C)C=C1 SDQFDHOLCGWZPU-UHFFFAOYSA-N 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229910021339 platinum silicide Inorganic materials 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000031915 positive regulation of coagulation Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910021332 silicide Inorganic materials 0.000 description 1
- FVBUAEGBCNSCDD-UHFFFAOYSA-N silicide(4-) Chemical compound [Si-4] FVBUAEGBCNSCDD-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- LAJZODKXOMJMPK-UHFFFAOYSA-N tellurium dioxide Chemical compound O=[Te]=O LAJZODKXOMJMPK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0082—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
- A61B5/0084—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters
- A61B5/0086—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters using infrared radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/01—Measuring temperature of body parts ; Diagnostic temperature sensing, e.g. for malignant or inflamed tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/01—Measuring temperature of body parts ; Diagnostic temperature sensing, e.g. for malignant or inflamed tissue
- A61B5/015—By temperature mapping of body part
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/02007—Evaluating blood vessel condition, e.g. elasticity, compliance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/0507—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves using microwaves or terahertz waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/413—Monitoring transplanted tissue or organ, e.g. for possible rejection reactions after a transplant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
- A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
- A61B5/6852—Catheters
- A61B5/6853—Catheters with a balloon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00017—Electrical control of surgical instruments
- A61B2017/00022—Sensing or detecting at the treatment site
- A61B2017/00084—Temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
- A61B2017/22001—Angioplasty, e.g. PCTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0062—Arrangements for scanning
- A61B5/0066—Optical coherence imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0073—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by tomography, i.e. reconstruction of 3D images from 2D projections
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0075—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
Abstract
An infrared, heat sensing catheter (10) particularly useful for identifying potentially fatal arterial plaques in patients with disease of the coronary or other arteries and its use, are detailed. In one embodiment, an infrared fiberoptic system (70) is employed at the tip of the catheter (10) to locate inflamed, heat producing, artherosclerotic plaque, which is at greater risk for rupture, fissure, or ulceration and consequent thrombosis and occlusion of the artery. In another embodiment, a catheter (10) with an infrared detector employed at its tip will likewise locate inflamed heat producing atherosclerotic plaque. The invention may be used to detect abscesses,infection, and cancerous regions by the heat such regions differentially display over the ambient temperature of immediately adjacent tissues. The invention may also be used to detect regions of cooler than ambient tissue in a vessel or organ which indicate cell death, thrombosis, hemorrhage, calcium or cholesterol accumulations or foreign materials.
Description
W O 97/10748 PCTnUS96/15217 DETECTING THERMAL DISCREPANCIES IN VESSEL WALLS
CROS~REF FR~ cE; TO R13LATI~D APLICATION
The present application claims the benefit of 3~ U.S.C. lll(b) P~vvisional application Serial No. 60/004,061 filed S~lc~b6l 20, 1995, and entitled ~thet~.c and Meth(~ Detecting Thermal Discrep~nrie~ in Blood Vessels.
BACKGRC)UND OF T~ INVENTION
This invention was made with ~ ,vf..-...P!nt support under Grant No. 91HL07 awarded by the National Heart Lung and Blood Tnctitute, giving the federal government certain rights in the invention. In addition, the invention described herein was made in the pt;~ru-l~lance of work under a NASA contract and is subject to the provisions of Section 305 of the National Aeronautics and Space Act of 1958, Public Law 85-568 (72 Stat. 435; 42 U.S.C. 2457).
A. Field of the Invention This invention relates to the medical ~ii~nosic and treatment of arterial disease by means of temperature dirrel~nLial sçn.cin~, and particularly, infrared-sensing with devices such as temperature probes, cameras, and cd~ . In particular, the invention provides c~hetl~r,s and methods of using c~th~ters to ~1i~nr)se arterial diseases detectable by ther nal discle~,A~ s in the arterial wall.
B. Description of the ~elated Art Problems In Diagnosis Plaque Physiology Atherosclerotic colonal~ artery disease is the leading cause of death in imlll~tri~li7ed c~l-ntries An atherosclerotic plaque is a thi~ n-~d drea in the wall of an artery. Typically, patients who have died of cofonaly disease may exhibit as many as several dozen at-h-erosclerotic plaques; however, in most in.ctanr~c of myocardial infarction, cardiaG arrest, or stroke, it is found that only one of these potential obstructions has, in fact, ruptured, fissured, or ulcerated. The rupture, fissure, or ulcer causec a large lhlo~ s (blood clot) to form on the inside of the artery, which may completely occlude the flow of blood through the artery, thereby injuring the heart or brain. A major prognostic and ~ gm)5tic dilennm~ for the car~liolc~ist is how to predict which placque is about to rupture.
CA 0223l425 1998-03-09 W O 97/10748 PCTrUS96/15217 Most ~ uled plaques are characterized by a large pool of cholesterol or necrotic debris and a thin fibrous cap with a dense infiltration of macro~ ages. The release of matrix-digesting enzymes by the cells is thought to coullil)ul~ to plaque rupture. Other thromboses are found on non-l.-yluled but infl~nP~i plaque surfaces.
Tnfl~mm~tion in an arterial plaque is the result of a series of biorh~micz~l and m~h~nic~l changes in the arterial wall. Plague, a thirk~nir~ in the arterial vessel wall results from the ~cum~ fion of cholesterol, proliferation of smooth muscle cells, secretion of a collagenous extracellular matrix by the cells, and ar~J~ iorl of Illac~ ages and, eventually, hemorrhage (bleeding), thrombosis (clotting) and r~1cifir~fiQn The consensus theory is that atherosclerotic plaque develops as a result of irritation or biorh~nnic~l damage of the endothelial cells.
The endothelial cells which line the interior of the vessel prevent h~a~ iate formation of blood clots and inhibit conl.~.,lion and proliferation of the underlying smooth muscle cells. Most investigators believe that atherosclerotic plaques can develop when endothelial cells are damaged or dysfunctional. Dy~rullclion in enrlothe~ cells is typically produced as a result of injury by cigarette smoke, high serum cholesterol (especially oxidized low density lipopl~,lei~l), hemodynamic alterations (such as those found at vessel branch points), some viruses (herpes simplex, cytomegalovirus) or bacteria (e.g., Chlamydia), hypertension, some hormonal factors in the plasma (inrll.~ling angiotensisn II, norepinephrine), and other factors as yet unknown. As a result of these gradual injuries to the enr3othe~ cells, an atherosclerotic plaque may grow slowly over many years. However, it is now well do~ d that if a plaque l~ ules, it often grows abl.. l,~ly.
When plaque rupture develops, there is hemorrhage into the plaque through the fissure where the surface of the plaque meets the bloodstream. Blood co~ f~s (forms a lhIOIII~ S) quickly upon contact with the collagen and lipid of the plaque. This blood clot may fhen grow to completely occlude the vessel or it may remain only partially occlusive. In the latter case, the new clot quite commonly becomes incorporated into the wall of the plaque, creating a larger plaque.
Plaques At Risk of R~."t~.l ;..~
Considerable evidence indic~~c that plaque rupture triggers 60% to 70% of fatal myocardial il.r~-;~iOI~s and that monocyte~ ac~phage~ contribute to rupture by releasing metall<,~ro~ Q ~e.g., coll~ ses, stromelysin) which can degrade and thereby weaken the overly fibrous cap. Van der Wal, et al., Circulation 89:3644 (1994); Nikkari, et al., Circulat~on 92:1393-1398 (19g5); Falk, et al., Circulation 92:2033-20335 (1995); Shah, et al., Circulation244 (19gS); I~avies, et al., Br Heart J 53:363-373 (1985); Co~ , J Athero~cler Res 6:1-17 (1966). In another 25% to 30% of fatal infarctions, the plaque does not rupture, but beneath the lIJI~O~I)U~ the endothelium is replaced by monocytes and infl,~,.--.-~1O~y cells. Van der Wal, et al., W O 97/10748 PCT~US96/15217 Cireulation 89:36~4 (1994); Farb, et al., Circulation 92:1701-1709 (1995). These cells may both respond to and aggravate intimal injury, pro,lloli"g ~Illollll)osis and vasoconstriction. Baju, et al., Cireulation 89:503-505 (1994).
Ullro~Lul~alely~ neither plaque rupture nor plaque erosion is predicable by clinical means.
Soluble markers (P-selectin, von Willebrand factor, angiotensen-converting enzyme, C-reactive - protein, D-dimer; Ikeda, et al., Cireulation 92:1~i93-1696 (1995); Merlini, et al., Cireulation 90:61-8 (1994); Berk, et al., Am J Cardiol 65:168-172 (1990)) and ~ livaled circulating i,.n~.. ~l.. ,y cells are found in patients with unstable angina pectoris, but it is not yet known whether these s~bstAnr~oc predict infarction or death. M~7one, et al., Cireulation 88:358-363 (1993). It is known, however, that the presence of such sllhst~nces cannot be used to locate the involved lesion.
~ow-shear regions opposite flow dividers are more likely to develop atherosc1erosis, (Ku, et al., Arterioselerosis 5:292-302 (1985)), but most patients who deve}op acute myocardial infarction or sudden cardiac death have not had prior ~ylll~LonlS, much less an angiogram. Farb, et al., Cireulation 92: 1701-1709 (199S).
Certain angiographic data has revealed that an irregular plaque profile is a fairly specific, though in~c~n~citive~ indicator of thrombosis. Kaski, et al., Cireulation 92:2058-2065 (1995). These st~noses are likely to progress to complete occtusion, while less severe st.onoses are equally likely to progress, but less often to the point of complete occlusion. ~ n ~n, et al., J Am Coll Cardiol 22: 1141-1154 (1993). However, because hemodynAmi.~Ally non~i~nifi~Ant st~nosp-s more nu.~lt;.ou~
than critical sLenoses and have not triggered collateral development, those which do dbluplly occlude actually account for most myocardial infarctions. Ambrose, et al., J Am cOn Cardiol I2:56-62 (1988); Little, et al., Cireulation 78:1157-1166 (1988).
Moreover, in postmortem studies, most occlusive thrombi are found over a ~u~lured or ulcerated plaque that is e<~ .A~ed to have produced a stenosis of less than 50% in ~ , . Shah, et al., Cireulation 244 (1995). Such stennse~ are not likely to cause angina or a positive treadmill test. ~In fact, most patients who die of myocardial infarction do not have three-vessel disease or severe left ventricular dy~fi...~ lion ) Farb, et al., Cireulation 92: 1701-1709 (1995).
In the vast ~llajoliLy of plaques causing a stenosis less than or equal to 50%, the surface outline is llnifornl, but the deep sl-u-,lure is highly variable and does not correlate directly with either the size of the plaque or the severity of the stenosis. Pa~L~;kalllP, et al., Circulation 91:1~1'11 1449 (199~); Mann and Davies Cireulation 94:928-931 (1996~.
Certain studies have been con~ ted to d.3L~"..i-le the ability to identify plaques likely to rupture using i.,Llaco.ol~y ull-~o~l~d. It is known that (1) angiography under~ s the extent of COl~ uy atherosclerosis, (2) high echo~ensity usually in-1ic~t~s dense fibrous tissue, (3) low CA 02231425 l998-03-09 W O 97/10748 PCT~US96/15217 echo-density is a feature of helllor.llage, thrombosis, or cholesterol, and (4) shadowing inrlic~c ~:~lçifi-~tion Yock, etal., Cardio 11-14(1994); McPerhson, etal., NEnglJMed316:304-309 (1987). However, recent studies indicate that intra-vascular ultrasound technology currently cannot disc.i."il-dl~ between table and unstable plaque. De Feyter, et al., Circulanon 92:140.3-1413 (1995~.
The rupture process is not completely l-n~ rstood, but it is known that the plaques most likely to rupture are those that have both a thin collagen cap (fibrous scar) and a point of physical w. l-nP,s~ in the underlying plaque. It is known that plaques with infl -nPd surfaces or a high density of activated macfo~ ag~s and a thin uve-lyil-g cap are at risk of thrombosis. Van der Wa1, et al., Cir~ 7tron 89:3644 (1994); Shah, et al., Circulation 244 (1995); Davies, et al., Br Heart J 53:363-373 (1985); Farb, et al., Circulation 92:1701-1709 (199~;); Van Damme, et al., Cardiovasc Pathol 3:9-17 (1994). Such points are thought to be located (as determined by modeling studies and pathologic analysis) at junctures where pools of cholesterol meet a more cellular and fi1orous part of the plaque. Typically, macrophages (infl~ "~ cells)~ which produce heat, have been found at these junctures. Since these infl~ u.ly cells release enzymes capable of degrading the collagen and other components of the extr~r~ r matrix, it is thought that they are crucial to the process of plaque rupture or fissuring.
Tr~ V~r~-lo~
T.. n~ ;on also plays an i.. ~,o- I.a ~ role in the rejection of tr~nt~pl ~nted organs, a process which begins by an attack of host T Iymphocytes in the grafted donor organ's endothelial cells.
Yeung et al. J. Heart Lung Transplant. 14:S215-220 (1995); Pucci et al. J. Heart Transplant.
9:339-45 (1990); Crisp et al. J. HeartLung Transplant. 13:1381-1392(1994). Recruitment and prolir~;l on of i,.ni... .. ~0.~ and smooth muscle cells are heat gcn.~aLing processes, whose effects are dt;l~,L~le in advance of the detection of vessel nal.owil,g using stress tests, ultrasound, or angiography. Johnson et al. J. Am. cOn~ Cardiol. 17: 449-57 (191); St. Goar et al. Circulation 85:979- 987 (1992). In addition to the host attack of "non-self" antigens of the donor organs, many trqnspl~nted tissues develop cytomegalovirus i"r.~Lioll~., an event that is also heat-gene,aLi-,g.
Grattan et al. JAMA 261:3~61-3566 (1989). 'Ihese events in transplant physiology are ones for which it would be valuable to track in patients recovering from such surgery.
r~F't~tn~
Another serious problem in ~ gnostic cardiology is rf~st~nosi~, a rel~ owi.lg of an artery that has undergone one or more interventional te~hniqll~s to relieve an original stenosis (caused by 3~ plaque) . Such te~ hnique$ include balloon angioplasty, athe, e~;Lor"y (shaving or cutting the plaque), W O 97/10748 PCT~US96/15217 and laser angioplasty. Balloon ~lgiupl&sLy of the cO.Olld~ arteries is a major advance in lrec.~l..en~
and has been pel~ulllled on hemodynqtnir~lly ~5ignifir~lt colon~r stenoses (those that are 70% to g9% of the cross-section~ di ~ P- of the vessel) with a success rate of 90%. In about 40% of the patients, however, r~ .o~;~ occurs in the vessel and most of the benefit gained by the procedure is lost. Thus, another major tii~nostic and prognostic dilemma for cardiologists not readily addressed by prior art devices or mPtholl~ is predicting which patients will develop re~steno,Sic, }~Pstenr~s;~ may occur when the removal of plaque by angioplasty or atherectomy injures the artery wall. The injury to the vessel wall causes the smooth muscle cells at that site to proliferate and to secrete an r~rtrarr~ r matrix which again narrows the artery. Both cell proliferation and secretion are exergonic (heat-generating~ processes. Additionally, it is known that ,na.;luphage conce,l~,d~ion in a vessel is correlated to the risk of restenosis.Many factors have been reported to predict which patients will develop rest~nosi~.
However, these studies are markedly at odds with each other and no factor has been strongly predictive of the resten~ C process. Thus, cigarette smoking, hypertension, hypercholesterolemia, unstable angina, age, sex, and many other factors have been only weakly predictive, at best.
Prior Art Devices/Methods A number of a~l)roaches and devices have been proposed to ~ gnose or treat vascular obstructions. U.S. Patent No. 3,866,599 relates to a fiberoptic catheter for insertion into the cardiovascular system for the nledsulel"elll of oxygen in blood. For the purpose of detecting o,.yge~dtion levels in the blood, optical fibers are used to first project infra-red and red light at the catheter tip into the blood. The infra-red and red light reflected by the blood is then returned through the optical fibers to an o~hl-.t~.. The ratio of infra-red light reflected to that absorbed by the blood is piûpûllional to the oxygen saturation in the blood. This catheter design is also one wherein there is at the distal end of the element a recess preventing the ends of the fibers from CO,.~ g the vessel wall and an exterior sleeve which can be expanded to further space the fibers from the wall of the vessel. However, the fiberoptic catheter of this patent does not permit d~ ;lion of heat.
In some prior art devices, temperature sensing elements have been used. U.S. Patent No.
4,î52,141 relates to r~belu~lic sensing of ~ ,.dlul-~ and/or other physical p~aul~lt;l~ using a system c~ ing (1) an optical fiber (2) means ;~r~ i"$~ a source of visible or near visible cle~ Llu..~ tic radiation pulses at one end of the fiber for directing the radiation along the fiber to another end of the fiber (3) a sensor positioned at or near the end of the fiber in a manner to receive the r~r~ m, mS)ri~ te it by the telllpeldule, and redirect the modulated radiation back s CA 0223l425 l998-03-09 W O 97/10748 PCT~US96/15217 through the optical fiber to the sensor (4) the sensor colllp.isil.g at least one optical element in the path of the source of radiation whose optical properties vary in rt;sl?onse to the m~gnihl-le of temperature changes and (S) means positioned at the end of the fiber ~eceivillg the mo~ ted ladidlion for mea~ul h.g a filnrtion related to the time of the resulting IllminP-scçnt radiation i~ .Si~y S decay after an eY~it: ~ion pulse in-liç~ting the le ~ ,ralul,3 of the sensor. These l~lllp~.àlu~e sensors were dPcignP~l to physically contact a surface and were built with an elastomeric bul,.,l~lce at the end of the fiber to which a thin layer of phosphor material had been deposited. The phocrhor reacts to the lell~c~dtul~e and emits radiation which travels up the fiber and is detecte~l by the sensor. Contact lem~,.alu..z ~ ;OIl.c require the ability of the c~theter to be placed in contact with the locus whose I~ Jt;ldtul~ is to be l.. e~-,.. ied.
U.S. Patent No. 4,986,671 relates to a fiber optic probe with a single sensor formed by a elastomeric lens coated with a light reflective and temperature dependent material over which is coated a layer of material that is al~sc,ll,Live of infrared radiation thereby allowing a determination Of rh~a-~-i5~ics of heat or heat transfer. One application is in a catheter for providing pleS.7uie, flow and Lel-lpe.dture of the blood in a blood vessel.
Other methods utili7ing differing means for heat detection are known. The sensitivity and/or toxicity of these devices is unknown. U.S. Pat. No. 4,140,393 relates to the use of birefring~l.e.lL material as a temperature probe. U.S. Pat. No. 4,136,566 suggests the use of the Jeldtule dependent light absorption characteristics of gallium arsenide for a temperature sensor.
U.S. Pat. No. 4,179,927 relates to a gaseous material having a L~ e.àLuie dependent light absorption.
Other approaches utilize eYrit~tion tP~hniques to detect heat. U.S. Pat. No. 4,075,493 relates to the use of a IllminP-~cPnt material as a temperature sensor, exciting radiation of one wavelength range being passed along the optical fiber from the l..e~,u.;llg i,..,L-ul,.~.ll, and I~ .d~ure dependent lllminpscpnt radiation being emitt_d from the sensor back along the COI~ ..;f '~ optical fiber for detection and ~---,a;,urt;..le--L by the i"~,LIull.e..L. It is the lllminPscPnt sensor terhnology which has found the greatest collullercial applicability in fiber optic ,u~wl~el~l~" ~ lal ily for reasons of stability, wide temperature range, ability to minimi7e the effect of non~ e.d1ule light variations, small sensor size and the like.
An example of a lnminPcc~Pnt fiberoptic probe that c m be used to measure the velocity of fluid flow, among other related parameters, is given in U.S. Pat. No. 4,621,929. Infrared radiation is directed to the sensor along the optical fiber and is absorbed by a layer of material provided for that purpose. Once heated, tne sensor is then allowed to be cooled by a flow of fluid, such cooling being ll.~-,..red by the IllminP-sce~t sensor. The rate of cooling is proportional to the heat transfer chala~ ,lics and flow of the ~u~ ulldhlg liquid.
W O 97/10748 PCTrUS96/15217 U.S. Patent No. 4,995,398 relates to the use of thermography during the course of by-pass heart surgery for the purpose of checking the success of the operation before closing the chest cavity. This patent d~c~ s the use of a s~ ~ g thermal camera, image procP~ing, ~ el alule dirrert;llLidls and displaying images in real time. The invention relies on the use of a cold injectate which when it mixes with warmer blood provides images captured on a thermal camera focusing - on the heart to detect sten-)s~-~ at the sites of distal ~ u~ ses.
U.S. Patent No. 5,046,501 relates to a method of identifying atherosclerotic plaque versus structurally viable tissues using a fluore~ beam at a single eYcit~tion wavelength of between 350 and 390 mn p~e~dbly from a laser which allows dirrt;lel.lid~ion of these tissues. No catheter was used in the examples of the patent. Thus, in situ imaging is not disclosed or taught by this patent.
Moreover, no te~hnique is described by this patent for predicting plaque rupture, r~t~no~i~ or tr~nsrl~nt vasculopathy.
U.S. Patent No. 5,057,105 relates to a hot tip catheter assembly comprising a heater, a cap, a thermocouple, power leads, and a central distal lumen to position the catheter in the artery. The thermocouple is in~ (led to continuously monitor the heating of the catheter tip in order to prevent overhe ~ing The tip when p~ûl)e.ly placed on a plaque build up, melts the plaque.
U.S . Patent No. 5,109,859 relates to ulll~uulld guided laser angioplasty Co~ g a laser at the tip of a catheter, an ull~asùu~d device also at the tip of the laser for gl-id~lre, and a proximal occlusion balloon to provide stabilization and a blood free envirulL,llelll. This patent a~pdl elllly also relates to ~ ;.. g the mass of a plaque tissue. There is no te~rhing that the ultrasound device of the patent can distinguish histological features (i. e., what cel~s and extr~rçllnl~r matrix are within the plaque). Thus, it is not likely that such a device could be used to predict plaque rupture.
Indeed, recent studies have found that intravascular ul~la~ound cannot identify which plaques are at risk of lU~lULillg. de Feytia Circulation 92:1408-13 (1995).
U.S . Patent No . 5,217,456 relates to an intra-vascular guidewire-colll~a1ible catheter which has a source of i11l..~.;.. ~iO.l and a ~yn~.hrolluus rluoresct;llce detector. Light in a wavelength that ;nduces fluorescence in tissues ~ . radially from an aperture on the side of the catheter.
Fluorescence emitted from the tissues enters the catheter through the same aperture and is conveyed to a spectral allaly~t;.. This h~ru~ a~ion can be used to dirr~,L~ iate healthy tissue from atherosclerotic plaque. However, this device does not distinguish between plaque on the basis of heat ~lirre~ lLial.
U.S. Patent No. S,275,594 relates to methods and ~pa.dlus for ~ ";~hing between atherosclerotic plaque and normal tissue by analy~illg photoPmi~ion~ from a target site. The system inrl~ r5 a source of laser energy for stim~ tiQn of fluorescence by non-calcified versus r~leified atherosclerotic plaque, and an analyzing means for d~ llh~ g whether a spectrum of W O 97/10748 PCT~US96/15217 fluorescence emitted by a tissue leyies~L~ calcified or non-calcified atherosclerotic plaque at a target site, based upon the time domain signal of calcium photoemission following fluorescent eY. itq-ti-)n of the cq1~ m When atherosclerotic plaque is identified, laser energy is used to ablate the plaque.
Prior art a~yroa~ hG5 to intravascular arterial ~ ..o~.~ and repair have been numerous yet have failed to provide certain capabilities. In particular, such prior art c ~ r~.~ and methods have failed to provide means for detecting and treating atherosclerotic plaque since they have not been able to differentiate between those plaques at risk of lU~JIUlillg and ocr1u(ling and those that are not presently at such risk even if they are capable of d~ .g the presence or absence of calcification of the plaque. Similarly, prior art approaches have not provided effective means for identifying specific arterial sites at risk for arterial rectenosi~ after angioplasty or atherecL~)nly.
Prior art apLloaclles have also failed to provide practical and effective means for detecting tr~n~ q-nt vasculopathy. Neither have prior art approaches been able to effectively identify patients who have arterial wall areas of lower rather than higher temperature, such as areas of extensive scarring, lipid pools where there is no cellular infiltration, or areas of hemorrhage and thrombosis which have yet to be coloni~d by infl- ~--.. l~ly cells.
SUMMARY OF THE INVENTION
The present invention o~,~;rco",es at least some of the failures of the prior art by providing an infrared-sensing catheter for dçtecting heat-producing infl~ u~y cells and vessel wall cells, and thus predicting the behavior of injured blood vessels in medical patients. The catheters and m~tho-l~ of the present invention provide effective means for det~cting and treating atherosclerotic plaque which is capable of dirrt;lG-.~i .I;,~g between, among other pathologies, those plaques at risk of luyluLillg and occh~ling and those that are not presently at risk. The calllelGrs and methods of 2~ the present invention also provide effective means for idenLiryi"g specific arterial sites at risk for arterial ~ si~ after angioplasty or athe.e.;lol,-y, or which patients are at risk due to vasculopathy, or tissue rejection. The C,dtLe~l~ and m~hotl~ of the present invention also are capable of t;rÇe;elively idt;~lliryhlg patients who have arterial wall areas of 11n--~uq11y low ~ y~ u~e and which represent p-~iously nn~letect~l arterial at-risk areas-just as excess heat can identify regions at risk due to inflqmmqtion, sub-normal heat (areas cooler than the rest of a vessel) intlic~tes a lack of actively metabolizing healthy cells (since heat in the body results from actively metabolizing cells) . Non-cellular areas are typically regions of he",u, .I,age, tbrombosis, cholesterol pools, or calcium--a11 inflirqtf rs of high risk plaques. The invention's devices and methods achieve these ends by idt;~liryh,g and analyzing thermal discrepqn~ies in the wall le:lllyelalult: of blood vessels.
The invention in one regard relates to ~l~pa.~.Lus for analyzing optical radiation of a vessel.
In another regard, the invention relates to methods for analyzing optical radiation, which methods are best prt:~elably achieved using the al~paldLuS of the invention.
Optical radiation of particular interest in the invention is that radiation which falls in the S optical ~ ull~ in the wavelength interval from about 2-14 ~m. An d1L.à.,Live feature of infrared is its peu. ~ ion through calcium (relative to white light and ultrasound). Benaron, et al., J Clin Monit 11:109-117 (199~).
The vessels of particular interest in the invention are those vessels where the access to a surface of which is problematic. Thus, where the internal ~ mPt~-r of a vessel is too small for ready access by a trarlition~l temperature probe ~i.e., a contact thermometer or t'nermocouple), the a~)~aldt.US and mP~thods of the invention will find utility. Similarly where the vessel, while of sl~fflriently large internal ~ mPtPr for access by a I~ aLule probe, has one or others of its openings naLrowed, occluded or otherwise blocked, the a~dldlus and methods of the invention will f~d utility. Thus, of particular interest in application of the a~)paldtUS and methods of the invention are vessels of the body, including vessels circulating and transporting sera (i.e. blood) such as arteries, veins, sinuses, heart cavities and chambers.
The invention relates to a~p~dlUs and methods in which there is at least one optical fiber used which is capable of l~ ".ill ;l~ optical radiation from a distal end of the fiber, usually inside a vessel, to a p.~,.i--.al end of the fiber, usually outside the vessel. Optical fibers of the invention wili exhibit certain key pal~l~et~ related to their ability to llansl--il wavelengths in the region of 2-14 ~m. These key parameters include optical lral~ar~l~y, flexibility and strength. The optical fibers of the hl~e.llio.l are those which may be extruded in ultrathin di:~mPtPrs and which Llal~u,il over the a~p.ol).idle infra-red spectral region. The infrared fiberoptic can be constructed from a variety of ~ .sl~ ., known to those of skill in the art such as ;circol3illlll fluoride (ZrF4), silica, 2~ or chalcogenide (AsSeTe). ZrF4 fibers are well suited to the apl)a~alus and mPtho-~ of the invention because such fibers have >90% l-"~ ion capabilities over 1 meter for small mPSerS.
The optical fibers useful in the a~alàlu~ and methods of the invention will also be ones capable of pl~i-emPnt proximate to a locus of a wall of the vessel being invectig~t~d This criterion ~0 is achieved in part by the flexibility of the fiber optic. In additional part, this criterion is met by the Ullldt~ nature of the .li ~ . of tbe fiber optic.
The ~a alu~ and mPtho-1s of the invention also utilize a balloon which encases a distal end of the fiber. The balloon, in one embodiment, may be one which is transparent to the optical radiation of interest. In that in~t~n~e, optical radiation ori~in~ting outside the balloon is ~
through the outer surface of the balloon to the inner surface of the balloon and on to the entry point WO 97/10748 PCT~US96/15217 for optical radiation into the optical fiber. It is hnpolL~lL~ in this emborlimPnt, for tbere to be little if any absorption, reflection or other diversion of the optical radiation ~~ g from the source (i.e., the vessel wall, a locus such as a plaque locus) during its Ll~ iQI~ through the surfaces of the balloon. Such ull~.al~ed absorption may be caused by blood or other body fluids.
Therefore, Llal~yale~ for l,u,L,oscs of the ill~e.llioll means an ability to Llal~lllil ~ui~Lal~Lially all optical radiation from a particular source through the balloon surfaces to the optical fiber.
It is important, in this embodiment, for there to be ~I,sl~u1;~11y total conduction of the heat, while having s~,bsl nl~ lly no loss of the heat e~ ; llg from the source (i.e., the vessel wall, a locus such as a plaque IOCUS) as it contacts the outer surface of the balloon. Therefore, opacity (opaque) for purposes of the invention means an ability to absorb ~ubsl~lially all optical radiation from a particular source on the outer balloon surface. Thereafter, the inner surface of the balloon will re-emit a propo.Lional amount of radiation to that absorbed on the outer surface imm~i:ltPly adjacentthelocusol;gi.,-~i..gtheradiation. Thisre-emittedradiationwillbedetectablebythefiber optic system encased inside the balloon.
The ~pdlalu~ and mPtho-l~ of the invention also utilize a detector capable of detecting a difference in the optical radiation of interest, between the locus and the average optical radiation along the vessel wall being inve~tig?~P~1 In certain preferred embodiments, the detector of the invention is one which has a sensitivity capable of detection of differences in infra-red radiation as small as 50 ~mK, and in the range of lO to lO0 ~mK.
Where the balloon is one which is Llal~Jalc;llL to the radiation directly emitted from the locus or from the vessel wall po-lious outside the specific locus, the detector will be one capable of cletecting the radiation which is ~ d through the balloon's outer and inner surfaces.
Where the balloon is one which is opaque to the radiation directly emitted from the locus or from the vessel wall portions outside the specific locus, the detector will be one capable of cletecting the radiation which is re-emitted from the balloon's inner surface opposite the balloon's outer surface which is directly in contact with the locus.
In p-~re--ed embo~1imPnt~ the alJ~ald~Us and methods of the invention will rely on detection of optical ladia~ion in the infra-red radiation ranges. In particular, as noted above, ranges of 2-14 micru,l.~ are of particular interest in the ..~)p~alus and mPt~o-l~ of the invention. Referring to Figure 2, it can be seen that it is possible to plot curves for radiation (-lulllbel~ of photons x l x 10l7~ being emitted by black bodies held at differing con~ temperatures ~T~, T2 and T3 each refer to temperatures in the range of 300-310 ~K which vary from one another increasingly by l ~K) in ~e wavelength range of 3 up to 6 micrometers. It can also be seen in ~e inset to Fig. 2, that in the range of ay~ ly 5.3 to 5.6 micfol..~;~e.;" black bodies held at co~
lell.~ el~lul~,s in the range of 300-310 ~K and dirr~ g from one another by only a single degree, appear as easily ~lietin~-ieh~71e curve segm~nt~> emitting photons from these black bodies in the range of appro~Yim~fely 0.21 x 10'7 to 0.40 x 10l7 photons. Thus, it is preferred to select a wavelength for s~mplin~ the r~ tion from the wall and specific locus on the wall of a vessel which will provide similarly fiietin~-i~h~llle curves.
In certain pr~e.rcd embodimPnt~, the ~alatus and methof~e of the invention may comprise at least two fibers, alllllJU~ the use of greater than two fibers is clearly possible where merited, such as when detection along the axis of the vessel is p.t:Çelled at greater than a single position ~imlllt~n~ously. In other preferred embo~lim~ntc~ where at least two fibers are utilized, at least one of the fibers is a reference fiber and another of the fibers is a signal fiber. The signal fiber is a fiber d~-ei~n~d to transmit all optical radiation focused into its length from its distal end to its proximal end. Conversely, the r~l~r~.~ce fiber is a fiber which is used as a control against which the signal fiber L~ ions may be co,l,p,ifed. Thus, where optical radiation exiting the pro~Lill,al end of the signal fiber is colll~aL~d to that exiting the p~ illlal end of the fcrel~nce fiber, a d~ ;on can be readily made as to relative a~ ull~ of optical radiation exiting the signal fiber which is due to other than optical radiation emitted by the locus of interest.
The a~ ,aidtus of the invention may also be optically connect~d at the distal end of the signal fiber to an optically reflective surface capable of directing optical radiation arising radially to said distal end, and on into said flber. U.S. Patent Application No. 08/434,477 in which certain of the present i~ ol~ are named co-illvellLol~, and which is incorporated herein by lt;r~nce, describes such an optically reflective surface. As opposed to the signai fiber, the r~relcllce fiber will typically be coated on its distal end with a material that ;~ 5~ y plC~V~;llL:i optical radiation from~ E it.
The a~pald~Us of the invention is also one in which the inner surface of the opaque ocrlu~1ing balloon emits a black body spectrum modulated by the tr~n~mi~sion spectrum of the balloon. The balloon, upon infl~fion, will s~b~ ly limit flow of fluids within the vessel. The flow limif~firtn n~luil~l iS one in which only so much flow occurs as will not cause a rise or fall in average ba~ ulld IR radiation along the vessel wall imm~ f~ly distal the inflated balloon.
In ~-lition in ~ ,relied embo~lin~Pn~, fhe a~ala~us of the invention is one where the balloon, upon infl~fion, substantially eYrh~d~Ps the presence of i~ l vesicular fluids between the fibers inside the balloon and the wall of the vessel most pl~ llale to the test locus.
In use, the alJpàLdus of the invention will be placed along an axis of the vessel. in this manner, it will be possible to bring the ~ii~nostic fiber array into close pru~ y with âlOcus to be tli~gl~ose~l In certain pl~rt;lled embo~limPnf~, the locus will be one which contains plaque. In particular, the a~aLalus as previously noted will be useful in ~leteeting among those plaques with which it is brought into pru~inlily, whether a given plaque is one at risk of rupluring. In most W O 97/10748 PCT~US96/15217 in~t~n~.c, the dp~ aLuS of the invention will be used to ~ nose thermal disc~ cies on the interior wall of a vessel.
The a~pa,d~us of the invention is in its most plert;LL~d embodiments a catheter. Typical of catheters used inside of blood vessels, the catheter of the invention will be one ~lesign~d for use with a guidewire. The guidewire will allow optional removal and lei-.seLLioll at the discretion of the surgeon, for example where after ~ g~G~ g a plaque at risk of rupturing using the catheter of the invention, the surgeon may wish to bring another flia~osti~ device or a Ll.~aL,eulic device such as â laser into the same position next to the problematic plaque.
The ~)I)drd~U~7 of the invention is also one where the detector is pl~f~,lal~ly optically co~ ed to a pLOAilllal end of the fiber, and if there is more than one fiber, to a proAi".al end of each of the fibers. In pl~Çelled embo(1imPnt~, ~e detector will be a multi-wavelength radiometer.
Such a radiometer will p~ al)ly be a spinning circular variable filter whose IL~ C~iC~iQn wavelength is a function of its angle of rotation. In such a filter, it is possib1e to prevent ~L ~ iC;.il~n of all but a narrow band of wavelengths of light by adjusting the rotational angle.
1~ Sâid differently, such a filter can be made to be Lial,~L,al~"l to highly selected wavelengths by its rotational Ch~a~ Lics. Thus, in certain embo(lim~m~, the filter will be one ll~l~a el~L to radiation with a wavelength of a~)lJroAillla~ely between 2 to 6 micrometers. In highly preferred embo~im~nt~thefllterwillbel~ aLellltor~ ionwithawavelengthofay~ y3miclolllel~
One of the keys to this invention as it relates to the ~i)a,alu~, is that it au~ aLically provides a rt;l~rence for each s~e~ ulll by s~mrling apl)roxi.. ~1ely 3 ,um. For the range of Lenly~làlures t,.yecled in biological Olgalli~ll~, 300-310 ~K, the blackbody spectrum at this waYelength iS ~ enti~lly the satne. This provides a zero for each signal and locks down the low wavelength side of the signal. Without this, there would be no way to flt a signal to a blackbody s~e~ ulll since the vertical scale would be "unfixed".
Where the al)paldlus of the invention utili_es the IIA ~ i h~""~.lion from more than one fiber ~rough a filter for colllyald~i~e pu~yoses~ it will be ~,~re..~d to utili_e an offset in the distal ffber ends. Thus, where the distal ends of the signal fiber and the reference ftber are offset from one another, the offset will be at a distance sllfflri~nt to allow sampling of radiation emitted from either fiber to pass the filter at a s~lbst~r~ti~lly i-l~nti~ l location on the filter.
The a~pa,d~us of the i,-ve"lion when used in conjull~lion with a radiometer, will p.crtLdl)ly be one optically CO'"~f .,~ed to at least one photoelectric device capable of converting the tr~mmitte i radiation into an electtical signal. The photoelectric device is plere,ably one electri~ ly connected to a device capable of digiti7ing the electrical signal (a digitizer).
Once the ay~ald~US of the invention has created a ~ligiti7ed signal, the digiti7ed signal is m ~hem~icsllly fitted to a curve selected from a spectrum of curves for black bodies held at temr~ , between a~ c;ly 300-310~ K. The curves of the contro}led black bodies are those plotted as llul"l,e~i, of photons emitted from each black body for each wavelengths. In ...,i where such a ~ligiti~ed signal is to be used to ~liagn(!se thermal discrep~nciPs in the interior wall of a blood vessel, the particular selection of black body control curves will be made with the knowledge of typical ttilllpt;l-l~U-~ of the human body.
Thus, in a p-~r~lled embodiment, tbe dppa alui~7 of the invention will be a catheter for analyzing infra-red radiation of a blood vessel. Such a ~ r~ L. ed device will C~lu~ e at least two fibers capable of ll ~~ the radiation and capable of pl~rPmPnt along an axis of the vessel pl~,~hllale to a plaque-co.~ locus of an interior wall of the vessel. At leas~ one of the fibers will be a reference fiber coated on its distal end with a material that i7uh'~ y prevents optical radiation from entering it, and at least one of the other of the fibers will be a signal fiber whose distal end is optically connected to an optically reflective surface capable of directing optical radiation arising radially to its distal end into and along its shaft. Such a pr~rt;l I ~d device will also have a balloon ~ the distal ends of each of the fibers, which balloon upon inflation will 1~ 7~lbs~ ;Ally limit the flow of fluids within the blood vessel. In addition, the balloon will ~.~I,s~ lly exclude fluids between the fibers and the wall of the vessel most pl~JAilllaLe to the locus to be tested. The balloon will be l,a,.s~art;-,t to or opaque to the radiation arising inside the vessel and will have an inner surface exhibiting spatially constant optical radiation emissivity. This inner surface of the opaque balloon will be one which emits a black body spectrum. The catheter will be one having a guidewire. It will also have a detector, optically connected to a proximal end of each of the fibers, and capable of detecting a dir~-el ce in the radiation between the locus and average optical .adidtioll along the wall of the vessel. The detector will further comprise a multi-wavelength radi- : with a spinning circular variable filter, the filter being such that its n;~ ;on wavelength is a fi-n~tion of its angle of rotation. The distal ends of the fibers will be offset from one another a distance sufficient to allow sampling of radiation emitted from either fiber to pass the filter at a s~bst~nti~lly identic~l position on the filter. Further, the radiometer will be optically conl-~ ed to at least one photoelectric device capable of converting the Ll.~ ~l and iiltered radiation into an electrical signal, which signal is capable of being l~igiti7Pd, and which digi~i7ed signal is ".~ lly fitted to a curve selected from a spectrum of curves for black bodies held at tempc.~-Lurcs between dp~ro,~ ,dtely 300-310Q K, where ~e curves are plotted as .Ul~C.i, of photons emitted from each of the black bodies for each of the wa~ ,g~
The invention also relates to an analytical method, suitable in certain embodiments for nosing medical conditions. Thus, the invention relates to a method for analyzing optical ~adidlioll of a locus in a vessel wall. The method of the invention con.~ ~s placing at least one 3~ optical fiber capable of L~ ; radiation proximate to the locus. In p~re,1~;d embo~lim~nti, W O 97/10748 PCT~US96/15217 the pl~c~mPnt of the fiber and balloon is accomplished by catheterization. Either prior to or after pl:~emPnt p,~o~il.ldle to the locus to be analyzed, a balloon ~n~ ing a distal end of the fiber is inflated within the vessel to cause the balloon to limit flow of fluids within the vessel. As previously detailed, the balloon is L~ ,a~ to or opaque to the thermal radiation and has an inner S surface ~AhibiLil-g spatially CO~ optical radiation emissivity. The mP~o~s of the invention further call for ~ li..g the radiation along the fiber to a detector capable of detectin~ a difference in the radiation between the locus and the average optical radiation along the vessel wall.
More specifically, the h.~/e lli.Jn relates to a method of det~ctin plaque at risk of lu~ulhlg along a blood vessel. This p-~,R.r~ method COIl~ ,~, inserting a guidewire into the blood vessel to be di~gnosed and then catheterizing the vessel along the guidewire with at least two fibers capable of l~ h~g infra-red radiation along an axis of the vessel plo)ici"~ale to a plaque-ccll~ainillg locus of an interior wall of the vessel. Thereafter, the steps of the method of the invention is carried out as described above.
The invention also relates to a method of surgically treating a patient with a plurality of plaque loci within a vessel. Such a method co~"~ es de~e""i~ g which one or more of the plurality of plaque loci has a l~.llpC,~Ule elevated above that of the average vessel wall temperature. Once such a dt,lt;""i"dion is made, the surgeon removes or reduces the plaque loci found to have an elevated temperature. This method has as its determin~tion step the methods described above for analyzing optical radiation of plaque locus in a vessel wall. Once plaque at risk is i~ntifieA, a number of therapies may be used to reduce the risk.
Accordingly, it is an object of the present invention to identify patients who have COIondl~y atherosclerotic plaque at risk of rupture by ide~lliryillg the specific plaque(s) at risk. Another object of the present invention is to identify patients at risk for arterial restenosis after angioplasty or ~ ' e,~u",y by idc.kiryh~g the specific arterial site(s) at risk. A further object of the present invention is to identify patients at risk of tr~n~pl~nt vasculopathy. Another object is to identify patients at risk for stroke, loss of mobility, and other illn~Ps by identifying sites of potential plaque rupture in the carotid arteries, the i"~,ace,eblal arteries, the aorta, and the iliac and femoral arteries. Another object of the present invention is to identify patients who have arterial areas of lower rather than higher temperature, such as an area of extensive scarring, a lipid pool with no cellular infiltration, or an area of hh~ l.~e and thrombosis which has yet to be colonized by ;..n~ ,t ,. ~ cells. The ~lelinp ~ion of a cholesterol pool is useful in following the regression of plaques. Idell~iryillg such areas for follow-up study will localize those likely to be infl~mp~d in the future.
Yet another object of the present invention is to deliver specific local therapy to the injured areas i~lPntifiP~ by the catheter. These therapies include, but are not limited to, therapies which W O 97/10748 PCT~US96/15217 prevent or limit infl~lTnm~tiQn (~ ui~ tt~hmPnt activation, and proliferation of inflz..,...!~'ofy cells), smooth muscle cell prolile.d~ioll, or endothelial cell infection, including antibodies~ ro~ g growth factor-~ (TGF-,~)~ nitric oxide (NO), NO synthase, glucocorticoids, u~ r~r~ll gamma, and heparan and heparin sulfate proteoglycans, and the various comple-l,e"L
DNAs that encode them.
The il~v~ ion's mPth()fl~ and devices will have a number of utilities. Each will reduce morbidity and mortality from ~.vnaly and carotid artery atherosclerosis. Each will reduce the in~i~ence of restenosis and thus the need for ~ ed~ed angioplasties or athtrt;.,k)lllies Each will also reduce the inri(lRnce of vasculopathy in organ-tr~n~pl~nt patients. In turn, these outcomes will produce the benefits of better health care, improved public health, and reduced health care costs.
These and other uses of the present invention will become clearer with the detailed description to follow.
~RIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a srhP,m~tic represRnt~tion of the dpp~alus of the present invention with its infra-red detection unit at its pro~ al end and the sensor tipped distal end of the catheter as well as the guide wire disposed within a flexible outer catheter (not shown) which ~u-- ~unds the optical fibers.
Figure 2 is a black body curve sl,e.;~lunl for temperatures T1, T2, and T3 (differing sP~ Pnti~lly by a single degree Kelvin) plotted as emitted radiation in photons (xlE17) versus wavelength (micrometers).
Figure 3 is a length-wise cross serti-)n~l view of the catheter tip of Figure 1 in place within a blood vessel near a plaque at risk of rupture.
Figure 4(a) is a graph depicting surface temperature of living carotid artery plaque in relation to cell density. Relative cell density equals the ratio of cell density in the area of interest to that of the bacLg~u..d area. Tt:~-yeLaLure me~..-~ ~--e -l~ were made at room temperature (20~C) on 24 samples from 22 patients 10-15 minutes after removal. Point >(O~C difference in l~---L,e a~ure) represents 27 observations.
Figure 4(b) shows the correlation between living human carotid plaque temperature and cell density when l--~.l-~ed in a 37 ~C chamber.
Figure 5 is a graph depicting plaque surface temperature as a function of cap thiclrn~c~.
Samples that had a non-infl~rnPd fibrous cap were subjected to pl~nimP~ry to measure distance from the 5umen to the center of the underlying cell cluster.
_ W O 97/10748 PCT~US96/15217 Figure 6 shows the correlation between thermistor and IR camera mea7ulcllle~ 7 in living human carotid plaque specimens (freshly excised, in a 37 ~C chamber) where r--0.9885 and p=
0.0001.
Figure 7 shows the coll~-,ldLioll of IR radiation with cell density in the specimens described in Fig. 6, above.
DESCRIPI'ION OF PREFERRED EMBODIMENTS
The ~thPt~r ~.~ ~d:ment Referring now to the figures, F~g. 1 shows a plt;r~ d embodiment of the ~pàraluS of the invention in use. A catheter ai)pa.dLus 10 is shown, which can be placed inside an artery (not shown) having with an interior arterial wall ~not shown) which possesses a plurality of plaque loci (not shown). The risk of rupture of either of the plaque loci is unknown until the methods and a~Jpalalus of the invention are applied.
Guidewire 20 has been surgically inserted into the artery and can be seen to extend both pro"imally 22 and distally 24. Guidewire 2Q can also be seen to proceed through catheter a~J~alaLu~7 10. Guidewire 20 is used to guide the pl~ om~nt of catheter al)~ala~us 10 to the area of the artery which contains plaque loci.
Catheter a~paldLus 10 Coll~ s at its distal end (the end farthest from the detector~ an inflatable balloon 40, a signal fiber 50, and a reference fiber 60. Inflatable balloon 40 is shown in its inflated state, which would cause it to rest firmly against an interior wall of an artery and against plaque loci. Depending upon the natural direction of blood flow within the artery, infl~tion of balloon 40 would sllb~t~nti~lly limit flow of blood either at position 32 or 34 or any of the similar points around the p~;~h~ e~ of the generally circular series of contact points between the balloon wall 42 and an interior artery wall, allowing n~ear,~ ,e~, being conducted by catheter apparatus 10 to proceed without i-ll~r~l~llce.
Balloon 40 coll,~,i,es a wall 42 which is made of an elastic material. The perimeters of balloon 40 are such that inflation causes sealing or closure of the balloon 40 at points along the arterial wall. When defl~t~A> balloon 40 retreats from its contact of the arterial wall, allowing reestablichmPnt of natural blood flow within the artery, and allowing facile movement of catheter a~aldtllS 10 in the artery to a next position, for instance to a position at which catheter apparatus 10 may be used to measure radiation emitted from another plaque locus. Activation of infl~tion/deflation of balloon 40 may be accomplished in any of a nurnber of ways known well to those of skill in the art of building angioplasty or embolectomy ç~the5er~ or balloon-tipped c~'~h~t~,r,~, The purpose of balloon 40 is to avoid problems associated with absorption of infra-red radiation by water between the source of infra-red radiation being med~ult;d and the distal catheter portion. Upon infl~tion and contact of the artery wall, the balloon wall 42 ~.. PS the lel"pe~ ule of the portions of the artery with which it is most p,~ The void area 46 excludes all water between the balloon wall interior and the distal signal fiber tip S6.
Signal fiber ~0 has a tr~n~ nt tip region S2 and an opaque body region 54 which is capable or incapable, respectively, of l-n~ ;u~ infra-red radiation efficiently. Opaque body region S4 may be a region in which signal fiber 50 is covered over by a rl~ 1ing or sleeve 56 which causes the region to become opaque and inrar~ e of efflciently t.~ ii.g or absorbing infra-red radiation. Tr~n~ cPnt region 52 may simply be an area in which signal fiber 50 is exposed. Signal fiber 50 is an optical fiber which can efficiently l,a,l;,lllit infra-red radiation. In order to collect such radiation from the surrounding milieu, signal fiber S0 may be fitted or otherwise used at its distal end with a collecting device 58 which focuses the infra-red r;ldi;ltion of the .,ulruulldillg milieu into the fiber for subsequent ~ sulission.
Unlike signal fiber 50, reference fiber 60 has no translucent region. Rather, reference fiber 60 has an opaque end C2 and an opaque region 64, both of which are incapable of ~ ;.lg infra-red radiation efflciently. As with the signal fiber 50, reference fiber 60, opaque region 64 may be a region in which r~r~-ellce fiber C0 is covered over by a c~ ing or sleeve 66 which causes the region to become opaque and incapable of effic;~ntly tran~mitting or absorbing infra-red r~fli~ti--n Opaque end 62 may be an area in which ~el~l~nce fiber 60 is coated with an infra-red reflective coating such as polished silver or alul..;.--~... In all other regards, r~r~ iellce fiber 60 is idl~ntic~l to signal fiber 50 in its ability to f~lnction as an optical fiber which can çfflcipntly lla~ lliL
infra-red radiation. It may be used, therefore, to set a baseline in order to compensate for any t~ .a~ule profile along signal fiber 50 from its distal to its prt~ lal end. As shown in Flg. 1, ,t;rele,lce fiber C0 is offset from signal fiber 50 in the proximal direction. This offset ~which can be equally well ~ccompli~hf~ by offsçtting distally) physically introduces a time delay between the radiation received and l,D .~ d by each fiber. As will be fli~cnc~ed immf~ t~ly below, this time delay is introduced in order to ensure that the signal and reference beams issuing from the pLox.i ends of each fiber strike the filter on the same spatial portion. By doing so, it is possible to rlimin~t~ ~lignm~nt problems or bandpass ~ imil~rites arising from a multi-filter system.
When in operation, the fiber-balloon array 70 collects therînal radiation which is ~,~ . .~, . .i proximally through signal fiber 50 and ler~rence fiber 60. Both fibers are positioneci to L~
through spinning ,~ if).~ er 80 at i-lçntir~l radial position 82 to impinge on ~ ;ti7~rs 92 or 90, respectively. Once a digiti7f~ signal is g~ 1 from each of the optical fiber ~ s;on~, the bac~ ulld signal created by the ~t:r~,ellce fiber 60 is subtracted by cc)~ u~ef 94 from the digiti7p~d s~gn~ t~ ed by the signal fiber 50. The resulting adjusted signal is m~thpm~ltir~lly fitted by CO~ )ulei 94 to a spe ~ of blaclc body curves 96 in order to ascertain the temperature of the particular locus.
Cnt~ ~' C~ .
Several options for materials for the other various con~one"L~ of the catheter devices described herein exist. The key parameters for the optical components are optical llal-i7~.,.1C~, flexibility and strength. Materials such as high strength polyester and polyethylene terephth ~late (PET) are very clear and easily extruded in ultrathin wall sizes. A high strength braided polyester is useful for ~ twisting motions over long rli~t~nr~Ps as may be required in certain emb~flimPnt~. Spacers/bearings can be made from Teflon~. The overall flexibility of the catheter will be appl~ Ply the same as similar-sized cardiovascular laser, fiberoptic, angioplasty and athere.ilu...;,il.g cathP~tp-r~. These devices should therefore be deliverable to small tli meter coronary arteries. A detector will be positioned at the proximal end of the catheter (outside the patient) utilizing InSb or, alternatively, ~IgCdTe, TeO2 or TAS detection systems.
The elongated flexible fiberoptic element will be connected at one end to an optical con.~ or through a ptol~,livt~ sheath. The optical connector is a standard item adapted to be slidably inserted into a thermal detector, and will include a plurality of openings in one side through which fluids or gases, int.h~-1;..g air, can be introduced into the catheter and emitted the.erlu---. The co ~ :,r will also include a coupling element for co~-~-e~li.. g to a plès~ult;
tr~n~lucPr to measure pl~;,.-le, there being an opening in the connector comm~lnirating with the coupling element and the pl'cssule lumen of the catheter. The coupling element may also be cullllel_led to a syringe to take a blood sample or to use a saline solution to flush the catheter.
The materials of which catheters are con~Llu.led may be any of those commonly used, inrh~-ling flexible plastics such as nylon, TeflonTM, vinyls such as polyvinyl chloride, polyurethane, and polyethylene, or various rubber compounds. Typically, the catheter will typically be 5 to 40 inches long and have an outer ~ m~t~Pr of about 1 to 2 millinA~ptprs~ The lumen inside the catheter can vary but typically will be about one half to 1 millimPter in ~ mPtçr.
The ",i..i...."" detectible heat dirrelelllial using the devices and materials of the present invention will be about 0.1 ~C. While the devices of the invention will be capable of finer thermal dis~ iol- biological variables are apt to introduce noise into the system. In most in~t~n.~ec, plaques which are in danger of rupturing will vary from those less at risk by at least 1.5~C.
CA Ot23l425 lsss-03-os Wo 97/10748 PCT/USg6/15217 At-Risk Pla~ue Generally then, as an overview of the device and method of the invention in Fig. 3, the infrared-sensing catheter 100 has identifiçd an ulcerated atherosclerotic p1aque 102 which is ac~~ ied by platelet ag2;-~alion 103 and vasoconstriction 104. Because of the presence of S ;.. rl "",~ cells 105 in this plaque 102, its temperature is higher than that of the immeAi~t~ly - ~c~nt vessel 107, and this change is sensed by tbe catheter 100. Some endothelial cells 108 have been lost (as a result of S~ ~P~f-~ e, infl~mm~ti~n, infarction, toxins, or balloon injury) causing platelets 109 to become aclivd~ed and to adhere to the damaged vessel wall 110. The activated platelets 109 release ~ that cause vasoconstriction, platelet ~g~sl~alion, and growth of smooth muscle cells; these mediators include ADP, se~ul(~llirl, thromboxane A2, platelet-derived growth factor, t~dnsrol-llillg growth factor-P., and PF4. The exposure of subendothelial collagen 111 and lipid 112 and the activation of platelets L/lvlllol~ el~yll~dlic activation of coagulation enzymes, which result in the rele~e of plasma mitogens and the activation of thrombin, an enzyme which cleaves fibrinogen to form fibrin. The c~lmin~tion of this process may be complete occlusion of the artery and consequent injury to the heart (or brain, in the case of a carotid, ve.t~.dl or cerebral artery).
Also shown is a monocyte 114, which has attached itself to adhesion molecules on the surface of activated endothelial cells. The monocyte becomes a macrophage involved in uptake of mo~lifieA cholesterol and the release, as by-products, of mitogens and proteolytic e~yllles that may prolnoLe rupture.
FY~m~?le I:
M~ o.ls Fi*y carotid elldall~reclollly spcc;..-e~-s were studied in the living state a*er gross inspection by a pathologist. Visible thrombi, noted in about 30% of the specim~n~ were typically removed by gentle irrigation, suggesting that they were surgical artifacts. The in~lic~tiQns for surgery were generally a carotid stenosis and LI~Sic.lt i~chemic attack or stroke.
Twenty-four spccilllells ~rom 22 patients were ~Y~minerl at room temperature (20~ C).
Another 26 specimens from 26 patients were ~ A in a hnmitlified incubator at 37~ C.
Within 15 minutes after removal of a specim~n~ a Cole-Parmer model 8402-20 thellllistor with a 24-gauge needle tip (accuracy, 0.1~ C: time cQn~tant 0.15) was used to measure the ~ e,a~uit~ of tile luminal surface in 20 locations. Temperatures were reproducible (+0.1~ C), and most r~ e.nell~ were found to be within 0.2~ C of each other and thus were desi~n~te~l as the bac~ uld temperature.
W O 97/10748 PCT~US96/15217 In most plaques, several locations with higher temperature were all found. The~se locations and the bachg-ound temperatures were marked with indelible ink of varying colors (recorded, but not coded so as to indicate the temperature to the pathologist) and re-measured to assure reproducibility. Tissues were then fixed in 10% formalin and cut le~Lhwise, embedded to reveal the intima and media, processed for histology, and stained with ht;ll.dlu~ylin and eosin or Masson's trichrome, or imm--n~st~in~d for ",a~ l~ophages using the HAM-56 and KP-1 antibodies '~Dako) as previously de~scribed. Nilckari, et al., Circulation 92:1393-1398 (1995). The cap thi('lrnP~5 and the cell density in a 300 x 400-,um region beneath the dyed regions was measured using a M~lrint~h Centris 650 and NIH Image software (version 1.43), available on the Internet from the National Tn~ s of Health, T'~ethP,~s-~ Maryland.
Preliminary ~A~ illlellL~ were also pt;l~.llled with a Jet Propulsion Laboratory platinum silicide camera, which we further calibrated against a Mach 5 scanning infrared camera (Flexi-therm, Westbury, NY), - which in turn was calibrated against beakers of water at various temperatures from 0 to 100~ C with a near perfect correlation, y = .99x + .31, where x was the temperature n~easul~,d by Illel.;u,~ thellllo~ Lel . The camera had a thermal resolution of 0.10~ C
and a spatial resolution of 0.15 mm.
Results Plaques exhibited multiple regions in which surface tempe.dLules varied reproducibly by 0.2 to 0.3~ C (~ 1.0~ C), and 37% of the plaques had 1 to 5 s~lbst~nti~lly warmer (0.4 to 2.2~
C) regions per plaque. For in~t~n~e, in typical i..~ c~, regions 1 mm apart had a reproducible ~emp~alu~ lirr~ lellce of 0.6~ C. Although the lumenal surfaces of the plaques exhibited visible heterogeneity, dirr~,fcnces in te,,,perdLu,e were not ~palenl to the naked eye. These temperature dirr.,r-,nces correlated positively with the underlying density of cells (r = 0.68, p = 0.00~1) (Fig.
4A), most of which were UlollO~ e-~r cells with the morphologic characteristics and u~f.fea~liviLy (with HAM-56 and KP-1) of ma~ ")h~ges.
Several mitotic figures were noted. Some foam cells were noted, but regions preAo~ ly populated by foam cells were cooler (and had lower cell density) than regions with monom~cle:lr infiltrates. Many plaques contained a few Iymphocytes and mast cells.
Te",l)erdlule varied inversely with cap thickness (r = -0.38, p--0.0006) (Fig. 5). The best correlation (r = 0.74, p = 0.0009) was given by the theoretically expected e4u~.Lion ~T =
relative cell density . cap thi~n~. Cooler regions were non-cellular: fresh thromboses, h~...o~ ge, scar, f ~k~ m or regions of cholesterol pooling without infl~ illr,lllàLion.
The warmer regions were not visibly dirrert;lll on gross inspection, even though many of them had a su~,~.r,~ layer of infl~ cells, some of which had small agg.~;~ion~ of CA 0 2 2 3 1 4 2 S 1 9 9 8 - 0 3 - o s wo 97/10748 PCT/US96/1~217 platelets~ Other large areas were free of infl~.. ~lo. ~ cells but lacked endothelial cells. These had probably been denuded during surgery, since po~ e"~ studies usually show only focal dem~ tion unless there is thrombosis or inflamm~tiQn Van Damme, et al., Cardiovasc Pathol 3:9-~7 (1994)-A minority of plaques ~a~L~ ly 20%) exhibited no detectable thermal heterogeneity Regions of deep or superficial inflq~nn~atil~n in these spc~ ..e~ were not marked with dye, inr1ic~ting that the o~lyillg temperature had not been measured. In a few of the regions co,-lainil~g cellular il,r,l~ld ~ alul~ had been measured, and they were no warmer than less cellular ~dj~cent areas This finding was believed by the inventors to possibly reflect decreased metabolic activity in specimans that were kept at room temperature for a longer interval after removal.
Therefore, a second series of pla~ues was analyzed in a 37~ C incubator. These 26 specimens from 26 patients with a mean age of 68 (range, 50 to 86) revealed a considerably closer correlation with cell density (r = .68, p < 0.0001), more therrnal heterogeneity (93% of specimens~, and a wider range of temperatures, typically I to 3~ C; some specimens only 10 mm apart were characterized by temperature differences as great as 4 to 5~ C. See, Fig. 4B (points re~rese,-~ed by solid ~ tt~on~ls are the relative cell den~itiç~ divided by the cap thi~n~s~ squared;
linear regression of these points resulted in the solid line shown).
The inventors also studied several specimen~ using a pl~tinl~m silicide, cooled, infrared camera with a thermal r_solution of 0~1~ C and a spatial resolution of 0 1 mm~ This camera detectad thermal heterogeneity in ex vivo .cpec.tnan~ As shown in Fig. 6, the IR camera when used to identify thermally distinct plaque COilel~ d well with direct contact tht,~ o measur~ in freshly excised human carotid artery plaques specimens (r= 0.9885, p < 0.0001).
Fig. 7 shows that this correlation of the IR carnera "~ea~u,ed l~ IaluL~s was also observed with cell density med~ult;llle.l~ It is noted by the inventors that cooled staring array carneras have even better tbermal resolution, and spatial resolutions are as low as 10 ~m.
r~
Most human carotid athereclc,llly specimens contain foci of increased heat ~pa e.llly produced by underlying cells, most of which are lllacLopl~âges. When studied at 37~ C, the ternperature variation was greater than 20~ C, consislel.~ with reduced metabolic activity at 20~ C
that makes th~e plaques more homogeneous in temperature.
In the samples studied at body temperature, a thlormi~tor with a l-rnm tip was able to detect difr~e~ces as great as 4~ C within difr~ parts of the same plaque that were only 10 mm apart.
Temperatures were highest when the cells were closest to the probe (i.e., at or just beneath the CA 02231425 1998-03-og lumen itself). Most of the lumenal sur~aces of the plaques had several regions characterized by superficial infl~mm~tion and en-lothi~ 1 den~ Qn.
Only some areas of surface infl~mm~tion were associated with visible thrombosis; most were associated with mic~uscol,ic thrombosis (e.g., a few fibrin strands and ~tt~rhe1 platelets) or none at all. These results suggest that i-.we~sed plaque heat is an indicator of plaques that are den~ ed and infl~tned and con~e.l~,e~.lly at risk of thrombosis.
The hl~e.~ , also found a few hot regions associated with foci of infl~tnm~tion just beneath thin but intact caps. Since these pla~ues are believed to be at increased risk of rupture, it is believed by the inventors that m~suli--g plaque temperature in vivo could enable one to identify such plaques.
F~ d~ )le II:
Li~ t~ of the Study A potential co--~under i(l~ntifi~d by the inventors is plaque angiogenesis (neovascularization3. T~e inventors studied living plaques ex vivo. In vivo, the presence and tone of the vasae vasorum might influen~e the temperature. However, since plaque angiogenesis correlates with infl~.. lion~ (Nikkari, et al., Circulation 92:1393-1398 (199S) and both are considered risk factors for plaque rupture, it is likely that temperature will still be predictive in vivo.
The inventors also believe that one must consider that what is true for atherosclerotic plaque in the carotid arteries may not be true in other sites, for example, the COI~Jnaly arteries. The pathology of the plaque is sollle~lldl different in the two locations. (Van Danune, et al., Cardiovasc Pathol 3 :9-17 (1994)) and the ris~ factors are also different. Kannel, J Cardiovasc ~isk 1:333-339 (1994); Sharrett, et al., Arterioscler Ihromb 14:1098-1104 (1994).
F~amrl~
F'ul --1 of Sp~l,n~ ~p~, Tomography, and I~ .f~
Infrared specL-~oscuL~ could prove useful in several ways. Pirst, it should be able to corroborate the location of l-.acro~)hdg~s by the massive ~mf)l-nt~ of nitric oxide they produce, since nitric oxide has a Ch~delt~ liC near-infrared ~ue~llu,--. Ohdan, et al., ~ransplantation 57:1674-1677 (1994). Near-infrared imaging of cholesterol has already been de .lon~lld~ed~ Cassis, et al., Anal Chem 65:1247-1256 (1993). Second, since infrared and near-infrared wavelengths penetrate tissue more deeply as wavelength increases, longer wavelengths should reveal metabolic activity in deeper (0.1- to 1-mm) regions.
WO 97/10748 PCT~US96/~5217 This rh~nl~nlRnnn could be used to develop co~ uled infrared tomography, possibly in conjùn~,Lion with inl~r~,rulllctry, in which an incident beam is split by a moving mirror to produce a rerelt;,-ce beam and a beam that is variably scattered and absorbed by the tissue The nonsyncbronous reflected wavelengths are reco~ d to reveal sLLu~,lulal detail with 20-f~m resolution. Benaron, et al., Science 259: 1463-1466 (1993); Brezinski, et al., Circulation 92: 1 -149 (1995).
I~ample IV:
Non;.~ D~ ~f~ of Plaques at Risk Alleln~lliv~&, to infrared dete~ti(~n are also desirable since infrared abso,~lio", convection, and tissue emissivity differences are likely to preclude non-invasive infrared tomography. Such alLe~l~aLives include imaging the infl~mm~tnry cells with gallillm (P~,~e,h~,-;~, et al., Circulatton 91: 1444-1449 (1995)) l8FDG positron sc~nnin~, radiolabeled anti-macrophage antibody fr~mPn~c, or m~n~tic resonance (to take advantage of ~e ~ ;?t~ ul e-depP,n~lP-nce of proton-spin relaxation).
MacFall, et al., Int J Hyperthermia 11:73-86 (1995).
These te~hniqllRs lack s~lffi~ient spatial resolution for detçcting infl;.,.~ "1f"y foci beneath the surface of moving col.)na.y arteries (particularly ci-~iu"~llex and distal vessels) and carmot be used 'on line' to direct plaque-specific interventional therapies. However, the resolution in these techni~uç,c may be a~eq~3tP in tnick-walled, relatively stationary arteries such as the aorta, carotid 2() and femoral arteries. Toussaint, et la., Arterioscler Ihromb Vas Biol 15:1533-1542 (1995);
Skinner, et al., Nature M~ in~ 1:69 (1995). If lumenal infl~mm~ti-~n can be ~ l,ed from adv~-,lilial infl~lnm~ti~)n~ the latter may prove useful in predicting progression of aortic aneurysms.
F-a~ V:
Therapeutic ~
Lc.~eri-,g serum cholesterol COI~fe-11~ onC by means of diet or drugs can reduce mortality, perhaps because reverse cholesterol LldU~I~ulL reduces the size of the lipid core. However, the most convincing trial to date indi ~ only a 35% decrease in coronary mortality with cholesterol-lowering t'nerapy (and little benefit in women). Scandinavian Simv~tatin Survival Study Group, Lancet 344:1383-1389 (1994). This finding suggests that other factors, such as hRrn~st~tic v~ri~ble,~, are ~rre~ g mortality. However, even with the same patient, plaques progress or regress relatively independently. Gould, Circulation 90:1558-1571 (1~94). This variability suggests that lesion-specific variables (for example, stenosis length, surface thrombosis, low shear stress due to low or turbulent flow, and vasoconsl-i~;lion) increase the risk of thrombosis.
CA 02231425 lsss-03-os Wo 97/10748 PCT/US96/15217 derrn~n, et al., J Am CoU Cardiol 22:1141-1154 (1993); Nobuyoshi, et la., J Am Coll C~rdiol 18:904-910 (1991).
If hot plaques producing stçnos~ in the "non-critical"' range of 10% to 70% are shown to be at high risk of rupture, should they undergo angiopl~ty? If the risk of dilation is similar to that of more severe st~nose~ xi.. ~,ly 1 % mortality, 2 % aorto-corunaly bypass), what is the benefit of collv~,lLing an unstable lesion into one with a 70% chance of long-term patency and a 30% chance of ,~.,t~ -~osis? Even before the recent trials in~lic~tin~ that stents reduce ,~ ..osis rates to 10% to 20%, the large Emory follow-up in~lic~ed an i~entic~l 96% five-year survival rate in patients with and without l~n~ , despite the increased need for repeat angioplasty or bypass surgery in the former group. These data suggest that angioplasty could be bqn~ if the near-term risk of sudden (spontaneous) occlusion is only about 5%.
FY5~ ?1e VI:
Medical Therapies Medical therapies would depend, in part, on whether the infl~mm~ti-)n is on the surface or beneath an intact cap. This ~ n may one day be made by angioscopy (especially with the use of light e ..i~ antibod;es) or by s~mplin~ blood for soluble markers of infl~mmqtjon (P-selectin, VCAM-l, and others). Magn~tic resonance imaging, ultrasound, and near-infrared imaging may also prove helpful.
Therapies might include local delivery of agents (peptides, peptide mimçtiç~, oligonucleotides, and others) that prevent monocyte ~ ui~ ent, ~t~rhm~nt activation, or DNA
synthesis. Conversely, Collagen synthesis might be stim~l d with ascorbic acid or tl~ lllh~g growth factor ,~ (which also acts to inhibit angiogenesis, infl~.. ~l;on, and smooth muscle proliferation in most models, though it can also provoke infl~mm~ion in non-infl~rned tissue and delay endothelial regeneration). Nathan, et al., J Cell Bol 113:981-986 (1991). Endothelial regeneration can be ~nh~nred by basic or acidic fibroblast growth factor or by vascular endothelial growth factor, among others. C~c~cell~, Circulation 91:2699-2702 (1995).
In SU~ living human carotid atherosclerotic plaques exhibit thermal micro-het~,lug,~nt;ily attributable mainly to nla~ ages at or near the lumen. These regions of illclGdsed temperature can be i-1~ntifi~ by t~.c.,llisk~l~ and infrared thermography. If hot plaques are indeed at high risk of thrombosis (or restenosis (Gertz, et al., Circulation 92:1-293 (l99S); Moreno, et al., Circulation 92:1-161 ~1995)) or-in the case of adventitial infl~mm~tion~of ant;ul~ ,al rupture, it may be possible to develop catheter-based and noninvasive means of imaging and treating these potentially life-llllGa~nhlg lesions. These technûlogies might also be used to detect subepithelial W O 97J10748 PCT~US96/1~217 clusters of ;nn;~ n~l~, or m~ n~nt cells in other organs by m ~letic resonance imaging or by endoscopy, oph/~ ..oscopy, laparoscopy, artherusc~y, or transcranial imaging.
* * * * * * * *
The present invention has been described in terms of particular emboriimPnt~ found or proposed to conll)rise ~r~r~ modes for the practice of the invention. It will be appreciated by those of skill in the art that, in light of the present ~ los~re, nunlerolls mc clifirqfinns and changes can be made in the particular embo~im~nt~ e~YPrnriifi~l without departing ~om the intçnfled scope of the invention. For example, while the present invention has been supported by examples in ~e biomedical arts, the ~alus and methods of the invention may be equally well applied to the analysis of wall we~k..~es of any vessel so long as such we~knesses exhibit or can be made to exhibit ~lirre~ .lial heating. Thus, m~nm~-1e vessels such as conduit, if heated externally may be subjected to internal analysis using the a~ald~us and methods of the invention. All such mo~lifi~inns are intçn~ed to be in~luded within the scope of the appended claims.
CROS~REF FR~ cE; TO R13LATI~D APLICATION
The present application claims the benefit of 3~ U.S.C. lll(b) P~vvisional application Serial No. 60/004,061 filed S~lc~b6l 20, 1995, and entitled ~thet~.c and Meth(~ Detecting Thermal Discrep~nrie~ in Blood Vessels.
BACKGRC)UND OF T~ INVENTION
This invention was made with ~ ,vf..-...P!nt support under Grant No. 91HL07 awarded by the National Heart Lung and Blood Tnctitute, giving the federal government certain rights in the invention. In addition, the invention described herein was made in the pt;~ru-l~lance of work under a NASA contract and is subject to the provisions of Section 305 of the National Aeronautics and Space Act of 1958, Public Law 85-568 (72 Stat. 435; 42 U.S.C. 2457).
A. Field of the Invention This invention relates to the medical ~ii~nosic and treatment of arterial disease by means of temperature dirrel~nLial sçn.cin~, and particularly, infrared-sensing with devices such as temperature probes, cameras, and cd~ . In particular, the invention provides c~hetl~r,s and methods of using c~th~ters to ~1i~nr)se arterial diseases detectable by ther nal discle~,A~ s in the arterial wall.
B. Description of the ~elated Art Problems In Diagnosis Plaque Physiology Atherosclerotic colonal~ artery disease is the leading cause of death in imlll~tri~li7ed c~l-ntries An atherosclerotic plaque is a thi~ n-~d drea in the wall of an artery. Typically, patients who have died of cofonaly disease may exhibit as many as several dozen at-h-erosclerotic plaques; however, in most in.ctanr~c of myocardial infarction, cardiaG arrest, or stroke, it is found that only one of these potential obstructions has, in fact, ruptured, fissured, or ulcerated. The rupture, fissure, or ulcer causec a large lhlo~ s (blood clot) to form on the inside of the artery, which may completely occlude the flow of blood through the artery, thereby injuring the heart or brain. A major prognostic and ~ gm)5tic dilennm~ for the car~liolc~ist is how to predict which placque is about to rupture.
CA 0223l425 1998-03-09 W O 97/10748 PCTrUS96/15217 Most ~ uled plaques are characterized by a large pool of cholesterol or necrotic debris and a thin fibrous cap with a dense infiltration of macro~ ages. The release of matrix-digesting enzymes by the cells is thought to coullil)ul~ to plaque rupture. Other thromboses are found on non-l.-yluled but infl~nP~i plaque surfaces.
Tnfl~mm~tion in an arterial plaque is the result of a series of biorh~micz~l and m~h~nic~l changes in the arterial wall. Plague, a thirk~nir~ in the arterial vessel wall results from the ~cum~ fion of cholesterol, proliferation of smooth muscle cells, secretion of a collagenous extracellular matrix by the cells, and ar~J~ iorl of Illac~ ages and, eventually, hemorrhage (bleeding), thrombosis (clotting) and r~1cifir~fiQn The consensus theory is that atherosclerotic plaque develops as a result of irritation or biorh~nnic~l damage of the endothelial cells.
The endothelial cells which line the interior of the vessel prevent h~a~ iate formation of blood clots and inhibit conl.~.,lion and proliferation of the underlying smooth muscle cells. Most investigators believe that atherosclerotic plaques can develop when endothelial cells are damaged or dysfunctional. Dy~rullclion in enrlothe~ cells is typically produced as a result of injury by cigarette smoke, high serum cholesterol (especially oxidized low density lipopl~,lei~l), hemodynamic alterations (such as those found at vessel branch points), some viruses (herpes simplex, cytomegalovirus) or bacteria (e.g., Chlamydia), hypertension, some hormonal factors in the plasma (inrll.~ling angiotensisn II, norepinephrine), and other factors as yet unknown. As a result of these gradual injuries to the enr3othe~ cells, an atherosclerotic plaque may grow slowly over many years. However, it is now well do~ d that if a plaque l~ ules, it often grows abl.. l,~ly.
When plaque rupture develops, there is hemorrhage into the plaque through the fissure where the surface of the plaque meets the bloodstream. Blood co~ f~s (forms a lhIOIII~ S) quickly upon contact with the collagen and lipid of the plaque. This blood clot may fhen grow to completely occlude the vessel or it may remain only partially occlusive. In the latter case, the new clot quite commonly becomes incorporated into the wall of the plaque, creating a larger plaque.
Plaques At Risk of R~."t~.l ;..~
Considerable evidence indic~~c that plaque rupture triggers 60% to 70% of fatal myocardial il.r~-;~iOI~s and that monocyte~ ac~phage~ contribute to rupture by releasing metall<,~ro~ Q ~e.g., coll~ ses, stromelysin) which can degrade and thereby weaken the overly fibrous cap. Van der Wal, et al., Circulation 89:3644 (1994); Nikkari, et al., Circulat~on 92:1393-1398 (19g5); Falk, et al., Circulation 92:2033-20335 (1995); Shah, et al., Circulation244 (19gS); I~avies, et al., Br Heart J 53:363-373 (1985); Co~ , J Athero~cler Res 6:1-17 (1966). In another 25% to 30% of fatal infarctions, the plaque does not rupture, but beneath the lIJI~O~I)U~ the endothelium is replaced by monocytes and infl,~,.--.-~1O~y cells. Van der Wal, et al., W O 97/10748 PCT~US96/15217 Cireulation 89:36~4 (1994); Farb, et al., Circulation 92:1701-1709 (1995). These cells may both respond to and aggravate intimal injury, pro,lloli"g ~Illollll)osis and vasoconstriction. Baju, et al., Cireulation 89:503-505 (1994).
Ullro~Lul~alely~ neither plaque rupture nor plaque erosion is predicable by clinical means.
Soluble markers (P-selectin, von Willebrand factor, angiotensen-converting enzyme, C-reactive - protein, D-dimer; Ikeda, et al., Cireulation 92:1~i93-1696 (1995); Merlini, et al., Cireulation 90:61-8 (1994); Berk, et al., Am J Cardiol 65:168-172 (1990)) and ~ livaled circulating i,.n~.. ~l.. ,y cells are found in patients with unstable angina pectoris, but it is not yet known whether these s~bstAnr~oc predict infarction or death. M~7one, et al., Cireulation 88:358-363 (1993). It is known, however, that the presence of such sllhst~nces cannot be used to locate the involved lesion.
~ow-shear regions opposite flow dividers are more likely to develop atherosc1erosis, (Ku, et al., Arterioselerosis 5:292-302 (1985)), but most patients who deve}op acute myocardial infarction or sudden cardiac death have not had prior ~ylll~LonlS, much less an angiogram. Farb, et al., Cireulation 92: 1701-1709 (199S).
Certain angiographic data has revealed that an irregular plaque profile is a fairly specific, though in~c~n~citive~ indicator of thrombosis. Kaski, et al., Cireulation 92:2058-2065 (1995). These st~noses are likely to progress to complete occtusion, while less severe st.onoses are equally likely to progress, but less often to the point of complete occlusion. ~ n ~n, et al., J Am Coll Cardiol 22: 1141-1154 (1993). However, because hemodynAmi.~Ally non~i~nifi~Ant st~nosp-s more nu.~lt;.ou~
than critical sLenoses and have not triggered collateral development, those which do dbluplly occlude actually account for most myocardial infarctions. Ambrose, et al., J Am cOn Cardiol I2:56-62 (1988); Little, et al., Cireulation 78:1157-1166 (1988).
Moreover, in postmortem studies, most occlusive thrombi are found over a ~u~lured or ulcerated plaque that is e<~ .A~ed to have produced a stenosis of less than 50% in ~ , . Shah, et al., Cireulation 244 (1995). Such stennse~ are not likely to cause angina or a positive treadmill test. ~In fact, most patients who die of myocardial infarction do not have three-vessel disease or severe left ventricular dy~fi...~ lion ) Farb, et al., Cireulation 92: 1701-1709 (1995).
In the vast ~llajoliLy of plaques causing a stenosis less than or equal to 50%, the surface outline is llnifornl, but the deep sl-u-,lure is highly variable and does not correlate directly with either the size of the plaque or the severity of the stenosis. Pa~L~;kalllP, et al., Circulation 91:1~1'11 1449 (199~); Mann and Davies Cireulation 94:928-931 (1996~.
Certain studies have been con~ ted to d.3L~"..i-le the ability to identify plaques likely to rupture using i.,Llaco.ol~y ull-~o~l~d. It is known that (1) angiography under~ s the extent of COl~ uy atherosclerosis, (2) high echo~ensity usually in-1ic~t~s dense fibrous tissue, (3) low CA 02231425 l998-03-09 W O 97/10748 PCT~US96/15217 echo-density is a feature of helllor.llage, thrombosis, or cholesterol, and (4) shadowing inrlic~c ~:~lçifi-~tion Yock, etal., Cardio 11-14(1994); McPerhson, etal., NEnglJMed316:304-309 (1987). However, recent studies indicate that intra-vascular ultrasound technology currently cannot disc.i."il-dl~ between table and unstable plaque. De Feyter, et al., Circulanon 92:140.3-1413 (1995~.
The rupture process is not completely l-n~ rstood, but it is known that the plaques most likely to rupture are those that have both a thin collagen cap (fibrous scar) and a point of physical w. l-nP,s~ in the underlying plaque. It is known that plaques with infl -nPd surfaces or a high density of activated macfo~ ag~s and a thin uve-lyil-g cap are at risk of thrombosis. Van der Wa1, et al., Cir~ 7tron 89:3644 (1994); Shah, et al., Circulation 244 (1995); Davies, et al., Br Heart J 53:363-373 (1985); Farb, et al., Circulation 92:1701-1709 (199~;); Van Damme, et al., Cardiovasc Pathol 3:9-17 (1994). Such points are thought to be located (as determined by modeling studies and pathologic analysis) at junctures where pools of cholesterol meet a more cellular and fi1orous part of the plaque. Typically, macrophages (infl~ "~ cells)~ which produce heat, have been found at these junctures. Since these infl~ u.ly cells release enzymes capable of degrading the collagen and other components of the extr~r~ r matrix, it is thought that they are crucial to the process of plaque rupture or fissuring.
Tr~ V~r~-lo~
T.. n~ ;on also plays an i.. ~,o- I.a ~ role in the rejection of tr~nt~pl ~nted organs, a process which begins by an attack of host T Iymphocytes in the grafted donor organ's endothelial cells.
Yeung et al. J. Heart Lung Transplant. 14:S215-220 (1995); Pucci et al. J. Heart Transplant.
9:339-45 (1990); Crisp et al. J. HeartLung Transplant. 13:1381-1392(1994). Recruitment and prolir~;l on of i,.ni... .. ~0.~ and smooth muscle cells are heat gcn.~aLing processes, whose effects are dt;l~,L~le in advance of the detection of vessel nal.owil,g using stress tests, ultrasound, or angiography. Johnson et al. J. Am. cOn~ Cardiol. 17: 449-57 (191); St. Goar et al. Circulation 85:979- 987 (1992). In addition to the host attack of "non-self" antigens of the donor organs, many trqnspl~nted tissues develop cytomegalovirus i"r.~Lioll~., an event that is also heat-gene,aLi-,g.
Grattan et al. JAMA 261:3~61-3566 (1989). 'Ihese events in transplant physiology are ones for which it would be valuable to track in patients recovering from such surgery.
r~F't~tn~
Another serious problem in ~ gnostic cardiology is rf~st~nosi~, a rel~ owi.lg of an artery that has undergone one or more interventional te~hniqll~s to relieve an original stenosis (caused by 3~ plaque) . Such te~ hnique$ include balloon angioplasty, athe, e~;Lor"y (shaving or cutting the plaque), W O 97/10748 PCT~US96/15217 and laser angioplasty. Balloon ~lgiupl&sLy of the cO.Olld~ arteries is a major advance in lrec.~l..en~
and has been pel~ulllled on hemodynqtnir~lly ~5ignifir~lt colon~r stenoses (those that are 70% to g9% of the cross-section~ di ~ P- of the vessel) with a success rate of 90%. In about 40% of the patients, however, r~ .o~;~ occurs in the vessel and most of the benefit gained by the procedure is lost. Thus, another major tii~nostic and prognostic dilemma for cardiologists not readily addressed by prior art devices or mPtholl~ is predicting which patients will develop re~steno,Sic, }~Pstenr~s;~ may occur when the removal of plaque by angioplasty or atherectomy injures the artery wall. The injury to the vessel wall causes the smooth muscle cells at that site to proliferate and to secrete an r~rtrarr~ r matrix which again narrows the artery. Both cell proliferation and secretion are exergonic (heat-generating~ processes. Additionally, it is known that ,na.;luphage conce,l~,d~ion in a vessel is correlated to the risk of restenosis.Many factors have been reported to predict which patients will develop rest~nosi~.
However, these studies are markedly at odds with each other and no factor has been strongly predictive of the resten~ C process. Thus, cigarette smoking, hypertension, hypercholesterolemia, unstable angina, age, sex, and many other factors have been only weakly predictive, at best.
Prior Art Devices/Methods A number of a~l)roaches and devices have been proposed to ~ gnose or treat vascular obstructions. U.S. Patent No. 3,866,599 relates to a fiberoptic catheter for insertion into the cardiovascular system for the nledsulel"elll of oxygen in blood. For the purpose of detecting o,.yge~dtion levels in the blood, optical fibers are used to first project infra-red and red light at the catheter tip into the blood. The infra-red and red light reflected by the blood is then returned through the optical fibers to an o~hl-.t~.. The ratio of infra-red light reflected to that absorbed by the blood is piûpûllional to the oxygen saturation in the blood. This catheter design is also one wherein there is at the distal end of the element a recess preventing the ends of the fibers from CO,.~ g the vessel wall and an exterior sleeve which can be expanded to further space the fibers from the wall of the vessel. However, the fiberoptic catheter of this patent does not permit d~ ;lion of heat.
In some prior art devices, temperature sensing elements have been used. U.S. Patent No.
4,î52,141 relates to r~belu~lic sensing of ~ ,.dlul-~ and/or other physical p~aul~lt;l~ using a system c~ ing (1) an optical fiber (2) means ;~r~ i"$~ a source of visible or near visible cle~ Llu..~ tic radiation pulses at one end of the fiber for directing the radiation along the fiber to another end of the fiber (3) a sensor positioned at or near the end of the fiber in a manner to receive the r~r~ m, mS)ri~ te it by the telllpeldule, and redirect the modulated radiation back s CA 0223l425 l998-03-09 W O 97/10748 PCT~US96/15217 through the optical fiber to the sensor (4) the sensor colllp.isil.g at least one optical element in the path of the source of radiation whose optical properties vary in rt;sl?onse to the m~gnihl-le of temperature changes and (S) means positioned at the end of the fiber ~eceivillg the mo~ ted ladidlion for mea~ul h.g a filnrtion related to the time of the resulting IllminP-scçnt radiation i~ .Si~y S decay after an eY~it: ~ion pulse in-liç~ting the le ~ ,ralul,3 of the sensor. These l~lllp~.àlu~e sensors were dPcignP~l to physically contact a surface and were built with an elastomeric bul,.,l~lce at the end of the fiber to which a thin layer of phosphor material had been deposited. The phocrhor reacts to the lell~c~dtul~e and emits radiation which travels up the fiber and is detecte~l by the sensor. Contact lem~,.alu..z ~ ;OIl.c require the ability of the c~theter to be placed in contact with the locus whose I~ Jt;ldtul~ is to be l.. e~-,.. ied.
U.S. Patent No. 4,986,671 relates to a fiber optic probe with a single sensor formed by a elastomeric lens coated with a light reflective and temperature dependent material over which is coated a layer of material that is al~sc,ll,Live of infrared radiation thereby allowing a determination Of rh~a-~-i5~ics of heat or heat transfer. One application is in a catheter for providing pleS.7uie, flow and Lel-lpe.dture of the blood in a blood vessel.
Other methods utili7ing differing means for heat detection are known. The sensitivity and/or toxicity of these devices is unknown. U.S. Pat. No. 4,140,393 relates to the use of birefring~l.e.lL material as a temperature probe. U.S. Pat. No. 4,136,566 suggests the use of the Jeldtule dependent light absorption characteristics of gallium arsenide for a temperature sensor.
U.S. Pat. No. 4,179,927 relates to a gaseous material having a L~ e.àLuie dependent light absorption.
Other approaches utilize eYrit~tion tP~hniques to detect heat. U.S. Pat. No. 4,075,493 relates to the use of a IllminP-~cPnt material as a temperature sensor, exciting radiation of one wavelength range being passed along the optical fiber from the l..e~,u.;llg i,..,L-ul,.~.ll, and I~ .d~ure dependent lllminpscpnt radiation being emitt_d from the sensor back along the COI~ ..;f '~ optical fiber for detection and ~---,a;,urt;..le--L by the i"~,LIull.e..L. It is the lllminPscPnt sensor terhnology which has found the greatest collullercial applicability in fiber optic ,u~wl~el~l~" ~ lal ily for reasons of stability, wide temperature range, ability to minimi7e the effect of non~ e.d1ule light variations, small sensor size and the like.
An example of a lnminPcc~Pnt fiberoptic probe that c m be used to measure the velocity of fluid flow, among other related parameters, is given in U.S. Pat. No. 4,621,929. Infrared radiation is directed to the sensor along the optical fiber and is absorbed by a layer of material provided for that purpose. Once heated, tne sensor is then allowed to be cooled by a flow of fluid, such cooling being ll.~-,..red by the IllminP-sce~t sensor. The rate of cooling is proportional to the heat transfer chala~ ,lics and flow of the ~u~ ulldhlg liquid.
W O 97/10748 PCTrUS96/15217 U.S. Patent No. 4,995,398 relates to the use of thermography during the course of by-pass heart surgery for the purpose of checking the success of the operation before closing the chest cavity. This patent d~c~ s the use of a s~ ~ g thermal camera, image procP~ing, ~ el alule dirrert;llLidls and displaying images in real time. The invention relies on the use of a cold injectate which when it mixes with warmer blood provides images captured on a thermal camera focusing - on the heart to detect sten-)s~-~ at the sites of distal ~ u~ ses.
U.S. Patent No. 5,046,501 relates to a method of identifying atherosclerotic plaque versus structurally viable tissues using a fluore~ beam at a single eYcit~tion wavelength of between 350 and 390 mn p~e~dbly from a laser which allows dirrt;lel.lid~ion of these tissues. No catheter was used in the examples of the patent. Thus, in situ imaging is not disclosed or taught by this patent.
Moreover, no te~hnique is described by this patent for predicting plaque rupture, r~t~no~i~ or tr~nsrl~nt vasculopathy.
U.S. Patent No. 5,057,105 relates to a hot tip catheter assembly comprising a heater, a cap, a thermocouple, power leads, and a central distal lumen to position the catheter in the artery. The thermocouple is in~ (led to continuously monitor the heating of the catheter tip in order to prevent overhe ~ing The tip when p~ûl)e.ly placed on a plaque build up, melts the plaque.
U.S . Patent No. 5,109,859 relates to ulll~uulld guided laser angioplasty Co~ g a laser at the tip of a catheter, an ull~asùu~d device also at the tip of the laser for gl-id~lre, and a proximal occlusion balloon to provide stabilization and a blood free envirulL,llelll. This patent a~pdl elllly also relates to ~ ;.. g the mass of a plaque tissue. There is no te~rhing that the ultrasound device of the patent can distinguish histological features (i. e., what cel~s and extr~rçllnl~r matrix are within the plaque). Thus, it is not likely that such a device could be used to predict plaque rupture.
Indeed, recent studies have found that intravascular ul~la~ound cannot identify which plaques are at risk of lU~lULillg. de Feytia Circulation 92:1408-13 (1995).
U.S . Patent No . 5,217,456 relates to an intra-vascular guidewire-colll~a1ible catheter which has a source of i11l..~.;.. ~iO.l and a ~yn~.hrolluus rluoresct;llce detector. Light in a wavelength that ;nduces fluorescence in tissues ~ . radially from an aperture on the side of the catheter.
Fluorescence emitted from the tissues enters the catheter through the same aperture and is conveyed to a spectral allaly~t;.. This h~ru~ a~ion can be used to dirr~,L~ iate healthy tissue from atherosclerotic plaque. However, this device does not distinguish between plaque on the basis of heat ~lirre~ lLial.
U.S. Patent No. S,275,594 relates to methods and ~pa.dlus for ~ ";~hing between atherosclerotic plaque and normal tissue by analy~illg photoPmi~ion~ from a target site. The system inrl~ r5 a source of laser energy for stim~ tiQn of fluorescence by non-calcified versus r~leified atherosclerotic plaque, and an analyzing means for d~ llh~ g whether a spectrum of W O 97/10748 PCT~US96/15217 fluorescence emitted by a tissue leyies~L~ calcified or non-calcified atherosclerotic plaque at a target site, based upon the time domain signal of calcium photoemission following fluorescent eY. itq-ti-)n of the cq1~ m When atherosclerotic plaque is identified, laser energy is used to ablate the plaque.
Prior art a~yroa~ hG5 to intravascular arterial ~ ..o~.~ and repair have been numerous yet have failed to provide certain capabilities. In particular, such prior art c ~ r~.~ and methods have failed to provide means for detecting and treating atherosclerotic plaque since they have not been able to differentiate between those plaques at risk of lU~JIUlillg and ocr1u(ling and those that are not presently at such risk even if they are capable of d~ .g the presence or absence of calcification of the plaque. Similarly, prior art approaches have not provided effective means for identifying specific arterial sites at risk for arterial rectenosi~ after angioplasty or atherecL~)nly.
Prior art apLloaclles have also failed to provide practical and effective means for detecting tr~n~ q-nt vasculopathy. Neither have prior art approaches been able to effectively identify patients who have arterial wall areas of lower rather than higher temperature, such as areas of extensive scarring, lipid pools where there is no cellular infiltration, or areas of hemorrhage and thrombosis which have yet to be coloni~d by infl- ~--.. l~ly cells.
SUMMARY OF THE INVENTION
The present invention o~,~;rco",es at least some of the failures of the prior art by providing an infrared-sensing catheter for dçtecting heat-producing infl~ u~y cells and vessel wall cells, and thus predicting the behavior of injured blood vessels in medical patients. The catheters and m~tho-l~ of the present invention provide effective means for det~cting and treating atherosclerotic plaque which is capable of dirrt;lG-.~i .I;,~g between, among other pathologies, those plaques at risk of luyluLillg and occh~ling and those that are not presently at risk. The calllelGrs and methods of 2~ the present invention also provide effective means for idenLiryi"g specific arterial sites at risk for arterial ~ si~ after angioplasty or athe.e.;lol,-y, or which patients are at risk due to vasculopathy, or tissue rejection. The C,dtLe~l~ and m~hotl~ of the present invention also are capable of t;rÇe;elively idt;~lliryhlg patients who have arterial wall areas of 11n--~uq11y low ~ y~ u~e and which represent p-~iously nn~letect~l arterial at-risk areas-just as excess heat can identify regions at risk due to inflqmmqtion, sub-normal heat (areas cooler than the rest of a vessel) intlic~tes a lack of actively metabolizing healthy cells (since heat in the body results from actively metabolizing cells) . Non-cellular areas are typically regions of he",u, .I,age, tbrombosis, cholesterol pools, or calcium--a11 inflirqtf rs of high risk plaques. The invention's devices and methods achieve these ends by idt;~liryh,g and analyzing thermal discrepqn~ies in the wall le:lllyelalult: of blood vessels.
The invention in one regard relates to ~l~pa.~.Lus for analyzing optical radiation of a vessel.
In another regard, the invention relates to methods for analyzing optical radiation, which methods are best prt:~elably achieved using the al~paldLuS of the invention.
Optical radiation of particular interest in the invention is that radiation which falls in the S optical ~ ull~ in the wavelength interval from about 2-14 ~m. An d1L.à.,Live feature of infrared is its peu. ~ ion through calcium (relative to white light and ultrasound). Benaron, et al., J Clin Monit 11:109-117 (199~).
The vessels of particular interest in the invention are those vessels where the access to a surface of which is problematic. Thus, where the internal ~ mPt~-r of a vessel is too small for ready access by a trarlition~l temperature probe ~i.e., a contact thermometer or t'nermocouple), the a~)~aldt.US and mP~thods of the invention will find utility. Similarly where the vessel, while of sl~fflriently large internal ~ mPtPr for access by a I~ aLule probe, has one or others of its openings naLrowed, occluded or otherwise blocked, the a~dldlus and methods of the invention will f~d utility. Thus, of particular interest in application of the a~)paldtUS and methods of the invention are vessels of the body, including vessels circulating and transporting sera (i.e. blood) such as arteries, veins, sinuses, heart cavities and chambers.
The invention relates to a~p~dlUs and methods in which there is at least one optical fiber used which is capable of l~ ".ill ;l~ optical radiation from a distal end of the fiber, usually inside a vessel, to a p.~,.i--.al end of the fiber, usually outside the vessel. Optical fibers of the invention wili exhibit certain key pal~l~et~ related to their ability to llansl--il wavelengths in the region of 2-14 ~m. These key parameters include optical lral~ar~l~y, flexibility and strength. The optical fibers of the hl~e.llio.l are those which may be extruded in ultrathin di:~mPtPrs and which Llal~u,il over the a~p.ol).idle infra-red spectral region. The infrared fiberoptic can be constructed from a variety of ~ .sl~ ., known to those of skill in the art such as ;circol3illlll fluoride (ZrF4), silica, 2~ or chalcogenide (AsSeTe). ZrF4 fibers are well suited to the apl)a~alus and mPtho-~ of the invention because such fibers have >90% l-"~ ion capabilities over 1 meter for small mPSerS.
The optical fibers useful in the a~alàlu~ and methods of the invention will also be ones capable of pl~i-emPnt proximate to a locus of a wall of the vessel being invectig~t~d This criterion ~0 is achieved in part by the flexibility of the fiber optic. In additional part, this criterion is met by the Ullldt~ nature of the .li ~ . of tbe fiber optic.
The ~a alu~ and mPtho-1s of the invention also utilize a balloon which encases a distal end of the fiber. The balloon, in one embodiment, may be one which is transparent to the optical radiation of interest. In that in~t~n~e, optical radiation ori~in~ting outside the balloon is ~
through the outer surface of the balloon to the inner surface of the balloon and on to the entry point WO 97/10748 PCT~US96/15217 for optical radiation into the optical fiber. It is hnpolL~lL~ in this emborlimPnt, for tbere to be little if any absorption, reflection or other diversion of the optical radiation ~~ g from the source (i.e., the vessel wall, a locus such as a plaque locus) during its Ll~ iQI~ through the surfaces of the balloon. Such ull~.al~ed absorption may be caused by blood or other body fluids.
Therefore, Llal~yale~ for l,u,L,oscs of the ill~e.llioll means an ability to Llal~lllil ~ui~Lal~Lially all optical radiation from a particular source through the balloon surfaces to the optical fiber.
It is important, in this embodiment, for there to be ~I,sl~u1;~11y total conduction of the heat, while having s~,bsl nl~ lly no loss of the heat e~ ; llg from the source (i.e., the vessel wall, a locus such as a plaque IOCUS) as it contacts the outer surface of the balloon. Therefore, opacity (opaque) for purposes of the invention means an ability to absorb ~ubsl~lially all optical radiation from a particular source on the outer balloon surface. Thereafter, the inner surface of the balloon will re-emit a propo.Lional amount of radiation to that absorbed on the outer surface imm~i:ltPly adjacentthelocusol;gi.,-~i..gtheradiation. Thisre-emittedradiationwillbedetectablebythefiber optic system encased inside the balloon.
The ~pdlalu~ and mPtho-l~ of the invention also utilize a detector capable of detecting a difference in the optical radiation of interest, between the locus and the average optical radiation along the vessel wall being inve~tig?~P~1 In certain preferred embodiments, the detector of the invention is one which has a sensitivity capable of detection of differences in infra-red radiation as small as 50 ~mK, and in the range of lO to lO0 ~mK.
Where the balloon is one which is Llal~Jalc;llL to the radiation directly emitted from the locus or from the vessel wall po-lious outside the specific locus, the detector will be one capable of cletecting the radiation which is ~ d through the balloon's outer and inner surfaces.
Where the balloon is one which is opaque to the radiation directly emitted from the locus or from the vessel wall portions outside the specific locus, the detector will be one capable of cletecting the radiation which is re-emitted from the balloon's inner surface opposite the balloon's outer surface which is directly in contact with the locus.
In p-~re--ed embo~1imPnt~ the alJ~ald~Us and methods of the invention will rely on detection of optical ladia~ion in the infra-red radiation ranges. In particular, as noted above, ranges of 2-14 micru,l.~ are of particular interest in the ..~)p~alus and mPt~o-l~ of the invention. Referring to Figure 2, it can be seen that it is possible to plot curves for radiation (-lulllbel~ of photons x l x 10l7~ being emitted by black bodies held at differing con~ temperatures ~T~, T2 and T3 each refer to temperatures in the range of 300-310 ~K which vary from one another increasingly by l ~K) in ~e wavelength range of 3 up to 6 micrometers. It can also be seen in ~e inset to Fig. 2, that in the range of ay~ ly 5.3 to 5.6 micfol..~;~e.;" black bodies held at co~
lell.~ el~lul~,s in the range of 300-310 ~K and dirr~ g from one another by only a single degree, appear as easily ~lietin~-ieh~71e curve segm~nt~> emitting photons from these black bodies in the range of appro~Yim~fely 0.21 x 10'7 to 0.40 x 10l7 photons. Thus, it is preferred to select a wavelength for s~mplin~ the r~ tion from the wall and specific locus on the wall of a vessel which will provide similarly fiietin~-i~h~llle curves.
In certain pr~e.rcd embodimPnt~, the ~alatus and methof~e of the invention may comprise at least two fibers, alllllJU~ the use of greater than two fibers is clearly possible where merited, such as when detection along the axis of the vessel is p.t:Çelled at greater than a single position ~imlllt~n~ously. In other preferred embo~lim~ntc~ where at least two fibers are utilized, at least one of the fibers is a reference fiber and another of the fibers is a signal fiber. The signal fiber is a fiber d~-ei~n~d to transmit all optical radiation focused into its length from its distal end to its proximal end. Conversely, the r~l~r~.~ce fiber is a fiber which is used as a control against which the signal fiber L~ ions may be co,l,p,ifed. Thus, where optical radiation exiting the pro~Lill,al end of the signal fiber is colll~aL~d to that exiting the p~ illlal end of the fcrel~nce fiber, a d~ ;on can be readily made as to relative a~ ull~ of optical radiation exiting the signal fiber which is due to other than optical radiation emitted by the locus of interest.
The a~ ,aidtus of the invention may also be optically connect~d at the distal end of the signal fiber to an optically reflective surface capable of directing optical radiation arising radially to said distal end, and on into said flber. U.S. Patent Application No. 08/434,477 in which certain of the present i~ ol~ are named co-illvellLol~, and which is incorporated herein by lt;r~nce, describes such an optically reflective surface. As opposed to the signai fiber, the r~relcllce fiber will typically be coated on its distal end with a material that ;~ 5~ y plC~V~;llL:i optical radiation from~ E it.
The a~pald~Us of the invention is also one in which the inner surface of the opaque ocrlu~1ing balloon emits a black body spectrum modulated by the tr~n~mi~sion spectrum of the balloon. The balloon, upon infl~fion, will s~b~ ly limit flow of fluids within the vessel. The flow limif~firtn n~luil~l iS one in which only so much flow occurs as will not cause a rise or fall in average ba~ ulld IR radiation along the vessel wall imm~ f~ly distal the inflated balloon.
In ~-lition in ~ ,relied embo~lin~Pn~, fhe a~ala~us of the invention is one where the balloon, upon infl~fion, substantially eYrh~d~Ps the presence of i~ l vesicular fluids between the fibers inside the balloon and the wall of the vessel most pl~ llale to the test locus.
In use, the alJpàLdus of the invention will be placed along an axis of the vessel. in this manner, it will be possible to bring the ~ii~nostic fiber array into close pru~ y with âlOcus to be tli~gl~ose~l In certain pl~rt;lled embo~limPnf~, the locus will be one which contains plaque. In particular, the a~aLalus as previously noted will be useful in ~leteeting among those plaques with which it is brought into pru~inlily, whether a given plaque is one at risk of rupluring. In most W O 97/10748 PCT~US96/15217 in~t~n~.c, the dp~ aLuS of the invention will be used to ~ nose thermal disc~ cies on the interior wall of a vessel.
The a~pa,d~us of the invention is in its most plert;LL~d embodiments a catheter. Typical of catheters used inside of blood vessels, the catheter of the invention will be one ~lesign~d for use with a guidewire. The guidewire will allow optional removal and lei-.seLLioll at the discretion of the surgeon, for example where after ~ g~G~ g a plaque at risk of rupturing using the catheter of the invention, the surgeon may wish to bring another flia~osti~ device or a Ll.~aL,eulic device such as â laser into the same position next to the problematic plaque.
The ~)I)drd~U~7 of the invention is also one where the detector is pl~f~,lal~ly optically co~ ed to a pLOAilllal end of the fiber, and if there is more than one fiber, to a proAi".al end of each of the fibers. In pl~Çelled embo(1imPnt~, ~e detector will be a multi-wavelength radiometer.
Such a radiometer will p~ al)ly be a spinning circular variable filter whose IL~ C~iC~iQn wavelength is a function of its angle of rotation. In such a filter, it is possib1e to prevent ~L ~ iC;.il~n of all but a narrow band of wavelengths of light by adjusting the rotational angle.
1~ Sâid differently, such a filter can be made to be Lial,~L,al~"l to highly selected wavelengths by its rotational Ch~a~ Lics. Thus, in certain embo(lim~m~, the filter will be one ll~l~a el~L to radiation with a wavelength of a~)lJroAillla~ely between 2 to 6 micrometers. In highly preferred embo~im~nt~thefllterwillbel~ aLellltor~ ionwithawavelengthofay~ y3miclolllel~
One of the keys to this invention as it relates to the ~i)a,alu~, is that it au~ aLically provides a rt;l~rence for each s~e~ ulll by s~mrling apl)roxi.. ~1ely 3 ,um. For the range of Lenly~làlures t,.yecled in biological Olgalli~ll~, 300-310 ~K, the blackbody spectrum at this waYelength iS ~ enti~lly the satne. This provides a zero for each signal and locks down the low wavelength side of the signal. Without this, there would be no way to flt a signal to a blackbody s~e~ ulll since the vertical scale would be "unfixed".
Where the al)paldlus of the invention utili_es the IIA ~ i h~""~.lion from more than one fiber ~rough a filter for colllyald~i~e pu~yoses~ it will be ~,~re..~d to utili_e an offset in the distal ffber ends. Thus, where the distal ends of the signal fiber and the reference ftber are offset from one another, the offset will be at a distance sllfflri~nt to allow sampling of radiation emitted from either fiber to pass the filter at a s~lbst~r~ti~lly i-l~nti~ l location on the filter.
The a~pa,d~us of the i,-ve"lion when used in conjull~lion with a radiometer, will p.crtLdl)ly be one optically CO'"~f .,~ed to at least one photoelectric device capable of converting the tr~mmitte i radiation into an electtical signal. The photoelectric device is plere,ably one electri~ ly connected to a device capable of digiti7ing the electrical signal (a digitizer).
Once the ay~ald~US of the invention has created a ~ligiti7ed signal, the digiti7ed signal is m ~hem~icsllly fitted to a curve selected from a spectrum of curves for black bodies held at temr~ , between a~ c;ly 300-310~ K. The curves of the contro}led black bodies are those plotted as llul"l,e~i, of photons emitted from each black body for each wavelengths. In ...,i where such a ~ligiti~ed signal is to be used to ~liagn(!se thermal discrep~nciPs in the interior wall of a blood vessel, the particular selection of black body control curves will be made with the knowledge of typical ttilllpt;l-l~U-~ of the human body.
Thus, in a p-~r~lled embodiment, tbe dppa alui~7 of the invention will be a catheter for analyzing infra-red radiation of a blood vessel. Such a ~ r~ L. ed device will C~lu~ e at least two fibers capable of ll ~~ the radiation and capable of pl~rPmPnt along an axis of the vessel pl~,~hllale to a plaque-co.~ locus of an interior wall of the vessel. At leas~ one of the fibers will be a reference fiber coated on its distal end with a material that i7uh'~ y prevents optical radiation from entering it, and at least one of the other of the fibers will be a signal fiber whose distal end is optically connected to an optically reflective surface capable of directing optical radiation arising radially to its distal end into and along its shaft. Such a pr~rt;l I ~d device will also have a balloon ~ the distal ends of each of the fibers, which balloon upon inflation will 1~ 7~lbs~ ;Ally limit the flow of fluids within the blood vessel. In addition, the balloon will ~.~I,s~ lly exclude fluids between the fibers and the wall of the vessel most pl~JAilllaLe to the locus to be tested. The balloon will be l,a,.s~art;-,t to or opaque to the radiation arising inside the vessel and will have an inner surface exhibiting spatially constant optical radiation emissivity. This inner surface of the opaque balloon will be one which emits a black body spectrum. The catheter will be one having a guidewire. It will also have a detector, optically connected to a proximal end of each of the fibers, and capable of detecting a dir~-el ce in the radiation between the locus and average optical .adidtioll along the wall of the vessel. The detector will further comprise a multi-wavelength radi- : with a spinning circular variable filter, the filter being such that its n;~ ;on wavelength is a fi-n~tion of its angle of rotation. The distal ends of the fibers will be offset from one another a distance sufficient to allow sampling of radiation emitted from either fiber to pass the filter at a s~bst~nti~lly identic~l position on the filter. Further, the radiometer will be optically conl-~ ed to at least one photoelectric device capable of converting the Ll.~ ~l and iiltered radiation into an electrical signal, which signal is capable of being l~igiti7Pd, and which digi~i7ed signal is ".~ lly fitted to a curve selected from a spectrum of curves for black bodies held at tempc.~-Lurcs between dp~ro,~ ,dtely 300-310Q K, where ~e curves are plotted as .Ul~C.i, of photons emitted from each of the black bodies for each of the wa~ ,g~
The invention also relates to an analytical method, suitable in certain embodiments for nosing medical conditions. Thus, the invention relates to a method for analyzing optical ~adidlioll of a locus in a vessel wall. The method of the invention con.~ ~s placing at least one 3~ optical fiber capable of L~ ; radiation proximate to the locus. In p~re,1~;d embo~lim~nti, W O 97/10748 PCT~US96/15217 the pl~c~mPnt of the fiber and balloon is accomplished by catheterization. Either prior to or after pl:~emPnt p,~o~il.ldle to the locus to be analyzed, a balloon ~n~ ing a distal end of the fiber is inflated within the vessel to cause the balloon to limit flow of fluids within the vessel. As previously detailed, the balloon is L~ ,a~ to or opaque to the thermal radiation and has an inner S surface ~AhibiLil-g spatially CO~ optical radiation emissivity. The mP~o~s of the invention further call for ~ li..g the radiation along the fiber to a detector capable of detectin~ a difference in the radiation between the locus and the average optical radiation along the vessel wall.
More specifically, the h.~/e lli.Jn relates to a method of det~ctin plaque at risk of lu~ulhlg along a blood vessel. This p-~,R.r~ method COIl~ ,~, inserting a guidewire into the blood vessel to be di~gnosed and then catheterizing the vessel along the guidewire with at least two fibers capable of l~ h~g infra-red radiation along an axis of the vessel plo)ici"~ale to a plaque-ccll~ainillg locus of an interior wall of the vessel. Thereafter, the steps of the method of the invention is carried out as described above.
The invention also relates to a method of surgically treating a patient with a plurality of plaque loci within a vessel. Such a method co~"~ es de~e""i~ g which one or more of the plurality of plaque loci has a l~.llpC,~Ule elevated above that of the average vessel wall temperature. Once such a dt,lt;""i"dion is made, the surgeon removes or reduces the plaque loci found to have an elevated temperature. This method has as its determin~tion step the methods described above for analyzing optical radiation of plaque locus in a vessel wall. Once plaque at risk is i~ntifieA, a number of therapies may be used to reduce the risk.
Accordingly, it is an object of the present invention to identify patients who have COIondl~y atherosclerotic plaque at risk of rupture by ide~lliryillg the specific plaque(s) at risk. Another object of the present invention is to identify patients at risk for arterial restenosis after angioplasty or ~ ' e,~u",y by idc.kiryh~g the specific arterial site(s) at risk. A further object of the present invention is to identify patients at risk of tr~n~pl~nt vasculopathy. Another object is to identify patients at risk for stroke, loss of mobility, and other illn~Ps by identifying sites of potential plaque rupture in the carotid arteries, the i"~,ace,eblal arteries, the aorta, and the iliac and femoral arteries. Another object of the present invention is to identify patients who have arterial areas of lower rather than higher temperature, such as an area of extensive scarring, a lipid pool with no cellular infiltration, or an area of hh~ l.~e and thrombosis which has yet to be colonized by ;..n~ ,t ,. ~ cells. The ~lelinp ~ion of a cholesterol pool is useful in following the regression of plaques. Idell~iryillg such areas for follow-up study will localize those likely to be infl~mp~d in the future.
Yet another object of the present invention is to deliver specific local therapy to the injured areas i~lPntifiP~ by the catheter. These therapies include, but are not limited to, therapies which W O 97/10748 PCT~US96/15217 prevent or limit infl~lTnm~tiQn (~ ui~ tt~hmPnt activation, and proliferation of inflz..,...!~'ofy cells), smooth muscle cell prolile.d~ioll, or endothelial cell infection, including antibodies~ ro~ g growth factor-~ (TGF-,~)~ nitric oxide (NO), NO synthase, glucocorticoids, u~ r~r~ll gamma, and heparan and heparin sulfate proteoglycans, and the various comple-l,e"L
DNAs that encode them.
The il~v~ ion's mPth()fl~ and devices will have a number of utilities. Each will reduce morbidity and mortality from ~.vnaly and carotid artery atherosclerosis. Each will reduce the in~i~ence of restenosis and thus the need for ~ ed~ed angioplasties or athtrt;.,k)lllies Each will also reduce the inri(lRnce of vasculopathy in organ-tr~n~pl~nt patients. In turn, these outcomes will produce the benefits of better health care, improved public health, and reduced health care costs.
These and other uses of the present invention will become clearer with the detailed description to follow.
~RIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a srhP,m~tic represRnt~tion of the dpp~alus of the present invention with its infra-red detection unit at its pro~ al end and the sensor tipped distal end of the catheter as well as the guide wire disposed within a flexible outer catheter (not shown) which ~u-- ~unds the optical fibers.
Figure 2 is a black body curve sl,e.;~lunl for temperatures T1, T2, and T3 (differing sP~ Pnti~lly by a single degree Kelvin) plotted as emitted radiation in photons (xlE17) versus wavelength (micrometers).
Figure 3 is a length-wise cross serti-)n~l view of the catheter tip of Figure 1 in place within a blood vessel near a plaque at risk of rupture.
Figure 4(a) is a graph depicting surface temperature of living carotid artery plaque in relation to cell density. Relative cell density equals the ratio of cell density in the area of interest to that of the bacLg~u..d area. Tt:~-yeLaLure me~..-~ ~--e -l~ were made at room temperature (20~C) on 24 samples from 22 patients 10-15 minutes after removal. Point >(O~C difference in l~---L,e a~ure) represents 27 observations.
Figure 4(b) shows the correlation between living human carotid plaque temperature and cell density when l--~.l-~ed in a 37 ~C chamber.
Figure 5 is a graph depicting plaque surface temperature as a function of cap thiclrn~c~.
Samples that had a non-infl~rnPd fibrous cap were subjected to pl~nimP~ry to measure distance from the 5umen to the center of the underlying cell cluster.
_ W O 97/10748 PCT~US96/15217 Figure 6 shows the correlation between thermistor and IR camera mea7ulcllle~ 7 in living human carotid plaque specimens (freshly excised, in a 37 ~C chamber) where r--0.9885 and p=
0.0001.
Figure 7 shows the coll~-,ldLioll of IR radiation with cell density in the specimens described in Fig. 6, above.
DESCRIPI'ION OF PREFERRED EMBODIMENTS
The ~thPt~r ~.~ ~d:ment Referring now to the figures, F~g. 1 shows a plt;r~ d embodiment of the ~pàraluS of the invention in use. A catheter ai)pa.dLus 10 is shown, which can be placed inside an artery (not shown) having with an interior arterial wall ~not shown) which possesses a plurality of plaque loci (not shown). The risk of rupture of either of the plaque loci is unknown until the methods and a~Jpalalus of the invention are applied.
Guidewire 20 has been surgically inserted into the artery and can be seen to extend both pro"imally 22 and distally 24. Guidewire 2Q can also be seen to proceed through catheter a~J~alaLu~7 10. Guidewire 20 is used to guide the pl~ om~nt of catheter al)~ala~us 10 to the area of the artery which contains plaque loci.
Catheter a~paldLus 10 Coll~ s at its distal end (the end farthest from the detector~ an inflatable balloon 40, a signal fiber 50, and a reference fiber 60. Inflatable balloon 40 is shown in its inflated state, which would cause it to rest firmly against an interior wall of an artery and against plaque loci. Depending upon the natural direction of blood flow within the artery, infl~tion of balloon 40 would sllb~t~nti~lly limit flow of blood either at position 32 or 34 or any of the similar points around the p~;~h~ e~ of the generally circular series of contact points between the balloon wall 42 and an interior artery wall, allowing n~ear,~ ,e~, being conducted by catheter apparatus 10 to proceed without i-ll~r~l~llce.
Balloon 40 coll,~,i,es a wall 42 which is made of an elastic material. The perimeters of balloon 40 are such that inflation causes sealing or closure of the balloon 40 at points along the arterial wall. When defl~t~A> balloon 40 retreats from its contact of the arterial wall, allowing reestablichmPnt of natural blood flow within the artery, and allowing facile movement of catheter a~aldtllS 10 in the artery to a next position, for instance to a position at which catheter apparatus 10 may be used to measure radiation emitted from another plaque locus. Activation of infl~tion/deflation of balloon 40 may be accomplished in any of a nurnber of ways known well to those of skill in the art of building angioplasty or embolectomy ç~the5er~ or balloon-tipped c~'~h~t~,r,~, The purpose of balloon 40 is to avoid problems associated with absorption of infra-red radiation by water between the source of infra-red radiation being med~ult;d and the distal catheter portion. Upon infl~tion and contact of the artery wall, the balloon wall 42 ~.. PS the lel"pe~ ule of the portions of the artery with which it is most p,~ The void area 46 excludes all water between the balloon wall interior and the distal signal fiber tip S6.
Signal fiber ~0 has a tr~n~ nt tip region S2 and an opaque body region 54 which is capable or incapable, respectively, of l-n~ ;u~ infra-red radiation efficiently. Opaque body region S4 may be a region in which signal fiber 50 is covered over by a rl~ 1ing or sleeve 56 which causes the region to become opaque and inrar~ e of efflciently t.~ ii.g or absorbing infra-red radiation. Tr~n~ cPnt region 52 may simply be an area in which signal fiber 50 is exposed. Signal fiber 50 is an optical fiber which can efficiently l,a,l;,lllit infra-red radiation. In order to collect such radiation from the surrounding milieu, signal fiber S0 may be fitted or otherwise used at its distal end with a collecting device 58 which focuses the infra-red r;ldi;ltion of the .,ulruulldillg milieu into the fiber for subsequent ~ sulission.
Unlike signal fiber 50, reference fiber 60 has no translucent region. Rather, reference fiber 60 has an opaque end C2 and an opaque region 64, both of which are incapable of ~ ;.lg infra-red radiation efflciently. As with the signal fiber 50, reference fiber 60, opaque region 64 may be a region in which r~r~-ellce fiber C0 is covered over by a c~ ing or sleeve 66 which causes the region to become opaque and incapable of effic;~ntly tran~mitting or absorbing infra-red r~fli~ti--n Opaque end 62 may be an area in which ~el~l~nce fiber 60 is coated with an infra-red reflective coating such as polished silver or alul..;.--~... In all other regards, r~r~ iellce fiber 60 is idl~ntic~l to signal fiber 50 in its ability to f~lnction as an optical fiber which can çfflcipntly lla~ lliL
infra-red radiation. It may be used, therefore, to set a baseline in order to compensate for any t~ .a~ule profile along signal fiber 50 from its distal to its prt~ lal end. As shown in Flg. 1, ,t;rele,lce fiber C0 is offset from signal fiber 50 in the proximal direction. This offset ~which can be equally well ~ccompli~hf~ by offsçtting distally) physically introduces a time delay between the radiation received and l,D .~ d by each fiber. As will be fli~cnc~ed immf~ t~ly below, this time delay is introduced in order to ensure that the signal and reference beams issuing from the pLox.i ends of each fiber strike the filter on the same spatial portion. By doing so, it is possible to rlimin~t~ ~lignm~nt problems or bandpass ~ imil~rites arising from a multi-filter system.
When in operation, the fiber-balloon array 70 collects therînal radiation which is ~,~ . .~, . .i proximally through signal fiber 50 and ler~rence fiber 60. Both fibers are positioneci to L~
through spinning ,~ if).~ er 80 at i-lçntir~l radial position 82 to impinge on ~ ;ti7~rs 92 or 90, respectively. Once a digiti7f~ signal is g~ 1 from each of the optical fiber ~ s;on~, the bac~ ulld signal created by the ~t:r~,ellce fiber 60 is subtracted by cc)~ u~ef 94 from the digiti7p~d s~gn~ t~ ed by the signal fiber 50. The resulting adjusted signal is m~thpm~ltir~lly fitted by CO~ )ulei 94 to a spe ~ of blaclc body curves 96 in order to ascertain the temperature of the particular locus.
Cnt~ ~' C~ .
Several options for materials for the other various con~one"L~ of the catheter devices described herein exist. The key parameters for the optical components are optical llal-i7~.,.1C~, flexibility and strength. Materials such as high strength polyester and polyethylene terephth ~late (PET) are very clear and easily extruded in ultrathin wall sizes. A high strength braided polyester is useful for ~ twisting motions over long rli~t~nr~Ps as may be required in certain emb~flimPnt~. Spacers/bearings can be made from Teflon~. The overall flexibility of the catheter will be appl~ Ply the same as similar-sized cardiovascular laser, fiberoptic, angioplasty and athere.ilu...;,il.g cathP~tp-r~. These devices should therefore be deliverable to small tli meter coronary arteries. A detector will be positioned at the proximal end of the catheter (outside the patient) utilizing InSb or, alternatively, ~IgCdTe, TeO2 or TAS detection systems.
The elongated flexible fiberoptic element will be connected at one end to an optical con.~ or through a ptol~,livt~ sheath. The optical connector is a standard item adapted to be slidably inserted into a thermal detector, and will include a plurality of openings in one side through which fluids or gases, int.h~-1;..g air, can be introduced into the catheter and emitted the.erlu---. The co ~ :,r will also include a coupling element for co~-~-e~li.. g to a plès~ult;
tr~n~lucPr to measure pl~;,.-le, there being an opening in the connector comm~lnirating with the coupling element and the pl'cssule lumen of the catheter. The coupling element may also be cullllel_led to a syringe to take a blood sample or to use a saline solution to flush the catheter.
The materials of which catheters are con~Llu.led may be any of those commonly used, inrh~-ling flexible plastics such as nylon, TeflonTM, vinyls such as polyvinyl chloride, polyurethane, and polyethylene, or various rubber compounds. Typically, the catheter will typically be 5 to 40 inches long and have an outer ~ m~t~Pr of about 1 to 2 millinA~ptprs~ The lumen inside the catheter can vary but typically will be about one half to 1 millimPter in ~ mPtçr.
The ",i..i...."" detectible heat dirrelelllial using the devices and materials of the present invention will be about 0.1 ~C. While the devices of the invention will be capable of finer thermal dis~ iol- biological variables are apt to introduce noise into the system. In most in~t~n.~ec, plaques which are in danger of rupturing will vary from those less at risk by at least 1.5~C.
CA Ot23l425 lsss-03-os Wo 97/10748 PCT/USg6/15217 At-Risk Pla~ue Generally then, as an overview of the device and method of the invention in Fig. 3, the infrared-sensing catheter 100 has identifiçd an ulcerated atherosclerotic p1aque 102 which is ac~~ ied by platelet ag2;-~alion 103 and vasoconstriction 104. Because of the presence of S ;.. rl "",~ cells 105 in this plaque 102, its temperature is higher than that of the immeAi~t~ly - ~c~nt vessel 107, and this change is sensed by tbe catheter 100. Some endothelial cells 108 have been lost (as a result of S~ ~P~f-~ e, infl~mm~ti~n, infarction, toxins, or balloon injury) causing platelets 109 to become aclivd~ed and to adhere to the damaged vessel wall 110. The activated platelets 109 release ~ that cause vasoconstriction, platelet ~g~sl~alion, and growth of smooth muscle cells; these mediators include ADP, se~ul(~llirl, thromboxane A2, platelet-derived growth factor, t~dnsrol-llillg growth factor-P., and PF4. The exposure of subendothelial collagen 111 and lipid 112 and the activation of platelets L/lvlllol~ el~yll~dlic activation of coagulation enzymes, which result in the rele~e of plasma mitogens and the activation of thrombin, an enzyme which cleaves fibrinogen to form fibrin. The c~lmin~tion of this process may be complete occlusion of the artery and consequent injury to the heart (or brain, in the case of a carotid, ve.t~.dl or cerebral artery).
Also shown is a monocyte 114, which has attached itself to adhesion molecules on the surface of activated endothelial cells. The monocyte becomes a macrophage involved in uptake of mo~lifieA cholesterol and the release, as by-products, of mitogens and proteolytic e~yllles that may prolnoLe rupture.
FY~m~?le I:
M~ o.ls Fi*y carotid elldall~reclollly spcc;..-e~-s were studied in the living state a*er gross inspection by a pathologist. Visible thrombi, noted in about 30% of the specim~n~ were typically removed by gentle irrigation, suggesting that they were surgical artifacts. The in~lic~tiQns for surgery were generally a carotid stenosis and LI~Sic.lt i~chemic attack or stroke.
Twenty-four spccilllells ~rom 22 patients were ~Y~minerl at room temperature (20~ C).
Another 26 specimens from 26 patients were ~ A in a hnmitlified incubator at 37~ C.
Within 15 minutes after removal of a specim~n~ a Cole-Parmer model 8402-20 thellllistor with a 24-gauge needle tip (accuracy, 0.1~ C: time cQn~tant 0.15) was used to measure the ~ e,a~uit~ of tile luminal surface in 20 locations. Temperatures were reproducible (+0.1~ C), and most r~ e.nell~ were found to be within 0.2~ C of each other and thus were desi~n~te~l as the bac~ uld temperature.
W O 97/10748 PCT~US96/15217 In most plaques, several locations with higher temperature were all found. The~se locations and the bachg-ound temperatures were marked with indelible ink of varying colors (recorded, but not coded so as to indicate the temperature to the pathologist) and re-measured to assure reproducibility. Tissues were then fixed in 10% formalin and cut le~Lhwise, embedded to reveal the intima and media, processed for histology, and stained with ht;ll.dlu~ylin and eosin or Masson's trichrome, or imm--n~st~in~d for ",a~ l~ophages using the HAM-56 and KP-1 antibodies '~Dako) as previously de~scribed. Nilckari, et al., Circulation 92:1393-1398 (1995). The cap thi('lrnP~5 and the cell density in a 300 x 400-,um region beneath the dyed regions was measured using a M~lrint~h Centris 650 and NIH Image software (version 1.43), available on the Internet from the National Tn~ s of Health, T'~ethP,~s-~ Maryland.
Preliminary ~A~ illlellL~ were also pt;l~.llled with a Jet Propulsion Laboratory platinum silicide camera, which we further calibrated against a Mach 5 scanning infrared camera (Flexi-therm, Westbury, NY), - which in turn was calibrated against beakers of water at various temperatures from 0 to 100~ C with a near perfect correlation, y = .99x + .31, where x was the temperature n~easul~,d by Illel.;u,~ thellllo~ Lel . The camera had a thermal resolution of 0.10~ C
and a spatial resolution of 0.15 mm.
Results Plaques exhibited multiple regions in which surface tempe.dLules varied reproducibly by 0.2 to 0.3~ C (~ 1.0~ C), and 37% of the plaques had 1 to 5 s~lbst~nti~lly warmer (0.4 to 2.2~
C) regions per plaque. For in~t~n~e, in typical i..~ c~, regions 1 mm apart had a reproducible ~emp~alu~ lirr~ lellce of 0.6~ C. Although the lumenal surfaces of the plaques exhibited visible heterogeneity, dirr~,fcnces in te,,,perdLu,e were not ~palenl to the naked eye. These temperature dirr.,r-,nces correlated positively with the underlying density of cells (r = 0.68, p = 0.00~1) (Fig.
4A), most of which were UlollO~ e-~r cells with the morphologic characteristics and u~f.fea~liviLy (with HAM-56 and KP-1) of ma~ ")h~ges.
Several mitotic figures were noted. Some foam cells were noted, but regions preAo~ ly populated by foam cells were cooler (and had lower cell density) than regions with monom~cle:lr infiltrates. Many plaques contained a few Iymphocytes and mast cells.
Te",l)erdlule varied inversely with cap thickness (r = -0.38, p--0.0006) (Fig. 5). The best correlation (r = 0.74, p = 0.0009) was given by the theoretically expected e4u~.Lion ~T =
relative cell density . cap thi~n~. Cooler regions were non-cellular: fresh thromboses, h~...o~ ge, scar, f ~k~ m or regions of cholesterol pooling without infl~ illr,lllàLion.
The warmer regions were not visibly dirrert;lll on gross inspection, even though many of them had a su~,~.r,~ layer of infl~ cells, some of which had small agg.~;~ion~ of CA 0 2 2 3 1 4 2 S 1 9 9 8 - 0 3 - o s wo 97/10748 PCT/US96/1~217 platelets~ Other large areas were free of infl~.. ~lo. ~ cells but lacked endothelial cells. These had probably been denuded during surgery, since po~ e"~ studies usually show only focal dem~ tion unless there is thrombosis or inflamm~tiQn Van Damme, et al., Cardiovasc Pathol 3:9-~7 (1994)-A minority of plaques ~a~L~ ly 20%) exhibited no detectable thermal heterogeneity Regions of deep or superficial inflq~nn~atil~n in these spc~ ..e~ were not marked with dye, inr1ic~ting that the o~lyillg temperature had not been measured. In a few of the regions co,-lainil~g cellular il,r,l~ld ~ alul~ had been measured, and they were no warmer than less cellular ~dj~cent areas This finding was believed by the inventors to possibly reflect decreased metabolic activity in specimans that were kept at room temperature for a longer interval after removal.
Therefore, a second series of pla~ues was analyzed in a 37~ C incubator. These 26 specimens from 26 patients with a mean age of 68 (range, 50 to 86) revealed a considerably closer correlation with cell density (r = .68, p < 0.0001), more therrnal heterogeneity (93% of specimens~, and a wider range of temperatures, typically I to 3~ C; some specimens only 10 mm apart were characterized by temperature differences as great as 4 to 5~ C. See, Fig. 4B (points re~rese,-~ed by solid ~ tt~on~ls are the relative cell den~itiç~ divided by the cap thi~n~s~ squared;
linear regression of these points resulted in the solid line shown).
The inventors also studied several specimen~ using a pl~tinl~m silicide, cooled, infrared camera with a thermal r_solution of 0~1~ C and a spatial resolution of 0 1 mm~ This camera detectad thermal heterogeneity in ex vivo .cpec.tnan~ As shown in Fig. 6, the IR camera when used to identify thermally distinct plaque COilel~ d well with direct contact tht,~ o measur~ in freshly excised human carotid artery plaques specimens (r= 0.9885, p < 0.0001).
Fig. 7 shows that this correlation of the IR carnera "~ea~u,ed l~ IaluL~s was also observed with cell density med~ult;llle.l~ It is noted by the inventors that cooled staring array carneras have even better tbermal resolution, and spatial resolutions are as low as 10 ~m.
r~
Most human carotid athereclc,llly specimens contain foci of increased heat ~pa e.llly produced by underlying cells, most of which are lllacLopl~âges. When studied at 37~ C, the ternperature variation was greater than 20~ C, consislel.~ with reduced metabolic activity at 20~ C
that makes th~e plaques more homogeneous in temperature.
In the samples studied at body temperature, a thlormi~tor with a l-rnm tip was able to detect difr~e~ces as great as 4~ C within difr~ parts of the same plaque that were only 10 mm apart.
Temperatures were highest when the cells were closest to the probe (i.e., at or just beneath the CA 02231425 1998-03-og lumen itself). Most of the lumenal sur~aces of the plaques had several regions characterized by superficial infl~mm~tion and en-lothi~ 1 den~ Qn.
Only some areas of surface infl~mm~tion were associated with visible thrombosis; most were associated with mic~uscol,ic thrombosis (e.g., a few fibrin strands and ~tt~rhe1 platelets) or none at all. These results suggest that i-.we~sed plaque heat is an indicator of plaques that are den~ ed and infl~tned and con~e.l~,e~.lly at risk of thrombosis.
The hl~e.~ , also found a few hot regions associated with foci of infl~tnm~tion just beneath thin but intact caps. Since these pla~ues are believed to be at increased risk of rupture, it is believed by the inventors that m~suli--g plaque temperature in vivo could enable one to identify such plaques.
F~ d~ )le II:
Li~ t~ of the Study A potential co--~under i(l~ntifi~d by the inventors is plaque angiogenesis (neovascularization3. T~e inventors studied living plaques ex vivo. In vivo, the presence and tone of the vasae vasorum might influen~e the temperature. However, since plaque angiogenesis correlates with infl~.. lion~ (Nikkari, et al., Circulation 92:1393-1398 (199S) and both are considered risk factors for plaque rupture, it is likely that temperature will still be predictive in vivo.
The inventors also believe that one must consider that what is true for atherosclerotic plaque in the carotid arteries may not be true in other sites, for example, the COI~Jnaly arteries. The pathology of the plaque is sollle~lldl different in the two locations. (Van Danune, et al., Cardiovasc Pathol 3 :9-17 (1994)) and the ris~ factors are also different. Kannel, J Cardiovasc ~isk 1:333-339 (1994); Sharrett, et al., Arterioscler Ihromb 14:1098-1104 (1994).
F~amrl~
F'ul --1 of Sp~l,n~ ~p~, Tomography, and I~ .f~
Infrared specL-~oscuL~ could prove useful in several ways. Pirst, it should be able to corroborate the location of l-.acro~)hdg~s by the massive ~mf)l-nt~ of nitric oxide they produce, since nitric oxide has a Ch~delt~ liC near-infrared ~ue~llu,--. Ohdan, et al., ~ransplantation 57:1674-1677 (1994). Near-infrared imaging of cholesterol has already been de .lon~lld~ed~ Cassis, et al., Anal Chem 65:1247-1256 (1993). Second, since infrared and near-infrared wavelengths penetrate tissue more deeply as wavelength increases, longer wavelengths should reveal metabolic activity in deeper (0.1- to 1-mm) regions.
WO 97/10748 PCT~US96/~5217 This rh~nl~nlRnnn could be used to develop co~ uled infrared tomography, possibly in conjùn~,Lion with inl~r~,rulllctry, in which an incident beam is split by a moving mirror to produce a rerelt;,-ce beam and a beam that is variably scattered and absorbed by the tissue The nonsyncbronous reflected wavelengths are reco~ d to reveal sLLu~,lulal detail with 20-f~m resolution. Benaron, et al., Science 259: 1463-1466 (1993); Brezinski, et al., Circulation 92: 1 -149 (1995).
I~ample IV:
Non;.~ D~ ~f~ of Plaques at Risk Alleln~lliv~&, to infrared dete~ti(~n are also desirable since infrared abso,~lio", convection, and tissue emissivity differences are likely to preclude non-invasive infrared tomography. Such alLe~l~aLives include imaging the infl~mm~tnry cells with gallillm (P~,~e,h~,-;~, et al., Circulatton 91: 1444-1449 (1995)) l8FDG positron sc~nnin~, radiolabeled anti-macrophage antibody fr~mPn~c, or m~n~tic resonance (to take advantage of ~e ~ ;?t~ ul e-depP,n~lP-nce of proton-spin relaxation).
MacFall, et al., Int J Hyperthermia 11:73-86 (1995).
These te~hniqllRs lack s~lffi~ient spatial resolution for detçcting infl;.,.~ "1f"y foci beneath the surface of moving col.)na.y arteries (particularly ci-~iu"~llex and distal vessels) and carmot be used 'on line' to direct plaque-specific interventional therapies. However, the resolution in these techni~uç,c may be a~eq~3tP in tnick-walled, relatively stationary arteries such as the aorta, carotid 2() and femoral arteries. Toussaint, et la., Arterioscler Ihromb Vas Biol 15:1533-1542 (1995);
Skinner, et al., Nature M~ in~ 1:69 (1995). If lumenal infl~mm~ti-~n can be ~ l,ed from adv~-,lilial infl~lnm~ti~)n~ the latter may prove useful in predicting progression of aortic aneurysms.
F-a~ V:
Therapeutic ~
Lc.~eri-,g serum cholesterol COI~fe-11~ onC by means of diet or drugs can reduce mortality, perhaps because reverse cholesterol LldU~I~ulL reduces the size of the lipid core. However, the most convincing trial to date indi ~ only a 35% decrease in coronary mortality with cholesterol-lowering t'nerapy (and little benefit in women). Scandinavian Simv~tatin Survival Study Group, Lancet 344:1383-1389 (1994). This finding suggests that other factors, such as hRrn~st~tic v~ri~ble,~, are ~rre~ g mortality. However, even with the same patient, plaques progress or regress relatively independently. Gould, Circulation 90:1558-1571 (1~94). This variability suggests that lesion-specific variables (for example, stenosis length, surface thrombosis, low shear stress due to low or turbulent flow, and vasoconsl-i~;lion) increase the risk of thrombosis.
CA 02231425 lsss-03-os Wo 97/10748 PCT/US96/15217 derrn~n, et al., J Am CoU Cardiol 22:1141-1154 (1993); Nobuyoshi, et la., J Am Coll C~rdiol 18:904-910 (1991).
If hot plaques producing stçnos~ in the "non-critical"' range of 10% to 70% are shown to be at high risk of rupture, should they undergo angiopl~ty? If the risk of dilation is similar to that of more severe st~nose~ xi.. ~,ly 1 % mortality, 2 % aorto-corunaly bypass), what is the benefit of collv~,lLing an unstable lesion into one with a 70% chance of long-term patency and a 30% chance of ,~.,t~ -~osis? Even before the recent trials in~lic~tin~ that stents reduce ,~ ..osis rates to 10% to 20%, the large Emory follow-up in~lic~ed an i~entic~l 96% five-year survival rate in patients with and without l~n~ , despite the increased need for repeat angioplasty or bypass surgery in the former group. These data suggest that angioplasty could be bqn~ if the near-term risk of sudden (spontaneous) occlusion is only about 5%.
FY5~ ?1e VI:
Medical Therapies Medical therapies would depend, in part, on whether the infl~mm~ti-)n is on the surface or beneath an intact cap. This ~ n may one day be made by angioscopy (especially with the use of light e ..i~ antibod;es) or by s~mplin~ blood for soluble markers of infl~mmqtjon (P-selectin, VCAM-l, and others). Magn~tic resonance imaging, ultrasound, and near-infrared imaging may also prove helpful.
Therapies might include local delivery of agents (peptides, peptide mimçtiç~, oligonucleotides, and others) that prevent monocyte ~ ui~ ent, ~t~rhm~nt activation, or DNA
synthesis. Conversely, Collagen synthesis might be stim~l d with ascorbic acid or tl~ lllh~g growth factor ,~ (which also acts to inhibit angiogenesis, infl~.. ~l;on, and smooth muscle proliferation in most models, though it can also provoke infl~mm~ion in non-infl~rned tissue and delay endothelial regeneration). Nathan, et al., J Cell Bol 113:981-986 (1991). Endothelial regeneration can be ~nh~nred by basic or acidic fibroblast growth factor or by vascular endothelial growth factor, among others. C~c~cell~, Circulation 91:2699-2702 (1995).
In SU~ living human carotid atherosclerotic plaques exhibit thermal micro-het~,lug,~nt;ily attributable mainly to nla~ ages at or near the lumen. These regions of illclGdsed temperature can be i-1~ntifi~ by t~.c.,llisk~l~ and infrared thermography. If hot plaques are indeed at high risk of thrombosis (or restenosis (Gertz, et al., Circulation 92:1-293 (l99S); Moreno, et al., Circulation 92:1-161 ~1995)) or-in the case of adventitial infl~mm~tion~of ant;ul~ ,al rupture, it may be possible to develop catheter-based and noninvasive means of imaging and treating these potentially life-llllGa~nhlg lesions. These technûlogies might also be used to detect subepithelial W O 97J10748 PCT~US96/1~217 clusters of ;nn;~ n~l~, or m~ n~nt cells in other organs by m ~letic resonance imaging or by endoscopy, oph/~ ..oscopy, laparoscopy, artherusc~y, or transcranial imaging.
* * * * * * * *
The present invention has been described in terms of particular emboriimPnt~ found or proposed to conll)rise ~r~r~ modes for the practice of the invention. It will be appreciated by those of skill in the art that, in light of the present ~ los~re, nunlerolls mc clifirqfinns and changes can be made in the particular embo~im~nt~ e~YPrnriifi~l without departing ~om the intçnfled scope of the invention. For example, while the present invention has been supported by examples in ~e biomedical arts, the ~alus and methods of the invention may be equally well applied to the analysis of wall we~k..~es of any vessel so long as such we~knesses exhibit or can be made to exhibit ~lirre~ .lial heating. Thus, m~nm~-1e vessels such as conduit, if heated externally may be subjected to internal analysis using the a~ald~us and methods of the invention. All such mo~lifi~inns are intçn~ed to be in~luded within the scope of the appended claims.
Claims (56)
1. An apparatus for analyzing optical radiation of a vessel, comprising:
at least one fiber capable of transmitting said radiation and capable of placement proximate to a locus of a wall of said vessel;
a balloon encasing a distal end of said fiber;
said balloon, transparent to said radiation or opaque to said radiation, and having a black inner surface; and, a detector capable of detecting a difference in said radiation between said locus and average optical radiation along said vessel wall.
at least one fiber capable of transmitting said radiation and capable of placement proximate to a locus of a wall of said vessel;
a balloon encasing a distal end of said fiber;
said balloon, transparent to said radiation or opaque to said radiation, and having a black inner surface; and, a detector capable of detecting a difference in said radiation between said locus and average optical radiation along said vessel wall.
2. The apparatus of claim 1, wherein said optical radiation is infra-red radiation.
3. The apparatus of claim 1, wherein said vessel is a blood vessel.
4. The apparatus of claim 1, further comprising at least two fibers.
5. The apparatus of claim 4, wherein at least one of said fibers is a reference fiber and another of said fibers is a signal fiber.
6. The apparatus of claim 5, wherein said distal end of said signal fiber is optically connected to an optically reflective surface capable of directing optical radiation arising radially to said distal end, into said fiber.
7. The apparatus of claim 5, wherein said reference fiber is coated on its distal end with a material that substantially prevents said optical radiation from entering said reference fiber.
8. The apparatus of claim 1, wherein said inner surface of said opaque balloon emits a black body spectrum.
9. The apparatus of claim 1, wherein said balloon, upon inflation, substantially limits flow of fluids within said vessel.
10. The apparatus of claim 1, wherein said balloon, upon inflation, substantially excludes said fluids between said fiber and said wall of said vessel most proximate to said locus.
11. The apparatus of claim 1, wherein said placement is along an axis of said vessel.
12. The apparatus of claim 1, wherein said locus contains plaque.
13. The apparatus of claim 12, wherein said plaque is at risk of rupturing, or at risk of thrombosis due to the presence of inflammatory cells on or beneath the luminal surface of said plaque.
14. The apparatus of claim 1, wherein said wall is interior of said vessel.
15. The apparatus of claim 1, further comprising a catheter.
16. The apparatus of claim 1, further comprising a guidewire.
17. The apparatus of claim 1, wherein said detector is optically connected to a proximal end of said fiber, and if more than one fiber, to a proximal end of each of said fibers.
18. The apparatus of claim 5, wherein said detector further comprises a multi-wavelength radiometer.
19. The apparatus of claim 18, wherein said radiometer further comprises a spinning circular variable filter whose transmission wavelength is a function of its angle of rotation.
20. The apparatus of claim 19, wherein said filter is transparent to radiation with a wavelength of approximately between 2 to 14 micrometers.
21. The apparatus of claim 19, wherein said filter is transparent to radiation with a wavelength of approximately between 3 to 7 micrometers.
22. The apparatus of claim 19, wherein said distal ends of said signal fiber and said reference fiber are offset from one another a distance sufficient to allow sampling of radiation emitted from either fiber to pass said filter at a substantially identical location on said filter.
23. The apparatus of claim 18, wherein said radiometer is optically connected to at least one photoelectric device capable of converting said radiation into an electrical signal.
24. The apparatus of claim 23, wherein said photoelectric device is electrically connected to a device capable of digitizing said electrical signal.
25. The apparatus of claim 24, wherein said digitized signal is mathematically fitted to a curve selected from a spectrum of curves for black bodies held at temperatures betweenapproximately 300-310° K, said curves plotted as numbers of photons emitted from each of said black bodies for each of said wavelengths.
26. A catheter for analyzing infra-red radiation of a blood vessel, comprising:
at least two fibers capable of transmitting said radiation and capable of placement along an axis of said vessel proximate to a plaque-containing locus of an interior wall of said vessel;
wherein at least one of said fibers is a reference fiber coated on its distal end with a material that substantially prevents said optical radiation from entering said reference fiber; and, wherein at least one of the other of said fibers is a signal fiber whose distal end is optically connected to an optically reflective surface capable of directing optical radiation arising radially to said distal end of said signal fiber, into said signal fiber;
a balloon encasing said distal ends of each of said fibers, and which balloon upon inflation substantially limits the flow of fluids within said vessel, and which balloon substantially excludes said fluids between said fibers and said wall of said vessel most proximate to said locus;
said balloon, transparent to said radiation, or opaque to said radiation and having an inner surface exhibiting spatially constant optical radiation emissivity, wherein said inner surface of said opaque balloon emits a black body spectrum;
a guidewire; and, a detector, optically connected to a proximal end of each of said fibers, capable of detecting a difference in said radiation between said locus and average optical radiation along said wall;
said detector further comprising a multi-wavelength radiometer with a spinning circular variable filter, said filter being such that its transmission wavelength is a function of its angle of rotation and is transparent to radiation with a wavelength of approximately 3 micrometers;
said distal ends of said fibers being offset from one another a distance sufficient to allow sampling of radiation emitted from either fiber to pass said filter at a substantially identical position on said filter;
said radiometer optically connected to at least one photoelectric device capable of converting said radiation into an electrical signal, which signal is capable of being digitized, and which digitized signal is mathematically fitted to a curve selected from a spectrum of curves for black bodies held at temperatures between approximately 300-310° K, said curves plotted as numbers of photons emitted from each of said black bodies for each of said wavelengths.
at least two fibers capable of transmitting said radiation and capable of placement along an axis of said vessel proximate to a plaque-containing locus of an interior wall of said vessel;
wherein at least one of said fibers is a reference fiber coated on its distal end with a material that substantially prevents said optical radiation from entering said reference fiber; and, wherein at least one of the other of said fibers is a signal fiber whose distal end is optically connected to an optically reflective surface capable of directing optical radiation arising radially to said distal end of said signal fiber, into said signal fiber;
a balloon encasing said distal ends of each of said fibers, and which balloon upon inflation substantially limits the flow of fluids within said vessel, and which balloon substantially excludes said fluids between said fibers and said wall of said vessel most proximate to said locus;
said balloon, transparent to said radiation, or opaque to said radiation and having an inner surface exhibiting spatially constant optical radiation emissivity, wherein said inner surface of said opaque balloon emits a black body spectrum;
a guidewire; and, a detector, optically connected to a proximal end of each of said fibers, capable of detecting a difference in said radiation between said locus and average optical radiation along said wall;
said detector further comprising a multi-wavelength radiometer with a spinning circular variable filter, said filter being such that its transmission wavelength is a function of its angle of rotation and is transparent to radiation with a wavelength of approximately 3 micrometers;
said distal ends of said fibers being offset from one another a distance sufficient to allow sampling of radiation emitted from either fiber to pass said filter at a substantially identical position on said filter;
said radiometer optically connected to at least one photoelectric device capable of converting said radiation into an electrical signal, which signal is capable of being digitized, and which digitized signal is mathematically fitted to a curve selected from a spectrum of curves for black bodies held at temperatures between approximately 300-310° K, said curves plotted as numbers of photons emitted from each of said black bodies for each of said wavelengths.
27. A method for analyzing optical radiation of a locus in a vessel wall, comprising:
placing at least one optical fiber, capable of transmitting said radiation, proximate to said locus;
inflating a balloon encasing a distal end of said fiber within said vessel to cause said balloon to limit flow of fluids within said vessel, said balloon being transparent to said radiation, or opaque to said radiation and having an inner surface exhibiting spatially constant optical radiation emissivity; and, transmitting said radiation along said fiber to a detector capable of detecting a difference in said radiation between said locus and average optical radiation along said vessel wall.
placing at least one optical fiber, capable of transmitting said radiation, proximate to said locus;
inflating a balloon encasing a distal end of said fiber within said vessel to cause said balloon to limit flow of fluids within said vessel, said balloon being transparent to said radiation, or opaque to said radiation and having an inner surface exhibiting spatially constant optical radiation emissivity; and, transmitting said radiation along said fiber to a detector capable of detecting a difference in said radiation between said locus and average optical radiation along said vessel wall.
28. The method of claim 27, wherein said optical radiation is infra-red radiation.
29. The method of claim 27, wherein said vessel is a blood vessel.
30. The method of claim 27, further comprising placing at least two fibers proximate to said locus.
31. The method of claim 30, wherein at least one of said fibers is a reference fiber and another of said fibers is a signal fiber.
32. The method of claim 31, wherein said distal end of said signal fiber is optically connected to an optically reflective surface capable of directing optical radiation arising radially to said distal end, into said fiber.
33. The method of claim 32, wherein said reference fiber is coated on its distal end with a material that substantially prevents optical radiation from entering said reference fiber.
34. The method of claim 27, wherein said inner surface of said balloon emits a black body spectrum.
35. The method of claim 27, wherein said placement of said fiber is along an axis of said vessel.
36. The method of claim 27, wherein said locus contains plaque.
37. The method of claim 36, wherein said plaque is at risk of rupturing or thrombosis.
38. The method of claim 27, wherein said wall is interior of said vessel.
39. The method of claim 27, wherein said placement of said fiber and said balloon is accomplished by catheterization.
40. The method of claim 39, wherein said catheterization further comprises insertion of a guidewire.
41. The method of claim 27, wherein said detector is optically connected to a proximal end of said fiber, and if more than one fiber, to a proximal end of each of said fibers.
42. The method of claim 31, wherein said detection further comprises passing said radiation through a multi-wavelength radiometer.
43. The method of claim 42, wherein said passing of said radiation through said radiometer further comprises spinning a circular variable filter whose transmission wavelength is a function of its angle of rotation, and passing said radiation through said spinning filter.
44. The method of claim 43, wherein said filter is transparent to and is used to sample radiation with a wavelength of approximately between 2 to 14 micrometers.
45. The method of claim 43, wherein said filter is transparent to and is used to sample radiation with a wavelength of approximately between 3 to 7 micrometers.
46. The method of claim 43, wherein said filter is transparent to and is used to sample radiation with a wavelength of approximately 3 micrometers.
47. The method of claim 42, further comprising offsetting distal ends of said signal fiber and said reference fiber from one another a distance sufficient to allow said sampling of radiation emitted from either fiber to pass said filter at a substantially identical location on said filter.
48. The method of claim 42, wherein detection is further accomplished by optically connecting said radiometer to at least one photoelectric device, and converting said radiation into an electrical signal.
49. The method of claim 48, wherein said detection is further accomplished by digitizing said electrical signal.
50. The method of claim 48, wherein detection is further accomplished by mathematically fitting said digitized signal to a curve selected from a spectrum of curves for black bodies held at temperatures between approximately 300-310° K, and plotting said curves as numbers of photons emitted from each of said black bodies for each of said wavelengths.
51. A method of detecting plaque at risk of rupturing along a blood vessel, comprising:
inserting a guidewire into said vessel;
catheterizing said vessel along said guidewire with at least two fibers capable of transmitting infra-red radiation along an axis of said vessel proximate to a plaque-containing locus of an interior wall of said vessel;
wherein at least one of said fibers is a reference fiber coated on its distal end with a material that substantially prevents said optical radiation from entering said reference fiber; and, wherein at least one of the other of said fibers is a signal fiber whose distal end is optically connected to an optically reflective surface capable of directing optical radiation arising radially to said distal end of said signal fiber, into said signal fiber;
inflating a balloon encasing said distal ends of each of said fibers, and which balloon upon inflation substantially limits the flow of fluids within said vessel, and which balloon substantially excludes said fluids between said fibers and said wall of said vessel most proximate to said locus;
said balloon, transparent to said infra-red radiation, or opaque to said infra-red radiation and having an inner surface exhibiting spatially constant optical radiation emissivity, wherein said inner surface of said opaque balloon emits a black body spectrum;
transmitting said infra-red radiation to a detector, optically connected to a proximal end of each of said fibers, capable of detecting a difference in said radiation between said locus and average optical radiation along said wall;
said detector further comprising a multi-wavelength radiometer with a spinning circular variable filter, said filter being such that its transmission wavelength is a function of its angle of rotation and is transparent to radiation with a wavelength of approximately 3 micrometers;
said distal ends of said fibers being offset from one another a distance sufficient to allow sampling of radiation emitted from either fiber to pass said filter at a substantially identical position on said filter;
said radiometer optically connected to at least one photoelectric device capable of converting said radiation into an electrical signal, which signal is capable of being digitized, and which digitized signal is mathematically fitted to a curve selected from a spectrum of curves for black bodies held at temperatures between approximately 300-310° K, said curves plotted as numbers of photons emitted from each of said black bodies for each of said wavelengths; and, determining if said plaque has a temperature elevated above that of said averagevessel wall temperature.
inserting a guidewire into said vessel;
catheterizing said vessel along said guidewire with at least two fibers capable of transmitting infra-red radiation along an axis of said vessel proximate to a plaque-containing locus of an interior wall of said vessel;
wherein at least one of said fibers is a reference fiber coated on its distal end with a material that substantially prevents said optical radiation from entering said reference fiber; and, wherein at least one of the other of said fibers is a signal fiber whose distal end is optically connected to an optically reflective surface capable of directing optical radiation arising radially to said distal end of said signal fiber, into said signal fiber;
inflating a balloon encasing said distal ends of each of said fibers, and which balloon upon inflation substantially limits the flow of fluids within said vessel, and which balloon substantially excludes said fluids between said fibers and said wall of said vessel most proximate to said locus;
said balloon, transparent to said infra-red radiation, or opaque to said infra-red radiation and having an inner surface exhibiting spatially constant optical radiation emissivity, wherein said inner surface of said opaque balloon emits a black body spectrum;
transmitting said infra-red radiation to a detector, optically connected to a proximal end of each of said fibers, capable of detecting a difference in said radiation between said locus and average optical radiation along said wall;
said detector further comprising a multi-wavelength radiometer with a spinning circular variable filter, said filter being such that its transmission wavelength is a function of its angle of rotation and is transparent to radiation with a wavelength of approximately 3 micrometers;
said distal ends of said fibers being offset from one another a distance sufficient to allow sampling of radiation emitted from either fiber to pass said filter at a substantially identical position on said filter;
said radiometer optically connected to at least one photoelectric device capable of converting said radiation into an electrical signal, which signal is capable of being digitized, and which digitized signal is mathematically fitted to a curve selected from a spectrum of curves for black bodies held at temperatures between approximately 300-310° K, said curves plotted as numbers of photons emitted from each of said black bodies for each of said wavelengths; and, determining if said plaque has a temperature elevated above that of said averagevessel wall temperature.
52. A method of surgically treating a patient with a plurality of plaque loci within a vessel of said patient, comprising:
determining which one or more of said plurality of plaque loci has a temperatureelevated above that of the average vessel wall temperature; and, removing or reducing plaque loci found to have said elevated temperature.
determining which one or more of said plurality of plaque loci has a temperatureelevated above that of the average vessel wall temperature; and, removing or reducing plaque loci found to have said elevated temperature.
53. The method of claim 51, wherein said determination step is accomplished by analyzing optical radiation of said plaque locus in said vessel wall, comprising:
placing at least one fiber, capable of transmitting said radiation, proximate to said locus, initiating a balloon encasing a distal end of said fiber within said vessel to cause said balloon to limit flow of fluids within said vessel, said balloon being transparent to said radiation, or opaque to said radiation and having an inner surface exhibiting spatially constant optical radiation emissivity; and, transmitting said radiation along said fiber to a detector capable of detecting a difference in said radiation between said locus and average optical radiation along said vessel wall.
placing at least one fiber, capable of transmitting said radiation, proximate to said locus, initiating a balloon encasing a distal end of said fiber within said vessel to cause said balloon to limit flow of fluids within said vessel, said balloon being transparent to said radiation, or opaque to said radiation and having an inner surface exhibiting spatially constant optical radiation emissivity; and, transmitting said radiation along said fiber to a detector capable of detecting a difference in said radiation between said locus and average optical radiation along said vessel wall.
54. The use of the device of claim 1 in the method of claim 27.
55. The use of the device of claim 1 to detect inflammation in an organ, vessel, body cavity or opening.
56. The use of the device of claim 1 to detect the absence of living cells in an organ, vessel, body cavity or opening.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US406195P | 1995-09-20 | 1995-09-20 | |
US60/004,061 | 1995-09-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2231425A1 true CA2231425A1 (en) | 1997-03-27 |
Family
ID=21708944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002231425A Abandoned CA2231425A1 (en) | 1995-09-20 | 1996-09-20 | Detecting thermal discrepancies in vessel walls |
Country Status (9)
Country | Link |
---|---|
US (4) | US5935075A (en) |
EP (1) | EP0955883B1 (en) |
JP (1) | JP2000511786A (en) |
AT (1) | ATE221338T1 (en) |
AU (1) | AU709432B2 (en) |
CA (1) | CA2231425A1 (en) |
DE (1) | DE69622764T2 (en) |
MX (1) | MX9802187A (en) |
WO (1) | WO1997010748A1 (en) |
Families Citing this family (439)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6763261B2 (en) | 1995-09-20 | 2004-07-13 | Board Of Regents, The University Of Texas System | Method and apparatus for detecting vulnerable atherosclerotic plaque |
US6615071B1 (en) | 1995-09-20 | 2003-09-02 | Board Of Regents, The University Of Texas System | Method and apparatus for detecting vulnerable atherosclerotic plaque |
AU709432B2 (en) | 1995-09-20 | 1999-08-26 | California Institute Of Technology | Detecting thermal discrepancies in vessel walls |
SE9600334D0 (en) | 1996-01-30 | 1996-01-30 | Radi Medical Systems | Combined flow, pressure and temperature sensor |
US7828749B2 (en) | 1996-05-17 | 2010-11-09 | Roche Diagnostics Operations, Inc. | Blood and interstitial fluid sampling device |
US7235056B2 (en) | 1996-05-17 | 2007-06-26 | Amira Medical | Body fluid sampling device and methods of use |
EP1579814A3 (en) | 1996-05-17 | 2006-06-14 | Roche Diagnostics Operations, Inc. | Methods and apparatus for sampling and analyzing body fluid |
US7666150B2 (en) | 1996-05-17 | 2010-02-23 | Roche Diagnostics Operations, Inc. | Blood and interstitial fluid sampling device |
US20020010406A1 (en) | 1996-05-17 | 2002-01-24 | Douglas Joel S. | Methods and apparatus for expressing body fluid from an incision |
US20020077564A1 (en) * | 1996-07-29 | 2002-06-20 | Farallon Medsystems, Inc. | Thermography catheter |
US6245026B1 (en) | 1996-07-29 | 2001-06-12 | Farallon Medsystems, Inc. | Thermography catheter |
US7603166B2 (en) | 1996-09-20 | 2009-10-13 | Board Of Regents University Of Texas System | Method and apparatus for detection of vulnerable atherosclerotic plaque |
US5906636A (en) | 1996-09-20 | 1999-05-25 | Texas Heart Institute | Heat treatment of inflamed tissue |
US6451044B1 (en) | 1996-09-20 | 2002-09-17 | Board Of Regents, The University Of Texas System | Method and apparatus for heating inflammed tissue |
US5904651A (en) * | 1996-10-28 | 1999-05-18 | Ep Technologies, Inc. | Systems and methods for visualizing tissue during diagnostic or therapeutic procedures |
US5871449A (en) * | 1996-12-27 | 1999-02-16 | Brown; David Lloyd | Device and method for locating inflamed plaque in an artery |
US20040015069A1 (en) * | 1996-12-27 | 2004-01-22 | Brown David Lloyd | System for locating inflamed plaque in a vessel |
US5944750A (en) * | 1997-06-30 | 1999-08-31 | Eva Corporation | Method and apparatus for the surgical repair of aneurysms |
US6203508B1 (en) | 1997-10-16 | 2001-03-20 | Scimed Life Systems, Inc. | Thermal and stress mapping of body lumens |
FR2771504B1 (en) * | 1997-11-24 | 2000-01-28 | Physique Cristalline Imn Cnrs | FIBER OPTIC SENSOR, MULTI-WAVELENGTH, COMPACT, FOR SPECTROSCOPY |
US6036924A (en) | 1997-12-04 | 2000-03-14 | Hewlett-Packard Company | Cassette of lancet cartridges for sampling blood |
US6391005B1 (en) | 1998-03-30 | 2002-05-21 | Agilent Technologies, Inc. | Apparatus and method for penetration with shaft having a sensor for sensing penetration depth |
GR1003178B (en) * | 1998-04-27 | 1999-07-26 | . | System of in-vivo intravascular thermometry of human and animal vessels and of animal tissues in general with the use of a catheter thermometer and a system of external adapter and computer |
US8024027B2 (en) * | 1998-09-03 | 2011-09-20 | Hyperspectral Imaging, Inc. | Infrared endoscopic balloon probes |
US6741884B1 (en) * | 1998-09-03 | 2004-05-25 | Hypermed, Inc. | Infrared endoscopic balloon probes |
US6447460B1 (en) * | 1998-12-09 | 2002-09-10 | Kci Licensing, Inc. | Method for automated exclusion of deep venous thrombosis |
US6165199A (en) * | 1999-01-12 | 2000-12-26 | Coaxia, Inc. | Medical device for removing thromboembolic material from cerebral arteries and methods of use |
US7524289B2 (en) * | 1999-01-25 | 2009-04-28 | Lenker Jay A | Resolution optical and ultrasound devices for imaging and treatment of body lumens |
US8442618B2 (en) * | 1999-05-18 | 2013-05-14 | Mediguide Ltd. | Method and system for delivering a medical device to a selected position within a lumen |
US7840252B2 (en) | 1999-05-18 | 2010-11-23 | MediGuide, Ltd. | Method and system for determining a three dimensional representation of a tubular organ |
US9572519B2 (en) * | 1999-05-18 | 2017-02-21 | Mediguide Ltd. | Method and apparatus for invasive device tracking using organ timing signal generated from MPS sensors |
US9833167B2 (en) | 1999-05-18 | 2017-12-05 | Mediguide Ltd. | Method and system for superimposing virtual anatomical landmarks on an image |
US7778688B2 (en) | 1999-05-18 | 2010-08-17 | MediGuide, Ltd. | System and method for delivering a stent to a selected position within a lumen |
US7343195B2 (en) * | 1999-05-18 | 2008-03-11 | Mediguide Ltd. | Method and apparatus for real time quantitative three-dimensional image reconstruction of a moving organ and intra-body navigation |
US7386339B2 (en) | 1999-05-18 | 2008-06-10 | Mediguide Ltd. | Medical imaging and navigation system |
US7426409B2 (en) * | 1999-06-25 | 2008-09-16 | Board Of Regents, The University Of Texas System | Method and apparatus for detecting vulnerable atherosclerotic plaque |
US6277082B1 (en) | 1999-07-22 | 2001-08-21 | C. R. Bard, Inc. | Ischemia detection system |
US6782289B1 (en) | 1999-10-08 | 2004-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and apparatus for characterizing lesions in blood vessels and other body lumens |
US7328058B2 (en) * | 2000-01-04 | 2008-02-05 | Gamma Medica-Ideas, Inc. | Intravascular imaging detector |
US8241274B2 (en) | 2000-01-19 | 2012-08-14 | Medtronic, Inc. | Method for guiding a medical device |
US6579243B2 (en) | 2000-03-02 | 2003-06-17 | Scimed Life Systems, Inc. | Catheter with thermal sensor for detection of vulnerable plaque |
DE10010694A1 (en) | 2000-03-04 | 2001-09-06 | Roche Diagnostics Gmbh | Lancet including tipped needle with body surrounding tip |
US6536949B1 (en) | 2000-03-07 | 2003-03-25 | Richard R. Heuser | Catheter for thermal evaluation of arteriosclerotic plaque |
US7090645B2 (en) * | 2000-04-04 | 2006-08-15 | Nv Thermocore Medical Systems Sa | Biased vascular temperature measuring device |
US6712771B2 (en) | 2000-06-16 | 2004-03-30 | Accumed Systems, Inc. | Temperature sensing catheter |
US7153273B2 (en) * | 2000-06-16 | 2006-12-26 | Accumed Systems, Inc. | Blood-flow-occluding, temperature-sensing catheters and methods of use |
US20040034303A1 (en) * | 2000-06-16 | 2004-02-19 | Korotko Joseph R. | Blood-flow-occluding, temperature-sensing catheters and methods of use |
FR2812532B1 (en) | 2000-08-01 | 2003-07-04 | Oreal | METHOD FOR ACQUIRING AN IMAGE OF A NON-DERMATHOGLYPHIC ZONE OF THE SKIN OR A HAIR ZONE BY MEANS OF AN ACQUISITION DEVICE INCLUDING A NON-OPTICAL SENSOR |
US6955174B2 (en) * | 2000-08-18 | 2005-10-18 | Uryovascular Systems, Inc. | Cryotherapy method for detecting and treating vulnerable plaque |
JP2004508074A (en) | 2000-08-24 | 2004-03-18 | ボルケーノ セラピューティックス, インコーポレイテッド | Thermographic catheter with flexible circuit temperature sensor |
US7401976B1 (en) * | 2000-08-25 | 2008-07-22 | Art Advanced Research Technologies Inc. | Detection of defects by thermographic analysis |
US20030120171A1 (en) * | 2000-09-08 | 2003-06-26 | Leonidas Diamantopoulos | Vasular temperature measuring device and process for measuring vascular temperature |
US6450971B1 (en) | 2000-10-05 | 2002-09-17 | Scimed Life Systems, Inc. | Temperature measuring balloon |
US20030149368A1 (en) * | 2000-10-24 | 2003-08-07 | Hennemann Willard W. | Method and apparatus for locating and detecting vascular plaque via impedence and conductivity measurements, and for cryogenically passivating vascular plaque and inhibiting vascular plaque progression and rupture |
AU2002230842A1 (en) | 2000-10-30 | 2002-05-15 | The General Hospital Corporation | Optical methods and systems for tissue analysis |
DE10053974A1 (en) | 2000-10-31 | 2002-05-29 | Roche Diagnostics Gmbh | Blood collection system |
JP2002136537A (en) * | 2000-11-01 | 2002-05-14 | Aloka Co Ltd | Blood vessel treatment apparatus and blood vessel treatment system |
US6673066B2 (en) * | 2000-11-10 | 2004-01-06 | Cardiostream, Inc. | Apparatus and method to diagnose and treat vulnerable plaque |
US6575623B2 (en) | 2000-11-10 | 2003-06-10 | Cardiostream, Inc. | Guide wire having extendable contact sensors for measuring temperature of vessel walls |
US9295391B1 (en) | 2000-11-10 | 2016-03-29 | The General Hospital Corporation | Spectrally encoded miniature endoscopic imaging probe |
US8641644B2 (en) | 2000-11-21 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
WO2002056751A2 (en) | 2001-01-22 | 2002-07-25 | Roche Diagnostics Gmbh | Lancet device having capillary action |
US6694181B2 (en) | 2001-02-12 | 2004-02-17 | Scimed Life Systems, Inc. | Methods and devices for detecting vulnerable plaque |
US6589182B1 (en) | 2001-02-12 | 2003-07-08 | Acuson Corporation | Medical diagnostic ultrasound catheter with first and second tip portions |
US6514214B2 (en) | 2001-02-13 | 2003-02-04 | Scimed Life Systems, Inc. | Intravascular temperature sensor |
EP1379162B1 (en) | 2001-03-01 | 2005-10-19 | Scimed Life Systems, Inc. | Catheters with fluorescent temperature sensors |
US20020147480A1 (en) * | 2001-04-04 | 2002-10-10 | Mamayek Donald S. | Treatment of lipid pool |
AT503309B1 (en) | 2001-05-01 | 2011-08-15 | Gen Hospital Corp | DEVICE FOR DETERMINING ATHEROSCLEROTIC BEARING BY MEASURING OPTICAL TISSUE PROPERTIES |
US6716178B1 (en) | 2001-05-31 | 2004-04-06 | Advanced Cardiovascular Systems, Inc. | Apparatus and method for performing thermal and laser doppler velocimetry measurements |
US6697667B1 (en) | 2001-05-31 | 2004-02-24 | Advanced Cardiovascular Systems, Inc. | Apparatus and method for locating coronary sinus |
US7329223B1 (en) * | 2001-05-31 | 2008-02-12 | Abbott Cardiovascular Systems Inc. | Catheter with optical fiber sensor |
US7532920B1 (en) | 2001-05-31 | 2009-05-12 | Advanced Cardiovascular Systems, Inc. | Guidewire with optical fiber |
ES2269717T3 (en) | 2001-06-08 | 2007-04-01 | Roche Diagnostics Gmbh | DEVICE OF EXTRACTION OF SAMPLES OF BODY FLUID AND CARTRIDGE WITH THE MEANS OF ANALYSIS TO BE USED WITH SUCH DEVICE. |
WO2002101343A2 (en) * | 2001-06-12 | 2002-12-19 | Pelikan Technologies, Inc. | Thermal sensor for fluid detection |
ES2357887T3 (en) | 2001-06-12 | 2011-05-03 | Pelikan Technologies Inc. | APPARATUS FOR IMPROVING THE BLOOD OBTAINING SUCCESS RATE FROM A CAPILLARY PUNCTURE. |
WO2002100460A2 (en) | 2001-06-12 | 2002-12-19 | Pelikan Technologies, Inc. | Electric lancet actuator |
EP1404232B1 (en) | 2001-06-12 | 2009-12-02 | Pelikan Technologies Inc. | Blood sampling apparatus and method |
US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
US7981056B2 (en) | 2002-04-19 | 2011-07-19 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US7041068B2 (en) | 2001-06-12 | 2006-05-09 | Pelikan Technologies, Inc. | Sampling module device and method |
US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
US8337419B2 (en) | 2002-04-19 | 2012-12-25 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7316700B2 (en) * | 2001-06-12 | 2008-01-08 | Pelikan Technologies, Inc. | Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties |
AU2002348683A1 (en) | 2001-06-12 | 2002-12-23 | Pelikan Technologies, Inc. | Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge |
US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7160255B2 (en) | 2001-07-12 | 2007-01-09 | Vahid Saadat | Method and device for sensing and mapping temperature profile of a hollow body organ |
US20030013986A1 (en) * | 2001-07-12 | 2003-01-16 | Vahid Saadat | Device for sensing temperature profile of a hollow body organ |
DE10142232B4 (en) | 2001-08-29 | 2021-04-29 | Roche Diabetes Care Gmbh | Process for the production of an analytical aid with a lancet and test element |
US7025734B1 (en) | 2001-09-28 | 2006-04-11 | Advanced Cardiovascular Systmes, Inc. | Guidewire with chemical sensing capabilities |
AU2002365096A1 (en) * | 2001-11-27 | 2003-07-09 | Imetrx, Inc. | Expandable device to profile the wall of a hollow body organ |
US6974557B1 (en) | 2001-12-18 | 2005-12-13 | Advanced Cardiovasculer Systems, Inc. | Methods for forming an optical window for an intracorporeal device and for joining parts |
US20030114732A1 (en) | 2001-12-18 | 2003-06-19 | Advanced Cardiovascular Systems, Inc. | Sheath for guiding imaging instruments |
US7736301B1 (en) * | 2001-12-18 | 2010-06-15 | Advanced Cardiovascular Systems, Inc. | Rotatable ferrules and interfaces for use with an optical guidewire |
US6947787B2 (en) | 2001-12-21 | 2005-09-20 | Advanced Cardiovascular Systems, Inc. | System and methods for imaging within a body lumen |
AU2003207615A1 (en) * | 2002-01-18 | 2003-12-02 | Std Manufacturing, Inc. | Ablation technology for catheter based delivery systems |
US7355716B2 (en) | 2002-01-24 | 2008-04-08 | The General Hospital Corporation | Apparatus and method for ranging and noise reduction of low coherence interferometry LCI and optical coherence tomography OCT signals by parallel detection of spectral bands |
CA2372637A1 (en) * | 2002-02-20 | 2003-08-20 | Institut National D'optique | Packaged optical sensors on the side of optical fibres |
US8145317B2 (en) | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods for renal neuromodulation |
US7620451B2 (en) | 2005-12-29 | 2009-11-17 | Ardian, Inc. | Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach |
US20080213331A1 (en) | 2002-04-08 | 2008-09-04 | Ardian, Inc. | Methods and devices for renal nerve blocking |
US8347891B2 (en) | 2002-04-08 | 2013-01-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen |
US6978174B2 (en) | 2002-04-08 | 2005-12-20 | Ardian, Inc. | Methods and devices for renal nerve blocking |
US9308043B2 (en) | 2002-04-08 | 2016-04-12 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for monopolar renal neuromodulation |
US7617005B2 (en) | 2002-04-08 | 2009-11-10 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US7853333B2 (en) | 2002-04-08 | 2010-12-14 | Ardian, Inc. | Methods and apparatus for multi-vessel renal neuromodulation |
US8131371B2 (en) | 2002-04-08 | 2012-03-06 | Ardian, Inc. | Methods and apparatus for monopolar renal neuromodulation |
US8150520B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods for catheter-based renal denervation |
US7756583B2 (en) | 2002-04-08 | 2010-07-13 | Ardian, Inc. | Methods and apparatus for intravascularly-induced neuromodulation |
US20140018880A1 (en) | 2002-04-08 | 2014-01-16 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for monopolar renal neuromodulation |
US8774922B2 (en) | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods |
US9636174B2 (en) | 2002-04-08 | 2017-05-02 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
US20070129761A1 (en) | 2002-04-08 | 2007-06-07 | Ardian, Inc. | Methods for treating heart arrhythmia |
US9308044B2 (en) | 2002-04-08 | 2016-04-12 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
US20070135875A1 (en) | 2002-04-08 | 2007-06-14 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US8145316B2 (en) | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US8774913B2 (en) | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for intravasculary-induced neuromodulation |
US8150519B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods and apparatus for bilateral renal neuromodulation |
US7653438B2 (en) | 2002-04-08 | 2010-01-26 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US7162303B2 (en) | 2002-04-08 | 2007-01-09 | Ardian, Inc. | Renal nerve stimulation method and apparatus for treatment of patients |
US7232451B2 (en) | 2002-04-19 | 2007-06-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8267870B2 (en) | 2002-04-19 | 2012-09-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling with hybrid actuation |
US7901362B2 (en) | 2002-04-19 | 2011-03-08 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8579831B2 (en) | 2002-04-19 | 2013-11-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7175642B2 (en) | 2002-04-19 | 2007-02-13 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US7648468B2 (en) | 2002-04-19 | 2010-01-19 | Pelikon Technologies, Inc. | Method and apparatus for penetrating tissue |
US7491178B2 (en) | 2002-04-19 | 2009-02-17 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7297122B2 (en) | 2002-04-19 | 2007-11-20 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8221334B2 (en) | 2002-04-19 | 2012-07-17 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8360992B2 (en) | 2002-04-19 | 2013-01-29 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7892183B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US8702624B2 (en) | 2006-09-29 | 2014-04-22 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US9795334B2 (en) | 2002-04-19 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7371247B2 (en) | 2002-04-19 | 2008-05-13 | Pelikan Technologies, Inc | Method and apparatus for penetrating tissue |
AU2003231749A1 (en) * | 2002-04-19 | 2003-11-03 | Pelikan Technologies, Inc. | Device and method for variable speed lancet |
US7976476B2 (en) | 2002-04-19 | 2011-07-12 | Pelikan Technologies, Inc. | Device and method for variable speed lancet |
US7909778B2 (en) | 2002-04-19 | 2011-03-22 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7547287B2 (en) | 2002-04-19 | 2009-06-16 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7141058B2 (en) * | 2002-04-19 | 2006-11-28 | Pelikan Technologies, Inc. | Method and apparatus for a body fluid sampling device using illumination |
US8784335B2 (en) | 2002-04-19 | 2014-07-22 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling device with a capacitive sensor |
US7229458B2 (en) | 2002-04-19 | 2007-06-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8372016B2 (en) | 2002-04-19 | 2013-02-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling and analyte sensing |
US7674232B2 (en) | 2002-04-19 | 2010-03-09 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7331931B2 (en) | 2002-04-19 | 2008-02-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7717863B2 (en) | 2002-04-19 | 2010-05-18 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US9248267B2 (en) | 2002-04-19 | 2016-02-02 | Sanofi-Aventis Deustchland Gmbh | Tissue penetration device |
US20030236443A1 (en) * | 2002-04-19 | 2003-12-25 | Cespedes Eduardo Ignacio | Methods and apparatus for the identification and stabilization of vulnerable plaque |
US7708701B2 (en) | 2002-04-19 | 2010-05-04 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device |
US7291117B2 (en) | 2002-04-19 | 2007-11-06 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
AU2003239375A1 (en) * | 2002-05-07 | 2003-11-11 | Volcano Therapeutics, Inc. | Systems and methods for detecting vulnerable plaque |
US20030220556A1 (en) * | 2002-05-20 | 2003-11-27 | Vespro Ltd. | Method, system and device for tissue characterization |
US20040082859A1 (en) | 2002-07-01 | 2004-04-29 | Alan Schaer | Method and apparatus employing ultrasound energy to treat body sphincters |
US7288244B2 (en) * | 2002-07-02 | 2007-10-30 | Nv Thermocore Medical Systems Sa | Determining vulnerable plaque in blood vessels |
WO2004012589A2 (en) * | 2002-08-05 | 2004-02-12 | Miravant Medical Technologies, Inc. | Catheter for diagnosis and treatment of diseased vessels |
US7689268B2 (en) * | 2002-08-05 | 2010-03-30 | Infraredx, Inc. | Spectroscopic unwanted signal filters for discrimination of vulnerable plaque and method therefor |
AU2003258124A1 (en) * | 2002-08-05 | 2004-02-23 | Miravant Medical Technologies | Light delivery catheter |
US7326238B1 (en) * | 2002-09-30 | 2008-02-05 | Abbott Cardiovascular Systems Inc. | Method and apparatus for treating vulnerable plaque |
US20060265043A1 (en) * | 2002-09-30 | 2006-11-23 | Evgenia Mandrusov | Method and apparatus for treating vulnerable plaque |
US7008411B1 (en) * | 2002-09-30 | 2006-03-07 | Advanced Cardiovascular Systems, Inc. | Method and apparatus for treating vulnerable plaque |
DE10249643A1 (en) * | 2002-10-24 | 2004-05-13 | Siemens Ag | Coronary heart disease diagnosis and treatment method in which plaque deposition in blood vessels of interest is monitored over time and compared with reference values stored in the memory of a data processing unit |
US6835177B2 (en) * | 2002-11-06 | 2004-12-28 | Sonosite, Inc. | Ultrasonic blood vessel measurement apparatus and method |
US7731900B2 (en) * | 2002-11-26 | 2010-06-08 | Roche Diagnostics Operations, Inc. | Body fluid testing device |
AU2003300540A1 (en) | 2002-12-23 | 2004-07-14 | F. Hoffmann-La Roche Ag | Body fluid testing device |
US7582258B2 (en) | 2002-12-23 | 2009-09-01 | Roche Diagnostics Operations, Inc. | Body fluid testing device |
US8574895B2 (en) | 2002-12-30 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
AU2003300052A1 (en) * | 2002-12-31 | 2004-08-10 | John Herbert Cafarella | Multi-sensor breast tumor detection |
US20040133109A1 (en) * | 2003-01-07 | 2004-07-08 | Scimed Life Systems, Inc. | Systems and methods for acoustic thermal imaging |
US7505809B2 (en) * | 2003-01-13 | 2009-03-17 | Mediguide Ltd. | Method and system for registering a first image with a second image relative to the body of a patient |
IL154101A0 (en) * | 2003-01-23 | 2003-07-31 | Univ Ramot | Minimally invasive controlled surgical system with feedback |
US7567349B2 (en) | 2003-03-31 | 2009-07-28 | The General Hospital Corporation | Speckle reduction in optical coherence tomography by path length encoded angular compounding |
US8054468B2 (en) | 2003-01-24 | 2011-11-08 | The General Hospital Corporation | Apparatus and method for ranging and noise reduction of low coherence interferometry LCI and optical coherence tomography OCT signals by parallel detection of spectral bands |
US7166088B2 (en) | 2003-01-27 | 2007-01-23 | Heuser Richard R | Catheter introducer system |
US20040167467A1 (en) * | 2003-02-21 | 2004-08-26 | Kent Harrison | Delivering cooled fluid to sites inside the body |
US7004911B1 (en) | 2003-02-24 | 2006-02-28 | Hosheng Tu | Optical thermal mapping for detecting vulnerable plaque |
US7153299B1 (en) | 2003-02-24 | 2006-12-26 | Maxwell Sensors Inc. | Optical apparatus for detecting and treating vulnerable plaque |
US7297154B2 (en) * | 2003-02-24 | 2007-11-20 | Maxwell Sensors Inc. | Optical apparatus for detecting and treating vulnerable plaque |
US6953425B2 (en) * | 2003-04-25 | 2005-10-11 | Medtronic Vascular, Inc. | Method of treating vulnerable plaque using a catheter-based radiation system |
US20040243022A1 (en) * | 2003-04-29 | 2004-12-02 | Medtronic Vascular, Inc. | Method and system of detecting vulnerable plaque by sensing motion of thin fibrous cap |
US7118567B2 (en) * | 2003-04-30 | 2006-10-10 | Medtronic Vascular, Inc. | Method for treating vulnerable plaque |
US20040236275A1 (en) * | 2003-05-20 | 2004-11-25 | Pruitt Sean R. | Catheter having a light emitting component |
ES2347248T3 (en) | 2003-05-30 | 2010-10-27 | Pelikan Technologies Inc. | PROCEDURE AND APPLIANCE FOR FLUID INJECTION. |
US6932776B2 (en) * | 2003-06-02 | 2005-08-23 | Meridian Medicalssystems, Llc | Method and apparatus for detecting and treating vulnerable plaques |
KR101546024B1 (en) | 2003-06-06 | 2015-08-20 | 더 제너럴 하스피탈 코포레이션 | Process and apparatus for a wavelength tunning source |
US7850621B2 (en) | 2003-06-06 | 2010-12-14 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
WO2006001797A1 (en) | 2004-06-14 | 2006-01-05 | Pelikan Technologies, Inc. | Low pain penetrating |
US20040260182A1 (en) * | 2003-06-23 | 2004-12-23 | Zuluaga Andres F. | Intraluminal spectroscope with wall contacting probe |
US7263398B2 (en) * | 2003-06-25 | 2007-08-28 | Meridian Medical Systems, Llc | Apparatus for measuring intravascular blood flow |
US7539530B2 (en) * | 2003-08-22 | 2009-05-26 | Infraredx, Inc. | Method and system for spectral examination of vascular walls through blood during cardiac motion |
US6949072B2 (en) * | 2003-09-22 | 2005-09-27 | Infraredx, Inc. | Devices for vulnerable plaque detection |
DE10343808B4 (en) * | 2003-09-22 | 2017-06-01 | Siemens Healthcare Gmbh | Medical examination and / or treatment system |
WO2005033659A2 (en) | 2003-09-29 | 2005-04-14 | Pelikan Technologies, Inc. | Method and apparatus for an improved sample capture device |
US7651506B2 (en) * | 2003-10-02 | 2010-01-26 | University Of Florida Research Foundation, Inc. | Frameless stereotactic guidance of medical procedures |
US9351680B2 (en) | 2003-10-14 | 2016-05-31 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a variable user interface |
US7195599B2 (en) * | 2003-10-22 | 2007-03-27 | Medtronic Vascular, Inc. | Instrumented catheter with distance compensation to sense vulnerable plaque |
KR101384553B1 (en) | 2003-10-27 | 2014-04-11 | 더 제너럴 하스피탈 코포레이션 | Method and apparatus for performing optical imaging using frequency-domain interferometry |
US7326195B2 (en) * | 2003-11-18 | 2008-02-05 | Boston Scientific Scimed, Inc. | Targeted cooling of tissue within a body |
US8668656B2 (en) | 2003-12-31 | 2014-03-11 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for improving fluidic flow and sample capture |
US7822454B1 (en) | 2005-01-03 | 2010-10-26 | Pelikan Technologies, Inc. | Fluid sampling device with improved analyte detecting member configuration |
US20050171437A1 (en) * | 2004-01-14 | 2005-08-04 | Neptec Optical Solutions, Inc. | Optical switching system for catheter-based analysis and treatment |
US20080234569A1 (en) * | 2004-01-20 | 2008-09-25 | Topspin Medical (Israel) Ltd. | Mri Probe for Prostate Imaging |
US7972298B2 (en) | 2004-03-05 | 2011-07-05 | Hansen Medical, Inc. | Robotic catheter system |
US7775087B2 (en) * | 2004-03-16 | 2010-08-17 | Northwestern University | Microchannel forming method and nanotipped dispensing device having a microchannel |
JP4554967B2 (en) * | 2004-03-25 | 2010-09-29 | テルモ株式会社 | Ultrasonic catheter and diagnostic imaging apparatus |
US8828203B2 (en) | 2004-05-20 | 2014-09-09 | Sanofi-Aventis Deutschland Gmbh | Printable hydrogels for biosensors |
EP1754016B1 (en) | 2004-05-29 | 2016-05-18 | The General Hospital Corporation | Process, system and software arrangement for a chromatic dispersion compensation using reflective layers in optical coherence tomography (oct) imaging |
US9775553B2 (en) | 2004-06-03 | 2017-10-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
EP1765194A4 (en) | 2004-06-03 | 2010-09-29 | Pelikan Technologies Inc | Method and apparatus for a fluid sampling device |
US7447408B2 (en) | 2004-07-02 | 2008-11-04 | The General Hospital Corproation | Imaging system and related techniques |
WO2006014993A1 (en) * | 2004-07-27 | 2006-02-09 | Medeikon Corporation | Device for tissue characterization |
US20060025840A1 (en) * | 2004-08-02 | 2006-02-02 | Martin Willard | Cooling tissue inside the body |
KR101332222B1 (en) | 2004-08-06 | 2013-11-22 | 더 제너럴 하스피탈 코포레이션 | Process, system and software arrangement for determining at least one location in a sample using an optical coherence tomography |
EP2272421A1 (en) | 2004-08-24 | 2011-01-12 | The General Hospital Corporation | Method and apparatus for imaging of vessel segments |
JP5334415B2 (en) | 2004-08-24 | 2013-11-06 | ザ ジェネラル ホスピタル コーポレイション | Process, system and software for measuring mechanical strain and elastic properties of samples |
US8545418B2 (en) | 2004-08-25 | 2013-10-01 | Richard R. Heuser | Systems and methods for ablation of occlusions within blood vessels |
US7365859B2 (en) | 2004-09-10 | 2008-04-29 | The General Hospital Corporation | System and method for optical coherence imaging |
US7366376B2 (en) | 2004-09-29 | 2008-04-29 | The General Hospital Corporation | System and method for optical coherence imaging |
US20060084866A1 (en) * | 2004-10-18 | 2006-04-20 | Gadi Lewkonya | Expanding imaging probe |
US20060084861A1 (en) * | 2004-10-18 | 2006-04-20 | Topspin Medical (Isreal) Ltd. | Magnet and coil configurations for MRI probes |
US7937143B2 (en) | 2004-11-02 | 2011-05-03 | Ardian, Inc. | Methods and apparatus for inducing controlled renal neuromodulation |
US7846147B2 (en) * | 2004-11-18 | 2010-12-07 | Advanced Cardiovascular Systems, Inc. | Vulnerable plaque treatment |
EP2278266A3 (en) | 2004-11-24 | 2011-06-29 | The General Hospital Corporation | Common-Path Interferometer for Endoscopic OCT |
US8922781B2 (en) | 2004-11-29 | 2014-12-30 | The General Hospital Corporation | Arrangements, devices, endoscopes, catheters and methods for performing optical imaging by simultaneously illuminating and detecting multiple points on a sample |
US8652831B2 (en) | 2004-12-30 | 2014-02-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte measurement test time |
US7560227B2 (en) * | 2005-02-28 | 2009-07-14 | University Of Massachusetts | Biomarkers of vulnerable atherosclerotic plaques and methods of use |
JP5583340B2 (en) * | 2005-04-18 | 2014-09-03 | ガスポロックス エイビー | Body cavity gas measuring device and measuring method |
KR101410867B1 (en) | 2005-04-28 | 2014-06-23 | 더 제너럴 하스피탈 코포레이션 | Systems, processes and software arrangements for evaluating information associated with an anatomical structure by an optical coherence ranging technique |
EP1889037A2 (en) | 2005-06-01 | 2008-02-20 | The General Hospital Corporation | Apparatus, method and system for performing phase-resolved optical frequency domain imaging |
DE602006017558D1 (en) | 2005-08-09 | 2010-11-25 | Gen Hospital Corp | DEVICE AND METHOD FOR CARRYING OUT POLARIZATION-BASED QUADRATURE DEMODULATION IN OPTICAL COHERENCE TOMOGRAPHY |
EP1937137B1 (en) | 2005-09-29 | 2022-06-15 | General Hospital Corporation | Method and apparatus for optical imaging via spectral encoding |
US7450241B2 (en) * | 2005-09-30 | 2008-11-11 | Infraredx, Inc. | Detecting vulnerable plaque |
WO2007041542A2 (en) * | 2005-09-30 | 2007-04-12 | Cornova, Inc. | Systems and methods for analysis and treatment of a body lumen |
US20070270717A1 (en) * | 2005-09-30 | 2007-11-22 | Cornova, Inc. | Multi-faceted optical reflector |
EP1945094B1 (en) | 2005-10-14 | 2018-09-05 | The General Hospital Corporation | Spectral- and frequency- encoded fluorescence imaging |
US7313499B2 (en) * | 2006-01-03 | 2007-12-25 | Ut-Battelle Llc | Apparatus for characterizing the temporo-spatial properties of a dynamic fluid front and method thereof |
JP5680826B2 (en) | 2006-01-10 | 2015-03-04 | ザ ジェネラル ホスピタル コーポレイション | Data generation system using endoscopic technology for encoding one or more spectra |
US8145018B2 (en) | 2006-01-19 | 2012-03-27 | The General Hospital Corporation | Apparatus for obtaining information for a structure using spectrally-encoded endoscopy techniques and methods for producing one or more optical arrangements |
US9087368B2 (en) | 2006-01-19 | 2015-07-21 | The General Hospital Corporation | Methods and systems for optical imaging or epithelial luminal organs by beam scanning thereof |
US8062321B2 (en) | 2006-01-25 | 2011-11-22 | Pq Bypass, Inc. | Catheter system for connecting adjacent blood vessels |
EP2659852A3 (en) | 2006-02-01 | 2014-01-15 | The General Hospital Corporation | Apparatus for applying a plurality of electro-magnetic radiations to a sample |
US10426548B2 (en) | 2006-02-01 | 2019-10-01 | The General Hosppital Corporation | Methods and systems for providing electromagnetic radiation to at least one portion of a sample using conformal laser therapy procedures |
WO2007092911A2 (en) | 2006-02-08 | 2007-08-16 | The General Hospital Corporation | Methods, arrangements and systems for obtaining information associated with an anatomical sample using optical microscopy |
US7749249B2 (en) | 2006-02-21 | 2010-07-06 | Kardium Inc. | Method and device for closing holes in tissue |
WO2007101026A2 (en) | 2006-02-24 | 2007-09-07 | The General Hospital Corporation | Methods and systems for performing angle-resolved fourier-domain optical coherence tomography |
US7742173B2 (en) | 2006-04-05 | 2010-06-22 | The General Hospital Corporation | Methods, arrangements and systems for polarization-sensitive optical frequency domain imaging of a sample |
WO2007133961A2 (en) | 2006-05-10 | 2007-11-22 | The General Hospital Corporation | Processes, arrangements and systems for providing frequency domain imaging of a sample |
WO2007133964A2 (en) | 2006-05-12 | 2007-11-22 | The General Hospital Corporation | Processes, arrangements and systems for providing a fiber layer thickness map based on optical coherence tomography images |
US20070270688A1 (en) | 2006-05-19 | 2007-11-22 | Daniel Gelbart | Automatic atherectomy system |
WO2007140331A2 (en) | 2006-05-25 | 2007-12-06 | Medtronic, Inc. | Methods of using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions |
US8920411B2 (en) | 2006-06-28 | 2014-12-30 | Kardium Inc. | Apparatus and method for intra-cardiac mapping and ablation |
US11389232B2 (en) | 2006-06-28 | 2022-07-19 | Kardium Inc. | Apparatus and method for intra-cardiac mapping and ablation |
US10028783B2 (en) | 2006-06-28 | 2018-07-24 | Kardium Inc. | Apparatus and method for intra-cardiac mapping and ablation |
US9119633B2 (en) | 2006-06-28 | 2015-09-01 | Kardium Inc. | Apparatus and method for intra-cardiac mapping and ablation |
US8449605B2 (en) | 2006-06-28 | 2013-05-28 | Kardium Inc. | Method for anchoring a mitral valve |
US7837610B2 (en) | 2006-08-02 | 2010-11-23 | Kardium Inc. | System for improving diastolic dysfunction |
US20080033300A1 (en) * | 2006-08-04 | 2008-02-07 | Anh Hoang | Systems and methods for monitoring temperature during electrosurgery or laser therapy |
EP2054712B1 (en) | 2006-08-25 | 2015-10-07 | The General Hospital Corporation | Apparatus and methods for enhancing optical coherence tomography imaging using volumetric filtering techniques |
US8882674B2 (en) * | 2006-09-28 | 2014-11-11 | Research Foundation Of The City University Of New York | System and method for in vivo imaging of blood vessel walls to detect microcalcifications |
US20090187108A1 (en) * | 2006-09-29 | 2009-07-23 | Cornova, Inc. | Systems and methods for analysis and treatment of a body lumen |
WO2008049118A2 (en) | 2006-10-19 | 2008-04-24 | The General Hospital Corporation | Apparatus and method for obtaining and providing imaging information associated with at least one portion of a sample and effecting such portion(s) |
US8077939B2 (en) * | 2006-11-22 | 2011-12-13 | General Electric Company | Methods and systems for enhanced plaque visualization |
US9113785B2 (en) * | 2006-12-22 | 2015-08-25 | Cornova, Inc. | Fluid media for bio-sensitive applications |
EP2662674A3 (en) | 2007-01-19 | 2014-06-25 | The General Hospital Corporation | Rotating disk reflection for fast wavelength scanning of dispersed broadbend light |
US9176319B2 (en) | 2007-03-23 | 2015-11-03 | The General Hospital Corporation | Methods, arrangements and apparatus for utilizing a wavelength-swept laser using angular scanning and dispersion procedures |
US10534129B2 (en) | 2007-03-30 | 2020-01-14 | The General Hospital Corporation | System and method providing intracoronary laser speckle imaging for the detection of vulnerable plaque |
US8045177B2 (en) | 2007-04-17 | 2011-10-25 | The General Hospital Corporation | Apparatus and methods for measuring vibrations using spectrally-encoded endoscopy |
US8115919B2 (en) | 2007-05-04 | 2012-02-14 | The General Hospital Corporation | Methods, arrangements and systems for obtaining information associated with a sample using optical microscopy |
US8003157B2 (en) | 2007-06-15 | 2011-08-23 | Abbott Cardiovascular Systems Inc. | System and method for coating a stent |
US8677650B2 (en) * | 2007-06-15 | 2014-03-25 | Abbott Cardiovascular Systems Inc. | Methods and devices for drying coated stents |
US20100174196A1 (en) * | 2007-06-21 | 2010-07-08 | Cornova, Inc. | Systems and methods for guiding the analysis and treatment of a body lumen |
JP5917803B2 (en) | 2007-07-31 | 2016-05-18 | ザ ジェネラル ホスピタル コーポレイション | System and method for emitting a beam scanning pattern for fast Doppler optical frequency domain imaging |
US8040608B2 (en) | 2007-08-31 | 2011-10-18 | The General Hospital Corporation | System and method for self-interference fluorescence microscopy, and computer-accessible medium associated therewith |
WO2009059034A1 (en) | 2007-10-30 | 2009-05-07 | The General Hospital Corporation | System and method for cladding mode detection |
US8906011B2 (en) | 2007-11-16 | 2014-12-09 | Kardium Inc. | Medical device for use in bodily lumens, for example an atrium |
US20090287191A1 (en) * | 2007-12-18 | 2009-11-19 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Circulatory monitoring systems and methods |
US20090292214A1 (en) * | 2008-05-22 | 2009-11-26 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Circulatory monitoring systems and methods |
US20100036263A1 (en) * | 2008-08-07 | 2010-02-11 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Circulatory monitoring systems and methods |
US20090287120A1 (en) | 2007-12-18 | 2009-11-19 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Circulatory monitoring systems and methods |
US20090292213A1 (en) * | 2008-05-21 | 2009-11-26 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Circulatory monitoring systems and methods |
US20090287101A1 (en) * | 2008-05-13 | 2009-11-19 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Circulatory monitoring systems and methods |
US9717896B2 (en) | 2007-12-18 | 2017-08-01 | Gearbox, Llc | Treatment indications informed by a priori implant information |
US8636670B2 (en) | 2008-05-13 | 2014-01-28 | The Invention Science Fund I, Llc | Circulatory monitoring systems and methods |
US20090287109A1 (en) * | 2008-05-14 | 2009-11-19 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Circulatory monitoring systems and methods |
US20090163856A1 (en) * | 2007-12-19 | 2009-06-25 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Treatment indications informed by a prior implant information |
US20090292212A1 (en) * | 2008-05-20 | 2009-11-26 | Searete Llc, A Limited Corporation Of The State Of Delaware | Circulatory monitoring systems and methods |
US20090175576A1 (en) * | 2008-01-08 | 2009-07-09 | Cornova, Inc. | Shaped fiber ends and methods of making same |
US8489172B2 (en) | 2008-01-25 | 2013-07-16 | Kardium Inc. | Liposuction system |
US9386944B2 (en) | 2008-04-11 | 2016-07-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte detecting device |
US9125562B2 (en) | 2009-07-01 | 2015-09-08 | Avinger, Inc. | Catheter-based off-axis optical coherence tomography imaging system |
US8062316B2 (en) | 2008-04-23 | 2011-11-22 | Avinger, Inc. | Catheter system and method for boring through blocked vascular passages |
US7898656B2 (en) | 2008-04-30 | 2011-03-01 | The General Hospital Corporation | Apparatus and method for cross axis parallel spectroscopy |
WO2009137701A2 (en) | 2008-05-07 | 2009-11-12 | The General Hospital Corporation | System, method and computer-accessible medium for tracking vessel motion during three-dimensional coronary artery microscopy |
US20090287304A1 (en) | 2008-05-13 | 2009-11-19 | Kardium Inc. | Medical Device for Constricting Tissue or a Bodily Orifice, for example a mitral valve |
ES2715633T3 (en) | 2008-05-20 | 2019-06-05 | Univ Health Network | Device and method for imaging and fluorescence monitoring |
US8861910B2 (en) | 2008-06-20 | 2014-10-14 | The General Hospital Corporation | Fused fiber optic coupler arrangement and method for use thereof |
EP2309923B1 (en) | 2008-07-14 | 2020-11-25 | The General Hospital Corporation | Apparatus and methods for color endoscopy |
CH699338B1 (en) * | 2008-08-06 | 2012-01-13 | Carag Ag | Device for measuring the blood flow in a body tissue. |
US8260390B2 (en) * | 2008-10-15 | 2012-09-04 | Angiolight, Inc. | Systems and methods for analysis and treatment of an occluded body lumen |
US9259270B2 (en) * | 2008-11-07 | 2016-02-16 | Joe Denton Brown | Apparatus and method for detecting overheating during laser surgery |
US9795442B2 (en) | 2008-11-11 | 2017-10-24 | Shifamed Holdings, Llc | Ablation catheters |
US8805466B2 (en) * | 2008-11-11 | 2014-08-12 | Shifamed Holdings, Llc | Low profile electrode assembly |
US8937724B2 (en) | 2008-12-10 | 2015-01-20 | The General Hospital Corporation | Systems and methods for extending imaging depth range of optical coherence tomography through optical sub-sampling |
US8864669B2 (en) * | 2008-12-29 | 2014-10-21 | Perseus-Biomed Inc. | Method and system for tissue imaging and analysis |
US8870772B2 (en) * | 2008-12-29 | 2014-10-28 | Perseus-Biomed Inc. | Method and system for tissue recognition |
US8882672B2 (en) | 2008-12-29 | 2014-11-11 | Perseus-Biomed Inc. | Method and system for tissue imaging and analysis |
US8652129B2 (en) | 2008-12-31 | 2014-02-18 | Medtronic Ardian Luxembourg S.A.R.L. | Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation |
US8974445B2 (en) | 2009-01-09 | 2015-03-10 | Recor Medical, Inc. | Methods and apparatus for treatment of cardiac valve insufficiency |
WO2010090837A2 (en) | 2009-01-20 | 2010-08-12 | The General Hospital Corporation | Endoscopic biopsy apparatus, system and method |
EP2382456A4 (en) | 2009-01-26 | 2012-07-25 | Gen Hospital Corp | System, method and computer-accessible medium for providing wide-field superresolution microscopy |
US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
GB0901609D0 (en) * | 2009-01-30 | 2009-03-11 | Laryngeal Mask Company The Ltd | Temperature measurement system |
US8939914B2 (en) | 2009-02-27 | 2015-01-27 | Thermimage, Inc. | Radiometers and related devices and methods |
US8939912B2 (en) * | 2009-02-27 | 2015-01-27 | Thermimage, Inc. | Tissue heating and monitoring system with seat |
US9351642B2 (en) | 2009-03-12 | 2016-05-31 | The General Hospital Corporation | Non-contact optical system, computer-accessible medium and method for measurement at least one mechanical property of tissue using coherent speckle technique(s) |
EP2424608B1 (en) | 2009-04-28 | 2014-03-19 | Avinger, Inc. | Guidewire support catheter |
WO2010135601A2 (en) * | 2009-05-20 | 2010-11-25 | Cornova, Inc. | Systems and methods for analysis and treatment of a body lumen |
CN102460118B (en) | 2009-05-28 | 2015-03-25 | 阿维格公司 | Optical coherence tomography for biological imaging |
WO2011003006A2 (en) | 2009-07-01 | 2011-01-06 | Avinger, Inc. | Atherectomy catheter with laterally-displaceable tip |
JP5819823B2 (en) | 2009-07-14 | 2015-11-24 | ザ ジェネラル ホスピタル コーポレイション | Device for measuring the flow and pressure inside a blood vessel and method of operating the device |
EP2482749B1 (en) | 2009-10-01 | 2017-08-30 | Kardium Inc. | Kit for constricting tissue or a bodily orifice, for example, a mitral valve |
EP2509498B1 (en) * | 2009-12-08 | 2020-09-16 | Avinger, Inc. | Devices for predicting and preventing restenosis |
EP2542145B1 (en) | 2010-03-05 | 2020-08-12 | The General Hospital Corporation | Systems which provide microscopic images of at least one anatomical structure at a particular resolution |
US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9069130B2 (en) | 2010-05-03 | 2015-06-30 | The General Hospital Corporation | Apparatus, method and system for generating optical radiation from biological gain media |
US9655677B2 (en) | 2010-05-12 | 2017-05-23 | Shifamed Holdings, Llc | Ablation catheters including a balloon and electrodes |
WO2011149972A2 (en) | 2010-05-25 | 2011-12-01 | The General Hospital Corporation | Systems, devices, methods, apparatus and computer-accessible media for providing optical imaging of structures and compositions |
WO2011150069A2 (en) | 2010-05-25 | 2011-12-01 | The General Hospital Corporation | Apparatus, systems, methods and computer-accessible medium for spectral analysis of optical coherence tomography images |
US10285568B2 (en) | 2010-06-03 | 2019-05-14 | The General Hospital Corporation | Apparatus and method for devices for imaging structures in or at one or more luminal organs |
US8672837B2 (en) | 2010-06-24 | 2014-03-18 | Hansen Medical, Inc. | Methods and devices for controlling a shapeable medical device |
WO2014039096A1 (en) | 2012-09-06 | 2014-03-13 | Avinger, Inc. | Re-entry stylet for catheter |
WO2014039099A1 (en) | 2012-09-06 | 2014-03-13 | Avinger, Inc. | Balloon atherectomy catheters with imaging |
US11382653B2 (en) | 2010-07-01 | 2022-07-12 | Avinger, Inc. | Atherectomy catheter |
US9345510B2 (en) | 2010-07-01 | 2016-05-24 | Avinger, Inc. | Atherectomy catheters with longitudinally displaceable drive shafts |
US8940002B2 (en) | 2010-09-30 | 2015-01-27 | Kardium Inc. | Tissue anchor system |
US9066720B2 (en) | 2010-10-25 | 2015-06-30 | Medtronic Ardian Luxembourg S.A.R.L. | Devices, systems and methods for evaluation and feedback of neuromodulation treatment |
US9510758B2 (en) | 2010-10-27 | 2016-12-06 | The General Hospital Corporation | Apparatus, systems and methods for measuring blood pressure within at least one vessel |
US11259867B2 (en) | 2011-01-21 | 2022-03-01 | Kardium Inc. | High-density electrode-based medical device system |
CA2764494A1 (en) | 2011-01-21 | 2012-07-21 | Kardium Inc. | Enhanced medical device for use in bodily cavities, for example an atrium |
US9452016B2 (en) | 2011-01-21 | 2016-09-27 | Kardium Inc. | Catheter system |
US9480525B2 (en) | 2011-01-21 | 2016-11-01 | Kardium, Inc. | High-density electrode-based medical device system |
US9072511B2 (en) | 2011-03-25 | 2015-07-07 | Kardium Inc. | Medical kit for constricting tissue or a bodily orifice, for example, a mitral valve |
EP2691038B1 (en) | 2011-03-28 | 2016-07-20 | Avinger, Inc. | Occlusion-crossing devices, imaging, and atherectomy devices |
US9949754B2 (en) | 2011-03-28 | 2018-04-24 | Avinger, Inc. | Occlusion-crossing devices |
WO2013013049A1 (en) | 2011-07-19 | 2013-01-24 | The General Hospital Corporation | Systems, methods, apparatus and computer-accessible-medium for providing polarization-mode dispersion compensation in optical coherence tomography |
EP3835718B1 (en) | 2011-08-25 | 2023-07-26 | The General Hospital Corporation | Apparatus for providing micro-optical coherence tomography inside a respiratory system |
US8958867B2 (en) | 2011-08-29 | 2015-02-17 | Infraredx, Inc. | Detection of lipid core plaque cap thickness |
US9005151B2 (en) | 2011-09-07 | 2015-04-14 | Choon Kee Lee | Thermal apparatus |
EP3653151A1 (en) | 2011-10-17 | 2020-05-20 | Avinger, Inc. | Atherectomy catheters and non-contact actuation mechanism for catheters |
WO2013066631A1 (en) | 2011-10-18 | 2013-05-10 | The General Hospital Corporation | Apparatus and methods for producing and/or providing recirculating optical delay(s) |
US9345406B2 (en) | 2011-11-11 | 2016-05-24 | Avinger, Inc. | Occlusion-crossing devices, atherectomy devices, and imaging |
USD777926S1 (en) | 2012-01-20 | 2017-01-31 | Kardium Inc. | Intra-cardiac procedure device |
USD777925S1 (en) | 2012-01-20 | 2017-01-31 | Kardium Inc. | Intra-cardiac procedure device |
US10398508B2 (en) * | 2012-02-07 | 2019-09-03 | Joe Denton Brown | Protective sheath and method of using same for laser surgery |
US9588113B2 (en) | 2012-02-22 | 2017-03-07 | Church & Dwight Co., Inc. | Methods for electronic analyte assaying |
EP3348220A1 (en) | 2012-03-08 | 2018-07-18 | Medtronic Ardian Luxembourg S.à.r.l. | Biomarker sampling in the context of neuromodulation devices and associated systems |
US9750568B2 (en) | 2012-03-08 | 2017-09-05 | Medtronic Ardian Luxembourg S.A.R.L. | Ovarian neuromodulation and associated systems and methods |
WO2013148306A1 (en) | 2012-03-30 | 2013-10-03 | The General Hospital Corporation | Imaging system, method and distal attachment for multidirectional field of view endoscopy |
US11406412B2 (en) | 2012-05-14 | 2022-08-09 | Avinger, Inc. | Atherectomy catheters with imaging |
EP2849660B1 (en) | 2012-05-14 | 2021-08-25 | Avinger, Inc. | Atherectomy catheter drive assemblies |
WO2013172972A1 (en) | 2012-05-14 | 2013-11-21 | Avinger, Inc. | Optical coherence tomography with graded index fiber for biological imaging |
US9017320B2 (en) | 2012-05-21 | 2015-04-28 | Kardium, Inc. | Systems and methods for activating transducers |
US11490797B2 (en) | 2012-05-21 | 2022-11-08 | The General Hospital Corporation | Apparatus, device and method for capsule microscopy |
US9198592B2 (en) | 2012-05-21 | 2015-12-01 | Kardium Inc. | Systems and methods for activating transducers |
US10827977B2 (en) | 2012-05-21 | 2020-11-10 | Kardium Inc. | Systems and methods for activating transducers |
US20140073907A1 (en) | 2012-09-12 | 2014-03-13 | Convergent Life Sciences, Inc. | System and method for image guided medical procedures |
US9498247B2 (en) | 2014-02-06 | 2016-11-22 | Avinger, Inc. | Atherectomy catheters and occlusion crossing devices |
US11284916B2 (en) | 2012-09-06 | 2022-03-29 | Avinger, Inc. | Atherectomy catheters and occlusion crossing devices |
US20140110296A1 (en) | 2012-10-19 | 2014-04-24 | Medtronic Ardian Luxembourg S.A.R.L. | Packaging for Catheter Treatment Devices and Associated Devices, Systems, and Methods |
JP6002048B2 (en) * | 2013-01-16 | 2016-10-05 | 日本アビオニクス株式会社 | Body temperature measuring device, body temperature measuring method and body temperature management system |
JP6560126B2 (en) | 2013-01-28 | 2019-08-14 | ザ ジェネラル ホスピタル コーポレイション | Apparatus and method for providing diffusion spectroscopy superimposed on optical frequency domain imaging |
US10893806B2 (en) | 2013-01-29 | 2021-01-19 | The General Hospital Corporation | Apparatus, systems and methods for providing information regarding the aortic valve |
WO2014121082A1 (en) | 2013-02-01 | 2014-08-07 | The General Hospital Corporation | Objective lens arrangement for confocal endomicroscopy |
US9057600B2 (en) | 2013-03-13 | 2015-06-16 | Hansen Medical, Inc. | Reducing incremental measurement sensor error |
EP2967371A4 (en) | 2013-03-15 | 2016-12-07 | Avinger Inc | Chronic total occlusion crossing devices with imaging |
US9271663B2 (en) | 2013-03-15 | 2016-03-01 | Hansen Medical, Inc. | Flexible instrument localization from both remote and elongation sensors |
JP6291025B2 (en) | 2013-03-15 | 2018-03-14 | アビンガー・インコーポレイテッドAvinger, Inc. | Optical pressure sensor assembly |
JP6378311B2 (en) | 2013-03-15 | 2018-08-22 | ザ ジェネラル ホスピタル コーポレイション | Methods and systems for characterizing objects |
CN105050614B (en) | 2013-03-15 | 2019-04-05 | 加利福尼亚大学董事会 | Stimulate the peptide with reduced toxicity of Cholesterol Efflux |
WO2014142954A1 (en) | 2013-03-15 | 2014-09-18 | Avinger, Inc. | Tissue collection device for catheter |
US9629595B2 (en) | 2013-03-15 | 2017-04-25 | Hansen Medical, Inc. | Systems and methods for localizing, tracking and/or controlling medical instruments |
US9014851B2 (en) | 2013-03-15 | 2015-04-21 | Hansen Medical, Inc. | Systems and methods for tracking robotically controlled medical instruments |
US10098694B2 (en) | 2013-04-08 | 2018-10-16 | Apama Medical, Inc. | Tissue ablation and monitoring thereof |
CA2908517A1 (en) | 2013-04-08 | 2014-10-16 | Apama Medical, Inc. | Cardiac ablation catheters and methods of use thereof |
US10349824B2 (en) | 2013-04-08 | 2019-07-16 | Apama Medical, Inc. | Tissue mapping and visualization systems |
WO2014186353A1 (en) | 2013-05-13 | 2014-11-20 | The General Hospital Corporation | Detecting self-interefering fluorescence phase and amplitude |
US11020016B2 (en) | 2013-05-30 | 2021-06-01 | Auris Health, Inc. | System and method for displaying anatomy and devices on a movable display |
JP6517198B2 (en) | 2013-07-08 | 2019-05-22 | アビンガー・インコーポレイテッドAvinger, Inc. | Identification of elastic layers guiding interventions |
EP3021735A4 (en) | 2013-07-19 | 2017-04-19 | The General Hospital Corporation | Determining eye motion by imaging retina. with feedback |
EP4349242A2 (en) | 2013-07-19 | 2024-04-10 | The General Hospital Corporation | Imaging apparatus and method which utilizes multidirectional field of view endoscopy |
WO2015013651A2 (en) | 2013-07-26 | 2015-01-29 | The General Hospital Corporation | System, apparatus and method utilizing optical dispersion for fourier-domain optical coherence tomography |
US9733460B2 (en) | 2014-01-08 | 2017-08-15 | The General Hospital Corporation | Method and apparatus for microscopic imaging |
US10736494B2 (en) | 2014-01-31 | 2020-08-11 | The General Hospital Corporation | System and method for facilitating manual and/or automatic volumetric imaging with real-time tension or force feedback using a tethered imaging device |
CA2938972A1 (en) | 2014-02-06 | 2015-08-13 | Avinger, Inc. | Atherectomy catheters and occlusion crossing devices |
US10194979B1 (en) | 2014-03-28 | 2019-02-05 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
US10194980B1 (en) | 2014-03-28 | 2019-02-05 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
US9980766B1 (en) | 2014-03-28 | 2018-05-29 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and systems for renal neuromodulation |
US10228556B2 (en) | 2014-04-04 | 2019-03-12 | The General Hospital Corporation | Apparatus and method for controlling propagation and/or transmission of electromagnetic radiation in flexible waveguide(s) |
US20170027450A1 (en) | 2014-04-13 | 2017-02-02 | H.T Bioimaging Ltd. | A device and method for cancer detection, diagnosis and treatment guidance using active thermal imaging |
EP3166512B1 (en) | 2014-07-08 | 2020-08-19 | Avinger, Inc. | High speed chronic total occlusion crossing devices |
EP3957232A1 (en) | 2014-07-24 | 2022-02-23 | University Health Network | Collection and analysis of data for diagnostic purposes |
KR102513779B1 (en) * | 2014-07-25 | 2023-03-24 | 더 제너럴 하스피탈 코포레이션 | Apparatus, devices and methods for in vivo imaging and diagnosis |
WO2016054079A1 (en) | 2014-09-29 | 2016-04-07 | Zyomed Corp. | Systems and methods for blood glucose and other analyte detection and measurement using collision computing |
US10722184B2 (en) | 2014-11-17 | 2020-07-28 | Kardium Inc. | Systems and methods for selecting, activating, or selecting and activating transducers |
US10368936B2 (en) | 2014-11-17 | 2019-08-06 | Kardium Inc. | Systems and methods for selecting, activating, or selecting and activating transducers |
US10776654B2 (en) | 2015-03-10 | 2020-09-15 | Infraredx, Inc. | Assessment of lipid core plaque integrity |
US10568520B2 (en) | 2015-07-13 | 2020-02-25 | Avinger, Inc. | Micro-molded anamorphic reflector lens for image guided therapeutic/diagnostic catheters |
US9727963B2 (en) | 2015-09-18 | 2017-08-08 | Auris Surgical Robotics, Inc. | Navigation of tubular networks |
WO2017087549A1 (en) | 2015-11-16 | 2017-05-26 | Apama Medical, Inc. | Energy delivery devices |
US10143526B2 (en) | 2015-11-30 | 2018-12-04 | Auris Health, Inc. | Robot-assisted driving systems and methods |
CN108882857A (en) | 2016-01-25 | 2018-11-23 | 阿维格公司 | With the modified OCT image conduit of lag |
US9554738B1 (en) | 2016-03-30 | 2017-01-31 | Zyomed Corp. | Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing |
CN108882948A (en) | 2016-04-01 | 2018-11-23 | 阿维格公司 | Rotary-cut art conduit with zigzag cutter |
EP3463123A4 (en) | 2016-06-03 | 2020-01-08 | Avinger, Inc. | Catheter device with detachable distal end |
JP7061080B2 (en) | 2016-06-30 | 2022-04-27 | アビンガー・インコーポレイテッド | Atherectomy catheter with a shaped distal tip |
US10244926B2 (en) | 2016-12-28 | 2019-04-02 | Auris Health, Inc. | Detecting endolumenal buckling of flexible instruments |
WO2018183727A1 (en) | 2017-03-31 | 2018-10-04 | Auris Health, Inc. | Robotic systems for navigation of luminal networks that compensate for physiological noise |
US10022192B1 (en) | 2017-06-23 | 2018-07-17 | Auris Health, Inc. | Automatically-initialized robotic systems for navigation of luminal networks |
KR102558063B1 (en) | 2017-06-28 | 2023-07-25 | 아우리스 헬스, 인코포레이티드 | Align electromagnetic field generator |
US11395703B2 (en) | 2017-06-28 | 2022-07-26 | Auris Health, Inc. | Electromagnetic distortion detection |
US10555778B2 (en) | 2017-10-13 | 2020-02-11 | Auris Health, Inc. | Image-based branch detection and mapping for navigation |
US11058493B2 (en) | 2017-10-13 | 2021-07-13 | Auris Health, Inc. | Robotic system configured for navigation path tracing |
AU2018384820A1 (en) | 2017-12-14 | 2020-05-21 | Auris Health, Inc. | System and method for estimating instrument location |
JP7059377B2 (en) | 2017-12-18 | 2022-04-25 | オーリス ヘルス インコーポレイテッド | Instrument tracking and navigation methods and systems within the luminal network |
JP7225259B2 (en) | 2018-03-28 | 2023-02-20 | オーリス ヘルス インコーポレイテッド | Systems and methods for indicating probable location of instruments |
US10524866B2 (en) | 2018-03-28 | 2020-01-07 | Auris Health, Inc. | Systems and methods for registration of location sensors |
EP3801190A4 (en) | 2018-05-30 | 2022-03-02 | Auris Health, Inc. | Systems and methods for location sensor-based branch prediction |
EP3801280A4 (en) | 2018-05-31 | 2022-03-09 | Auris Health, Inc. | Robotic systems and methods for navigation of luminal network that detect physiological noise |
MX2020012904A (en) | 2018-05-31 | 2021-02-26 | Auris Health Inc | Image-based airway analysis and mapping. |
WO2019231891A1 (en) | 2018-05-31 | 2019-12-05 | Auris Health, Inc. | Path-based navigation of tubular networks |
US10813612B2 (en) | 2019-01-25 | 2020-10-27 | Cleerly, Inc. | Systems and method of characterizing high risk plaques |
WO2021038495A1 (en) | 2019-08-30 | 2021-03-04 | Auris Health, Inc. | Instrument image reliability systems and methods |
CN114340542B (en) | 2019-08-30 | 2023-07-21 | 奥瑞斯健康公司 | Systems and methods for weight-based registration of position sensors |
KR20220056220A (en) | 2019-09-03 | 2022-05-04 | 아우리스 헬스, 인코포레이티드 | Electromagnetic Distortion Detection and Compensation |
JP2022553223A (en) | 2019-10-18 | 2022-12-22 | アビンガー・インコーポレイテッド | occlusion crossing device |
US11602372B2 (en) | 2019-12-31 | 2023-03-14 | Auris Health, Inc. | Alignment interfaces for percutaneous access |
WO2021137109A1 (en) | 2019-12-31 | 2021-07-08 | Auris Health, Inc. | Alignment techniques for percutaneous access |
JP2023508521A (en) | 2019-12-31 | 2023-03-02 | オーリス ヘルス インコーポレイテッド | Identification and targeting of anatomical features |
US11232564B2 (en) | 2020-01-07 | 2022-01-25 | Cleerly, Inc. | Systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking |
AU2021205821A1 (en) | 2020-01-07 | 2022-07-21 | Cleerly, Inc. | Systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking |
US20230289963A1 (en) | 2022-03-10 | 2023-09-14 | Cleerly, Inc. | Systems, devices, and methods for non-invasive image-based plaque analysis and risk determination |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3273395A (en) | 1963-08-05 | 1966-09-20 | Barnes Eng Co | Automatic ambient temperature compensation for a medical thermometer |
US3638640A (en) | 1967-11-01 | 1972-02-01 | Robert F Shaw | Oximeter and method for in vivo determination of oxygen saturation in blood using three or more different wavelengths |
US3866599A (en) | 1972-01-21 | 1975-02-18 | Univ Washington | Fiberoptic catheter |
US3913568A (en) | 1973-01-22 | 1975-10-21 | American Optical Corp | Nasopharyngoscope |
US4005605A (en) | 1974-07-22 | 1977-02-01 | Mikron Instrument Company, Inc. | Remote reading infrared thermometer |
US4140393A (en) | 1976-02-23 | 1979-02-20 | University Of Arizona | Birefringent crystal thermometer |
SU649410A1 (en) * | 1976-12-01 | 1979-02-28 | Ижевский Государственный Медицинский Институт | Device for registering internal organs heat radiation |
US4075493A (en) | 1976-12-16 | 1978-02-21 | Ronald Alves | Optical temperature measurement technique utilizing phosphors |
US4136566A (en) | 1977-06-24 | 1979-01-30 | University Of Utah | Semiconductor temperature sensor |
US4281645A (en) | 1977-06-28 | 1981-08-04 | Duke University, Inc. | Method and apparatus for monitoring metabolism in body organs |
US4179927A (en) | 1977-09-28 | 1979-12-25 | Electric Power Research Institute, Inc. | Temperature sensing device |
US4200110A (en) | 1977-11-28 | 1980-04-29 | United States Of America | Fiber optic pH probe |
USRE32204E (en) | 1980-06-09 | 1986-07-15 | Mansfield Scientific, Inc. | Electrode assembly for temporary pacing and heart measurements |
US5542915A (en) | 1992-08-12 | 1996-08-06 | Vidamed, Inc. | Thermal mapping catheter with ultrasound probe |
US4621929A (en) | 1983-10-12 | 1986-11-11 | Luxtron Corporation | Fiber optic thermal anemometer |
US4602642A (en) | 1984-10-23 | 1986-07-29 | Intelligent Medical Systems, Inc. | Method and apparatus for measuring internal body temperature utilizing infrared emissions |
US4790324A (en) | 1984-10-23 | 1988-12-13 | Intelligent Medical Systems, Inc. | Method and apparatus for measuring internal body temperature utilizing infrared emissions |
US4799479A (en) | 1984-10-24 | 1989-01-24 | The Beth Israel Hospital Association | Method and apparatus for angioplasty |
US4776334A (en) | 1985-03-22 | 1988-10-11 | Stanford University | Catheter for treatment of tumors |
US5318024A (en) * | 1985-03-22 | 1994-06-07 | Massachusetts Institute Of Technology | Laser endoscope for spectroscopic imaging |
US5106387A (en) | 1985-03-22 | 1992-04-21 | Massachusetts Institute Of Technology | Method for spectroscopic diagnosis of tissue |
WO1986006163A1 (en) | 1985-04-17 | 1986-10-23 | Fremed, Inc. | Infrared electronic thermometer and method for measuring temperature |
US4699147A (en) | 1985-09-25 | 1987-10-13 | Cordis Corporation | Intraventricular multielectrode cardial mapping probe and method for using same |
US4752141A (en) * | 1985-10-25 | 1988-06-21 | Luxtron Corporation | Fiberoptic sensing of temperature and/or other physical parameters |
US4784149A (en) | 1986-01-13 | 1988-11-15 | Optical Sensors, Inc. | Infrared thermometer with automatic calibration |
US5000185A (en) | 1986-02-28 | 1991-03-19 | Cardiovascular Imaging Systems, Inc. | Method for intravascular two-dimensional ultrasonography and recanalization |
US4794931A (en) | 1986-02-28 | 1989-01-03 | Cardiovascular Imaging Systems, Inc. | Catheter apparatus, system and method for intravascular two-dimensional ultrasonography |
JPS62207435A (en) | 1986-03-07 | 1987-09-11 | テルモ株式会社 | Catheter for measuring cardiac output |
US4988671A (en) | 1987-05-20 | 1991-01-29 | Hoechst Celanese Corp. | Process for producing a superconductive complex metal oxide |
DE3718139C1 (en) | 1987-05-29 | 1988-12-08 | Strahlen Umweltforsch Gmbh | Cardiac catheter |
US4777955A (en) | 1987-11-02 | 1988-10-18 | Cordis Corporation | Left ventricle mapping probe |
EP0415997A4 (en) * | 1988-05-18 | 1992-04-08 | Kasevich Associates, Inc. | Microwave balloon angioplasty |
DE3830704A1 (en) | 1988-09-09 | 1990-03-22 | Falah Redha | MEDICAL INSTRUMENT |
US5046501A (en) * | 1989-01-18 | 1991-09-10 | Wayne State University | Atherosclerotic identification |
US4986671A (en) * | 1989-04-12 | 1991-01-22 | Luxtron Corporation | Three-parameter optical fiber sensor and system |
US5400788A (en) | 1989-05-16 | 1995-03-28 | Hewlett-Packard | Apparatus that generates acoustic signals at discrete multiple frequencies and that couples acoustic signals into a cladded-core acoustic waveguide |
US5057105A (en) * | 1989-08-28 | 1991-10-15 | The University Of Kansas Med Center | Hot tip catheter assembly |
US5109859A (en) * | 1989-10-04 | 1992-05-05 | Beth Israel Hospital Association | Ultrasound guided laser angioplasty |
US4995398A (en) * | 1990-04-30 | 1991-02-26 | Turnidge Patrick A | Coronary angiography imaging system |
US5558093A (en) | 1990-05-18 | 1996-09-24 | Cardiovascular Imaging Systems, Inc. | Guidewire with imaging capability |
US5197470A (en) * | 1990-07-16 | 1993-03-30 | Eastman Kodak Company | Near infrared diagnostic method and instrument |
JPH05506174A (en) | 1990-09-14 | 1993-09-16 | アメリカン・メディカル・システムズ・インコーポレーテッド | Combined hyperthermia and dilatation catheter |
US5275594A (en) * | 1990-11-09 | 1994-01-04 | C. R. Bard, Inc. | Angioplasty system having means for identification of atherosclerotic plaque |
US5293872A (en) | 1991-04-03 | 1994-03-15 | Alfano Robert R | Method for distinguishing between calcified atherosclerotic tissue and fibrous atherosclerotic tissue or normal cardiovascular tissue using Raman spectroscopy |
US5682899A (en) | 1991-05-16 | 1997-11-04 | Ami-Med Corporation | Apparatus and method for continuous cardiac output monitoring |
US5174299A (en) | 1991-08-12 | 1992-12-29 | Cardiac Pacemakers, Inc. | Thermocouple-based blood flow sensor |
US5541296A (en) * | 1991-08-30 | 1996-07-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Monocyte adhesion protein and monoclonal antibody thereto |
EP0549476B1 (en) * | 1991-12-24 | 1998-09-23 | Tokyo Gas Co., Ltd. | Surface combustion burner |
US5419767A (en) * | 1992-01-07 | 1995-05-30 | Thapliyal And Eggers Partners | Methods and apparatus for advancing catheters through severely occluded body lumens |
US5237996A (en) | 1992-02-11 | 1993-08-24 | Waldman Lewis K | Endocardial electrical mapping catheter |
JPH05228098A (en) * | 1992-02-20 | 1993-09-07 | Asahi Optical Co Ltd | Thermoendoscope |
US5217456A (en) * | 1992-02-24 | 1993-06-08 | Pdt Cardiovascular, Inc. | Device and method for intra-vascular optical radial imaging |
US5355880A (en) | 1992-07-06 | 1994-10-18 | Sandia Corporation | Reliable noninvasive measurement of blood gases |
US5792050A (en) | 1992-07-06 | 1998-08-11 | Alam; Mary K. | Near-infrared noninvasive spectroscopic determination of pH |
US5435308A (en) | 1992-07-16 | 1995-07-25 | Abbott Laboratories | Multi-purpose multi-parameter cardiac catheter |
US5336178A (en) | 1992-11-02 | 1994-08-09 | Localmed, Inc. | Intravascular catheter with infusion array |
US5439000A (en) | 1992-11-18 | 1995-08-08 | Spectrascience, Inc. | Method of diagnosing tissue with guidewire |
NL9300028A (en) | 1993-01-07 | 1994-08-01 | Academisch Ziekenhuis Utrecht | Method for measuring the electrical impedance in blood vessels and catheterization system using a catheter to carry out that method. |
US5373849A (en) | 1993-01-19 | 1994-12-20 | Cardiovascular Imaging Systems, Inc. | Forward viewing imaging catheter |
US5279565A (en) | 1993-02-03 | 1994-01-18 | Localmed, Inc. | Intravascular treatment apparatus and method |
US5429136A (en) | 1993-04-21 | 1995-07-04 | Devices For Vascular Intervention, Inc. | Imaging atherectomy apparatus |
US5453448A (en) | 1993-12-09 | 1995-09-26 | Pdt Cardiovascular, Inc. | In vivo method for estimating the lipid contant of an atheromatous lesion |
JP3403233B2 (en) | 1994-01-20 | 2003-05-06 | テルモ株式会社 | Balloon catheter |
US5623940A (en) | 1994-08-02 | 1997-04-29 | S.L.T. Japan Co., Ltd. | Catheter apparatus with a sensor |
US5582170A (en) | 1994-12-01 | 1996-12-10 | University Of Massachusetts Medical Center | Fiber optic sensor for in vivo measurement of nitric oxide |
US5620438A (en) | 1995-04-20 | 1997-04-15 | Angiomedics Ii Incorporated | Method and apparatus for treating vascular tissue following angioplasty to minimize restenosis |
US5596995A (en) | 1995-05-02 | 1997-01-28 | Heart Rhythm Technologies, Inc. | Biomedical device having a temperature sensing system |
US5606974A (en) | 1995-05-02 | 1997-03-04 | Heart Rhythm Technologies, Inc. | Catheter having ultrasonic device |
US5733739A (en) | 1995-06-07 | 1998-03-31 | Inphocyte, Inc. | System and method for diagnosis of disease by infrared analysis of human tissues and cells |
US6615071B1 (en) * | 1995-09-20 | 2003-09-02 | Board Of Regents, The University Of Texas System | Method and apparatus for detecting vulnerable atherosclerotic plaque |
AU709432B2 (en) * | 1995-09-20 | 1999-08-26 | California Institute Of Technology | Detecting thermal discrepancies in vessel walls |
US6763261B2 (en) * | 1995-09-20 | 2004-07-13 | Board Of Regents, The University Of Texas System | Method and apparatus for detecting vulnerable atherosclerotic plaque |
US5782752A (en) * | 1996-04-05 | 1998-07-21 | Vista Medical Technologies, Inc. | Device for carrying two units in end to end disposition and for moving one of the units alongside the other of the units |
US5708275A (en) | 1996-06-07 | 1998-01-13 | Honeywell Inc. | PH measurement utilizing a light source |
US5924997A (en) | 1996-07-29 | 1999-07-20 | Campbell; Thomas Henderson | Catheter and method for the thermal mapping of hot spots in vascular lesions of the human body |
US5871449A (en) | 1996-12-27 | 1999-02-16 | Brown; David Lloyd | Device and method for locating inflamed plaque in an artery |
US5849028A (en) | 1997-05-16 | 1998-12-15 | Irvine Biomedical, Inc. | Catheter and method for radiofrequency ablation of cardiac tissue |
EP1025797A1 (en) | 1999-02-08 | 2000-08-09 | David Lloyd Brown | System for locating inflamed plaque in a vessel |
-
1996
- 1996-09-20 AU AU73689/96A patent/AU709432B2/en not_active Ceased
- 1996-09-20 DE DE69622764T patent/DE69622764T2/en not_active Expired - Fee Related
- 1996-09-20 AT AT96935912T patent/ATE221338T1/en not_active IP Right Cessation
- 1996-09-20 US US08/717,449 patent/US5935075A/en not_active Expired - Lifetime
- 1996-09-20 CA CA002231425A patent/CA2231425A1/en not_active Abandoned
- 1996-09-20 WO PCT/US1996/015217 patent/WO1997010748A1/en active IP Right Grant
- 1996-09-20 EP EP96935912A patent/EP0955883B1/en not_active Expired - Lifetime
- 1996-09-20 JP JP09512963A patent/JP2000511786A/en not_active Ceased
-
1998
- 1998-03-20 MX MX9802187A patent/MX9802187A/en unknown
-
1999
- 1999-03-15 US US09/268,609 patent/US6475159B1/en not_active Expired - Lifetime
-
2002
- 2002-08-16 US US10/222,342 patent/US6993382B2/en not_active Expired - Fee Related
-
2005
- 2005-11-14 US US11/273,683 patent/US7513876B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU7368996A (en) | 1997-04-09 |
MX9802187A (en) | 1998-11-29 |
US20060094980A1 (en) | 2006-05-04 |
WO1997010748A1 (en) | 1997-03-27 |
US7513876B2 (en) | 2009-04-07 |
EP0955883B1 (en) | 2002-07-31 |
US6993382B2 (en) | 2006-01-31 |
JP2000511786A (en) | 2000-09-12 |
US20030004430A1 (en) | 2003-01-02 |
DE69622764D1 (en) | 2002-09-05 |
ATE221338T1 (en) | 2002-08-15 |
EP0955883A1 (en) | 1999-11-17 |
US5935075A (en) | 1999-08-10 |
US6475159B1 (en) | 2002-11-05 |
AU709432B2 (en) | 1999-08-26 |
EP0955883A4 (en) | 1999-11-24 |
DE69622764T2 (en) | 2003-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2231425A1 (en) | Detecting thermal discrepancies in vessel walls | |
WO1997010748A9 (en) | Detecting thermal discrepancies in vessel walls | |
US7426409B2 (en) | Method and apparatus for detecting vulnerable atherosclerotic plaque | |
US6615071B1 (en) | Method and apparatus for detecting vulnerable atherosclerotic plaque | |
US6763261B2 (en) | Method and apparatus for detecting vulnerable atherosclerotic plaque | |
US7329223B1 (en) | Catheter with optical fiber sensor | |
Casscells et al. | Thermal detection of cellular infiltrates in living atherosclerotic plaques: possible implications for plaque rupture and thrombosis | |
US7297154B2 (en) | Optical apparatus for detecting and treating vulnerable plaque | |
US7603166B2 (en) | Method and apparatus for detection of vulnerable atherosclerotic plaque | |
Swain et al. | Methods of measuring skin blood flow | |
US20080045842A1 (en) | Conformable tissue contact catheter | |
CN105877910A (en) | Integrated system for accurate diagnosis and treatment of hardened blood vessels or tumors | |
US20040102722A1 (en) | Apparatus and method for palpographic characterization of vulnerable plaque and other biological tissue | |
KR20070058523A (en) | Method and apparatus for imaging of vessel segments | |
Moreno et al. | Detection of high‐risk atherosclerotic coronary plaques by intravascular spectroscopy | |
Mignani et al. | Fibre-optic sensors in health care | |
Baldini et al. | Optical-fiber medical sensors | |
Zhan et al. | Intravascular photoacoustic and autofluorescence imaging for detecting intraplaque hemorrhage: a feasibility study | |
Pope et al. | Dual imaging of arterial walls: intravascular ultrasound and fluorescence spectroscopy | |
McConnell | Imaging techniques to predict cardiovascular risk | |
van de Poll et al. | Coronary atherosclerotic plaque characterization using IVUS elastography and Raman spectroscopy | |
Brezinski et al. | High resolution intraarterial imaging with optical coherence tomography | |
Osborn et al. | Multimodality Intravascular Imaging Technology | |
Larin et al. | Noninvasive functional imaging of tissue abnormalities using optical coherence tomography | |
Rodrigues et al. | Study of normal, fibrous, and calcified aortic valve tissue by Raman and reflectance spectroscopy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |